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CHAPTER ONE 
GENERAL INTRODUCTION 
1.0.0: BACKGROUND 
Beside other molecular hallmarks of cancer cells’ drug resistance and metastasis, a 
remarkable feature among drug-resistant and metastatic cancer cells is an increased level of 
transglutaminase 2 (TG2) protein (Budillon et al. 2011). An extensive review of literature on 
TG2 is here presented, with emphases on its historical background, uniqueness among other 
members of the transglutaminase family, structural and functional elements, biochemical 
multi-functionality, tissue distribution and sub-cellular localization, and substrate specificity. 
The relationship between TG2 biochemistry and cellular physiology, with pertinence to 
disease pathology is also presented with particular emphasis on its role in cancer biology, 
drug resistance and metastasis.   
 
1.1.0: HISTORY OF TRANSGLUTAMINASES 
In 1923, Barkan and Gaspar reported the cross-linking of fibrin polymers for the first time 
(Barkan & Gaspar, 1923); then, in 1948, Laki and Lóránd attributed the cross-linking to a 
Ca
2+ 
-dependent protein called ‘fibrin-stabilizing serum factor’ or ‘Laki-Lóránd factor’ (Laki 
& Lóránd, 1948; Lóránd, 1948; Lóránd, 1950). Subsequently, the ‘serum factor’ was purified 
by Loewy and colleagues (Loewy et al. 1957); and upon demonstration that haemophilia 
occurs as a result of its deficiency in the blood of haemophiliac patients, the enzyme was 
termed ‘blood coagulation factor XIII’ (Duckert et al. 1960). Lóránd et al. (1966), observed 
that the ‘blood coagulation factor XIII’ was an isoenzyme belonging to the transglutaminase 
family. However, the term transglutaminase was first used by Waelsch and colleagues, while 
reporting the ability of a soluble liver protein fraction (containing TG2) to incorporate 
labelled amines into proteins in the presence of Ca
2+ 
(Waelsch et al. 1957). The designation, 
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transglutaminase was later amended by the Enzyme Commission (EC 2.3.2.13, 
transglutaminase = R-glutamyl-peptide, amine-γ-glutamyl transferase). Achyuthan & 
Greenberg (1987), demonstrated the ability of transglutaminase 2 (TG2) to bind GTP with the 
resultant inhibition of its activity; justifying the reason why TG2 was named a G protein with 
a role in signal transduction (Nakaoka et al. 1994). 
 
Harding & Rogers (1971), identified gamma-glutamyl-epsilon-lysine cross-links in hair 
protein extracts; upon demonstration that this cross-linking enzyme was neither identical to 
factor XIII nor transglutaminase 2 (Chung & Folk, 1972), the enzyme was labelled an 
‘epidermal’ or ‘hair follicle’ transglutaminase (TGe). Subsequently, it was observed that both 
membrane-bound and soluble fractions of the hair protein extract showed transglutaminase 
(TG) activity (Thacher & Rice, 1985), suggesting the presence of further epidermal 
transglutaminases. The insoluble, ‘keratinocyte-specific’ (corresponding to TGk) 
transglutaminase was detectable in in cultured keratinocytes unlike the soluble ‘epidermal’ 
TGe (Lichti et al. 1985). Furthermore, the demonstration of the expression of TGk, TGc 
(cytosolic TG), and TGe in both hair follicle and epidermal keratinocytes (Rubin & Rice, 
1986) generated confusion and led to the numbering of transglutaminase isoenzymes and 
their corresponding genes (Parenteau et al. 1986; Kim et al. 1992). To further reduce 
ambiguity, transglutaminase messenger RNA is designated with ‘TGM’ and the gene product 
is denoted by ‘TG’, both followed by an Arabic number. Thenceforth, TGM1/TG1, 
TGM2/TG2, and TGM3/TG3 were respectively assigned to TGk, TGc, and TGe; with their 
corresponding gene products. This system of naming allowed for the classification of new TG 
family members that were subsequently discovered. 
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Other transglutaminase enzymes have been discovered either by protein isolation or through 
sequence homology, hence, the isolation of TGp (TG4) from prostate adenocarcinoma cells 
by Bures et al. (1980). More recently, Aeschlimann and colleagues have identified three new 
family members of TG: TGx (TG5), TGy (TG6), and TGz (TG7) (Aeschlimann et al. 1998; 
Grenard et al. 2001). A catalytically inactive erythrocyte membrane protein band 4.2 was also 
discovered to belong to the TG family. Though, it has over 30% similarity with other TG 
isoenzymes, a cysteine to alanine substitution appears to render it catalytically inactive 
(Korsgren et al. 1990). Today, a total of nine different transglutaminase isoenzymes have 
been identified in man. 
 
1.2.0: THE TRANSGLUTAMINASE (TGase) FAMILY 
Nine transglutaminase genes have been identified, out of which eight encode active enzymes 
(Grenard et al. 2001). Only six of the TG enzymes have been isolated and characterised at the 
protein level (Esposito & Caputo, 2005), and include the intracellular TG1, TG3 and TG5 
isoforms, which are predominantly expressed in the epithelial tissue; the ubiquitously 
expressed TG2, which occur in intracellular and extracellular forms; TG4, which is expressed 
in the prostate gland; and factor XIII (FXIII), which is expressed in the blood. Others have 
been isolated at messenger RNA level, including TG6 which is expressed in the testis, lungs, 
and brain (Mehta, 2005; Thomas et al. 2013); TG7, which is ubiquitously expressed, but most 
prominently distributed in the testis and lungs (Mehta, 2005); and band 4.2 (table1), which is 
an enzymatically inactive component protein of the erythrocyte membrane that serves to 
maintain erythrocyte integrity (Lorand & Graham, 2003). In addition to diversity at genetic 
level, transglutaminases undergo a number of post-translational modifications such as 
phosphorylation, nitrosylation, fatty acylation and proteolytic cleavage (Aeschlimann & 
Paulsson, 1994; Lorand & Graham, 2003).  
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Table 1: Members of the transglutaminase (TGase) enzyme family, their nomenclature, tissue 
distribution, biological functions, and pathological involvement (Odii and Coussons, 2014) 
TGase Nomenclature Tissue distribution, 
cellular and sub-cellular 
localization  
Biological Functions Pathology 
TG1 Keratinocyte TG, 
particulate TG, TG1, 
TGK 
Squamous epithelia, 
keratinocytes, 
cytosolic, 
membrane 
Barrier function in stratified 
squamous epithelia, cornified 
envelope formation in 
keratinocyte differentiation  
Lamellar Ichthyosis (Candi 
et al 1998) 
TG2 Liver TG, tissue TG, 
cytosolic TG, 
erythrocyte TG, Ghα, 
endothelial TG 
Ubiquitously distributed 
in many types of tissue, 
cell membrane, cytosol, 
nucleus, extracellular  
Apoptosis, cell survival 
signalling, cell 
differentiation, matrix 
stabilization, endocytosis, etc  
Autoimmune diseases, 
neurodegenerative 
diseases, malignancies, 
metabolic diseases, etc 
(Facchiano & Facchiano, 
2006) 
TG3 Epidermal TG, callus 
TG, hair follicle TG, 
bovine snout TG 
Epidermis, hair follicle, 
brain, cytosolic 
Terminal differentiation of 
keratinocytes, hair follicles  
Human epidermis diseases 
TG4 Prostate TG, TGp, 
androgen regulated 
major secretory protein, 
vesiculase, 
dorsal prostate protein 1 
(DP1), type 4 TG 
Prostate gland, prostatic 
fluids, and seminal 
plasma, extracellular 
Reproduction and fertility, 
especially in rodents where it 
is involved in semen 
coagulation 
Not known  
TG5 TGX, type 5 TG, TG5 Ubiquitously expressed 
but predominant in 
female reproductive 
tissues, skeletal muscle, 
and foetal tissues, 
foreskin keratinocytes, 
epithelial barrier lining, 
cytosolic 
Epidermal differentiation Secondarily involved in 
hyperkeratotic phenotype 
in 
ichthyosis and in psoriasis, 
Overexpressed or absent in 
different areas of the 
Darier’s disease lesions 
(Candi et al 2002). 
TG6 TGY, type 6 TG, TG6,  Testis, lungs, and brain, 
cellular localization is yet 
to be defined 
Central nervous 
system development, motor 
function, late stage cell 
envelope formation in the 
epidermis 
and the hair follicle 
Spinocerebellar ataxias 
(Wang et al. 2010; Sailer 
& Houlden, 2012); 
polyglutamine (polyQ) 
diseases (Guan et al 2013) 
TG7 TGZ, type 7 TG, TG7, 
transglutaminase 7 
Ubiquitously expressed, 
prominent in testis and 
lungs, cellular and sub-
cellular localization are 
unknown  
 Not known 
FXIII
A 
Factor XIII A, fibrin 
stabilizing factor, 
fibrinoligase, plasma 
TG, 
Laki-Lorand factor 
Chondrocytes platelets, 
placenta, astrocytes, 
macrophages, synovial 
fluid, heart, eye, bone, 
dendritic cells in the 
dermis  
Wound healing, blood 
clotting, bone growth 
 
F13A1 deficiency 
characterized by impaired 
wound healing, 
spontaneous abortion in 
women,  subcutaneous 
and intramuscular 
haematomas, severe 
bleeding tendency 
Band 
4.2 
Erythrocyte 
protein band 4.2, B4.2, 
ATP-binding 
erythrocyte membrane 
protein band 4.2 
Surface of erythrocyte 
membranes, bone 
marrow, foetal liver, 
spleen, membranal  
Key component of 
erythrocyte skeletal network, 
maintains erythrocyte 
integrity 
Spherocytic elliptocytosis 
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Transglutaminases catalyse the calcium-dependent post-translational modification of proteins 
by the insertion of isopeptide bonds between or within polypeptide chains with the resultant 
formation of polymerised cross-linked proteins (Aeschlimann & Paulsson, 1994). This 
product include the formation of isopeptide linkages between the γ-carboxamide group of the 
protein-bound glutamine residue and the ε-amino group of lysine residue, resulting to the 
formation of stable, insoluble, macromolecular complexes as products. Additionally, 
transglutaminases catalyse a number of distinct reactions that result in the post-translational 
modification of a specific glutamine residue in the substrate. The transglutaminase-catalysed 
reaction modifies the properties of protein substrates by altering their functions (Chen & 
Mehta, 1999; Esposito & Caputo, 2005). 
 
The biochemical mechanism responsible for TG activity involves ‘ping pong’ kinetics. The 
first, rate-limiting step is the formation of a thiol ester with an active cysteine site via the 
transamidation of γ-carboxamide group of the glutamine residue (with consequent release of 
ammonia) followed by the transfer of the acyl intermediate to a nucleophilic substrate, such 
as the ε-amino group of a peptide-bound lysine residue (Figure 1.0). Consequently, an 
intermolecular isopeptide ε-(γ-glutamyl)lysine cross-link is formed, whereas the monomeric 
protein units themselves may become internally cross-linked (Porta et al. 1991). In 
transamidation reactions, lysine can be replaced by lower molecular mass amines, especially 
polyamines, with the resultant formation of N-mono(γ-glutamyl)polyamine. The reaction can 
proceed to a covalent cross-linking between two polypeptide chains through a N,N-bis(γ-
glutamyl)polyamine bridge, in the presence of a further reactive glutamine residues. In the 
absence of polyamines, water can act as a nucleophile and cause deamidation of protein-
bound glutamine residues to convert Gln to Glu in the absence of suitable amines (Porta et al. 
1991; Esposito & Caputo, 2005).        
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Figure 1.0: Biochemical activities of TG2 at various cellular locations; the cytosol, nucleus, 
cell membrane, and extracellular space are denoted with C, N, M, and E respectively. Part (a) 
represents Ca
2+
-dependent activities, part (b) represents TG2’s biochemical functions that 
occur independent of Ca
2+
 (Adapted from Fesus & Piacentini, 2002). 
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A high degree of sequence similarity is shared among the various transglutaminase gene 
products, with the sequences around the active sites predominantly conserved. Investigation 
of the three-dimensional structure of FXIIIA and TG2 showed a cysteine proteinase-like 
active site made up of the catalytic triads, cysteine, histidine and aspartic acid that is needed 
for transamidation (Yee et al. 1994; Liu et al. 2002). A four-sequential domain arrangement 
is highly conserved in TG isoforms (Lorand & Graham, 2003). It is constituted by an N-
terminal β-sandwich, a catalytic core, and two C-terminal β-barrel domains. It has been 
proposed that glutamyl and lysyl substrates approach the enzymes from different directions, 
with glutamyl approaching from the direction of two β-barrels, and lysyl residues 
approaching the enzymes from the direction of the active site (Lorand & Graham, 2003). 
Although, the relative orientations of residues in the substrate-binding site region are highly 
conserved in TGs, there is a profound charge distribution variation surrounding the substrate 
binding site among the various isoenzymes. This disparity may justify the differences in 
substrate specificities and hence, the specialized functions of each isoenzyme (Esposito & 
Caputo, 2005).  
 
 
 
Figure1.1: A schematic representation of the four distinct domains shared by TGase: an N-
terminal β-sandwich, a catalytic core (containing Cys277, His335 and Asp358), and two C-
terminal β-barrel domains (adapted from Fesus & Piacentini, 2002). 
8 
 
1.3.0: TRANSGLUTAMINASE 2 (TG2), A UNIQUE MEMBER OF THE 
TRANSGLUTAMINASE FAMILY 
The human TGM2 gene localises to chromosome 20q11-12 and its exons span approximately 
37 kb (Gentile et al. 1994). The protein product, transglutaminase 2 (TG2) is made up of 687 
amino acids and has a calculated molecular mass of 77.3 kDa (Fesus & Piacentini, 2002; 
Gentile et al. 1994; Fraij & Gonzales, 1997). However, following the transcription of TG2 in 
the free cytoplasmic space, it is N-terminally modified by the removal of the first methionine 
residue and the N-acetylation of the next to the last alanine residue (Ikura et al. 1989). 
Transglutaminase 2 (TG2) is also known as tissue transglutaminase (tTG), cytosolic, type II, 
or liver transglutaminase. It is a unique member of the TGase family of enzymes; because in 
addition to the general transglutaminase enzymes’ primary activity of calcium-dependent 
posttranslational modification of proteins, it can also bind and hydrolyse GTP and may act as 
a small G protein (Lorand & Graham, 2003). It also has a protein disulfide isomerase activity 
and may function as a protein kinase (Hasegawa et al. 2003; Mishra & Murphy, 2004). 
Besides acting intra-cellularly, TG2 can play some extracellular roles by taking part in cell 
adhesion processes and stabilization of the extracellular matrix (Verderio et al. 2004). The 
uniqueness of TG2 as evidenced by its structural and functional elements, biochemical 
multifunctionality, ubiquitous tissue distribution and sub-cellular localization, and substrate 
specificity are discussed in the following subsections. 
 
1.3.1: Structural and functional elements of TG2 
The difference between other TGs and TG2, and the reasons for its multifunctionality are 
suggested by its structure, which is similar to those of other transglutaminases, but exhibits 
some specific features which are not characteristic of other transglutaminase gene products. 
Transglutaminase 2 is structurally composed of four distinct globular domains (figure 1.2): an 
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NH2-terminal β-sandwich which contains fibronectin and integrin binding sites, a catalytic 
core which contains the catalytic triads (Cys277, His335 and Asp358) for acyl-transfer 
reaction and a conserved tryptophan essential for this catalytic reaction (Murthy et al. 2002), 
and two COOH-terminal β-barrel domain with the second barrel domains containing a 
phospholipase C binding sequence (Hwang et al. 1995: Liu et al. 2002). 
 
Unlike other transglutaminase enzymes, TG2 possesses a distinctive guanidine nucleotide-
binding site, located in the cleft between the catalytic core and the first β-barrel (figure 1.3) 
(Liu et al. 2002), this sequence is coded by exon 10 of the TG2 gene, which is characterised 
by lower sequence homology with the same exons in other transglutaminases. Some 
GDP/GTP-interacting residues and those necessary for GTP hydrolysis are situated in other 
domains (Iismaa et al. 2000). In the GDP-bound form of TG2, access to the transamidation 
active site is blocked by two loops, and the active site cysteine is attached to a tyrosine 
residue by hydrogen bonding. In the latent conformation of TG2, there is a significant inter-
domain interaction between the catalytic domain 2 and domains 3 and 4, which reduces the 
accessibility of the active centre (Liu et al. 2002). 
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Figure 1.2: Schematic representation of the functional elements of TG2 indicating the four 
structural domains (arrows) and amino acid positions (top), with the different functional 
regions indicated: fibronectin/integrin binding site (FN/integrin), binding site for pro-
apoptotic BH3-only protein, nuclear localisation sequences 1 and 2 (NLS1 and NLS2), 
calcium binding site (Ca
2+
), GTP binding site, and phospholipase C (PLC) receptor site 
(adapted from Fesus & Piacentini, 2002).  
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Figure 1.3: A representation of the overall structure of a human tissue transglutaminase 
(TG2) dimer with bound GDP. TG2 is shown in ribbon drawing with the β-sandwich domain, 
the catalytic core domain, and the first and second β-barrel domain shown in green, red, cyan, 
and light green, respectively. The loops connecting the first β-barrel domain to the catalytic 
core and the second β-barrel are shown in blue. GDP is shown as a ball-and-stick model 
between the catalytic core and the first β-barrel (Liu et al. 2002). 
 
The structural conformation of TG2 in its Ca
2+
-bound form is yet to be resolved. A putative 
Ca
2+
-binding site, homologous to the one demonstrated in FXIIIA by Fox et al (1999), is 
distorted in the TG2 structure by the bound nucleotide (Liu et al. 2002). The binding of Ca
2+
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to the catalytic domain of TG2 alters the conformation of proteins as domains 3 and 4 are 
moved further apart from the catalytic domain, thus making the active site of TG2 accessible 
(Mariani et al. 2000; Liu et al. 2002); the hydrogen-bonded tyrosine is also displaced in the 
process (Noguchi et al. 2001). The ability of GTP to inhibit the transamidation activity of 
TG2 is determined by the potential of GTP to bind and subsequently hydrolyse Ser171 and 
Lys173 residues of the second domain (Iismaa et al. 2000).  
 
1.3.2: Tissue distribution and sub-cellular localization of TG2 
The expression of TG2 is not restricted to only few tissues or certain cell types, neither is it 
confined to a particular location in a cell (Thomazy & Fesus, 1989). Essentially, the cellular 
distribution of TG2 is ubiquitous, with its expression levels highest in endothelial cells and 
monocyte-derived macrophages; although, it is significantly expressed in vascular smooth 
muscle cells, connective tissue fibroblasts, osteoblasts, neurons, hepatocytes, astrocytes, and 
epidermal keratinocytes (as reviewed by Fesus & Piacentini, 2002; Lorand & Graham, 2003).  
 
Transglutaminase 2 is constitutively expressed in different types of cells, while in some other 
cells its expression is induced by external stimuli or as part of their differentiation/maturation 
(Zemskov et al. 2006). At the cellular level, TG2 is localized both inside the cell and on the 
cell surface as shown by the schematic representation in figure 1.4. 
 
 
 
 
 
 
13 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4: Cellular distribution of TG2 (black dot in yellow circle): TG2 is localised in the 
nucleus (nuclear TG2), cytoplasm (cytosolic TG2), and cell surface (extracellular TG2). It is 
translocated into the nucleus through the help of importin, while TG2 externalisation to the 
cell surface occurs through unknown mechanisms.   
 
1.3.2.1: Intracellular transglutaminase 2 
The intracellular location of TG2 is predominantly in the cytosol, however it has also been 
reported to be present in the nucleus and associated with the mitochondria (Telci & Griffin, 
2006). It is a cytosolic protein with greater proportion of its cellular pool (70-80%) present in 
the cytoplasm (Griffin et al. 2002; Lorand & Graham, 2003). As a result of low concentration 
of Ca
2+
 within the cytoplasm, the transamidating activity of TG2 is thought to remain 
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dormant inside the cell, while the protein functions as a GTPase (Nakaoka et al. 1994; Fesus 
& Piacentini, 2002). However, cytosolic TG2 can be activated by most cellular stressors 
which trigger extracellular calcium ion influx or release of calcium ion from the intracellular 
stores (Zemskov et al. 2006). The nuclear localisation of TG2 has been reported to be 
approximately 5% or less (Lesort et al. 1998). Cytosolic TG2 migrates to the nucleus in 
response to specific stimuli (Milakovic et al. 2004), and importin-3 is responsible for its 
translocation into the nucleus (Peng et al. 1999); where it can either function as a G-protein 
(Singh et al. 1995) or as a transamidase activated by nuclear  Ca
2+
  signals to cross-link 
histones (Ballestar et al. 2001). 
 
1.3.2.2: Cell surface transglutaminase 2  
A significant proportion of TG2 is found in association with membranes of different cell 
types (Aeschlimann & Thomazy, 2000). The localisation of TG2 on the surfaces of various 
cells types as well as in the extracellular matrix has been established (Upchurch et al. 1991). 
Irrespective of the lack of a leader sequence or transmembrane domain, which would have 
helped in the translocation of TG2 to the surface by the conventional endoplasmic 
recticulum/golgi route, the enzyme is secreted from cells in a controlled manner (Gentile et 
al. 1991; Gaudry et al. 1999; Di Venere, et al. 2000). However, the mechanism of TG2 
translocation across the phospholipid bilayer and the pathway of its externalization are not 
well understood. Available data shows that the externalization of TG2 is determined by a 
number of factors, which include a fibronectin-binding site in the N-terminal β-sandwich 
domain of TG2 (Gaudry et al. 1999), and the presence of a non-proline cis peptide bond at 
Tyr
274
 as justified by the loss of both the transamidation activity and secretion of the enzyme, 
following the mutation of this bond (Balklava et al. 2002). The third criterion for TG2 
externalization is the presence of a Cys
277 
intact site, necessary for the deposition of the 
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enzyme into the matrix (Balklava et al. 2002). Among these criteria, the presence of non-
proline cis peptide bonds is a conserved feature in a number of transglutaminases (Weiss et 
al. 1998), and was first identified in Factor XIII, which has two non-proline cis peptide bonds 
(Hettasch & Greenberg, 1994).  
 
On externalization, cell surface TG2 has been shown to facilitate cellular interactions with the 
surrounding extracellular matrix (ECM); which are critical physiological processes 
underlying many key aspects of cell behaviour, including cell adhesion, growth, migration, 
differentiation, programmed cell death, and ECM assembly (Zemskov et al. 2006).  In turn, 
these cellular processes are vital to embryogenesis and tissue morphogenesis, wound healing 
and tissue repair, as well as tumour growth and metastasis. Gentile et al. (1992) first 
suggested the involvement of transglutaminase 2 in the mediation of cell-matrix adhesion. 
They investigated the effect of TG2 over-expression on the spreading of fibroblasts and their 
increased resistance to trypsinization. Subsequent convincing proofs at both cellular and 
molecular levels support involvement of TG2 in the mediation of cellular interactions with 
ECM and it has been demonstrated that TG2 serves as an adhesion receptor for fibronectin 
(FN) on the cell surface (Verderio et al. 1998; Akimov et al. 2000; Belkin et al. 2001; Kabir-
Salmani et al. 2005). 
 
1.3.2.2.1: Transglutaminase 2 – fibronectin interaction 
Fibronectin (FN) is a high molecular weight (~540kD) dimeric modular glycoprotein present 
in the plasma membrane and ECM (Magnusson & Mosher, 1998). It is synthesised by most 
cell types, where it interacts with a variety of adhesion receptors, including one or more FN-
binding integrins (α5β1, αVβ3, αVβ5, αVβ6, α4β1, α4β7, αIIbβ3, α8β1, α9β1), and other 
transmembrane proteins; resulting in effects on cell proliferation, migration, and 
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differentiation (Mould & Humphries, 2004; Humphries et al. 2004). Pathologically, FN is 
profoundly involved in wound healing, inflammation, blood clotting and thrombosis, as well 
as tumour growth and angiogenesis (Zemskov et al. 2006). FN in its polymeric form, is 
represented in the extracellular matrix by fibrillar matrices (Wierzbicka-Patynowski & 
Schwarzbauer, 2003), which not only promote cell adhesion, but as well serve as a scaffold 
for assembly of other ECM molecules; and provide important orientations for surrounding 
cells, initiating cascades of signals upon interaction with cell surface receptors (Sottile  et al. 
2000; Pereira et al. 2002; Sottile & Hocking, 2002).   
 
TG2 has very high affinity for FN, to which it has been shown bind at 2:1 stoichiometry 
(LeMosy et al. 1992), independent of either Ca
2+ 
or the transamidating and GTPase activities 
of TG2 (Turner & Lorand, 1989). The interaction of extracellular TG2 with FN has been 
shown to be involved in cell-matrix adhesion (Akimov et al. 2000) and many other adhesion-
dependent phenomena, such as cell migration, matrix assembly and signalling (Akimov & 
Belkin, 2001; Verderio et al. 2003). The gelatin-binding domain (42kD) serves as the only 
binding site for TG2 on FN and binds TG2 with similar affinity as the whole FN (Radek et al. 
1993). Furthermore, the adhesive function of TG2 is favoured by the fact that the 42kD 
gelatin-binding domain of FN contains no interaction sites for the numerous FN-binding 
integrins, as well as other FN-associated adhesion receptors (figure 1.5) (Hang et al. 2005). 
Therefore, TG2 and integrins can independently bind distinct domains of FN, consequently 
existing in collaboration rather than engaging in competition in the cell adhesion process 
(Zemskov et al. 2006). It has been established in different cell types that the binding of TG2 
to the 42kD fragment of FN results in stable cell adhesion, limited spreading and formation of 
specialized adhesive structures at the cell-substrate interface (Belkin et al. 2001; Akimov & 
Belkin, 2001). 
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Figure 1.5: A representation of the molecular interactions of FN with tTG and other adhesion 
receptors showing the localization of the binding sites for tTG, integrins and other adhesion 
receptors on the FN molecule. Modular structure of FN is presented for one of its chains, with 
type I modules shown in red, type II modules in green, and type III modules in blue. Yellow 
coloured domains (A and B) are  Pro–His–Ser–Arg–Asn (PHSRN) peptides, one of the FN 
cell-binding domains that activates integrins, purple domain (1) represents an extended 
binding site for incoming FN (an epitope for mAb L8) (Hang et al. 2005; Zemskov et al. 
2006). 
 
1.3.2.2.2: Transglutaminase 2 – integrin interaction 
Integrins represent a large class of transmembrane adhesion receptors constituted by non-
related α and β subunits (Hynes, 2002). In different cell types apart from red blood cells, 24 
integrin heterodimers constituted by 8 β subunits and 18 α subunits have been identified, 
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serving as receptors for a number of ECM ligands and taking part in adhesion between cells 
(Hynes, 2002; Humphries et al. 2004). Regardless of the co-existence of TG2 and integrins at 
different FN-binding domians, where they streamline the cell adhesion process; TG2 also 
associates with integrins to maintain cell-extracellular matrix (ECM) interactions.  
 
The role of integrins in wound healing, blood clothing and thrombosis, viral and bacterial 
infection, inflammation, tumour growth and angiogenesis, as well as other pathological and 
physiological states are testaments to the fundamental functions of integrins in cell-matrix 
adhesion (Zemskov et al. 2006). In different cell types, transglutaminase 2 has been shown to 
associate with many integrin receptors, by binding to the extracellular domains of the β1 and 
β3 integrin subunits (Akimov et al. 2000; Akimov & Belkin, 2001; Belkin et al. 2001). 
 
The stable non-covalent TG2-integrin complexes are formed independent of the 
transamidating activity of TG2, and there is no evidence of integrins serving as enzymatic 
substrates of TG2 or other transglutaminases (Akimov et al. 2000). Furthermore, Akimov et 
al. (2000), in a set of biochemical experiments performed on cells that do not synthesize FN, 
demonstrated that the TG2-integrin interaction is not FN-mediated but direct. They further 
observed that integrin-TG2 complexes have 1:1 stoichiometry and all cell-surface TG2 is 
bound to integrin receptors; with the possibility of up to 40% of β1 integrins associating with 
TG2 in various cell types (Akimov et al. 2000; Akimov & Belkin, 2001). The ability of TG2 
to form ternary adhesive complexes with integrins and FN, where all the three proteins 
successfully interact with each other (Zemskov et al. 2006), highlights the importance of TG2 
effects on cell adhesion and indicates an unconventional role of TG2 as a co-receptor in cell-
matrix interactions (Akimov et al. 2000). 
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1.4.0: BIOCHEMISTRY OF TG2 
Transglutaminase 2 is a multifunctional protein that serves as a mediator between several 
distinct biochemical functions at various cellular locations (figure 1.4). The diverse 
physiological implications of TG2 are testament to the importance of its diverse biochemical 
activities in cellular functions.   
 
The cross-linking activities of TG2 are Ca
2+
-dependent and result from acyl-transfer reaction 
between γ-carboxamide group of a specific protein-bound glutamine and either the ε-amino 
group of a distinct protein-bound lysine residue or primary amines like polyamines and 
histamine (Fesus & Piacentini, 2002). The reaction primarily involves the exchange of 
primary amines for ammonia at the γ-carboxamide group of glutamine residues, in the 
presence of Ca
2+ 
(Mehta & Chen, 1999). The binding of Ca
2+
 is vital to the cross-link 
formation because it initiates a conformational change that exposes a cysteine residue in the 
active site domain; the cysteine reacts with the glutamine substrate, resulting to the formation 
of an acyl-enzyme intermediate and release of ammonia (Iismaa et al. 2003). The subsequent 
reaction between the acyl-enzyme complex and a primary amine results to the formation of γ-
glutamyl-amino cross-link, and concomitant release of the enzyme (Aeschlimann & Paulsson, 
1994; Iismaa et al. 2003; Pinkas et al. 2007). Other biochemical functions of TG2 include 
site-specific deamidation, during which water can replace amine donor substrate, amounting 
to the deamidation of the recognized glutamines (Fesus & Piacentini, 2002). Furthermore, 
TG2, just like factor XIIIA, exhibits isopeptidase activity in the presence of Ca
2+
, and has 
been shown to hydrolyse γ:ε isopeptides (Parameswaran et al. 1997).  
 
At the cell membrane, TG2 plays a role in transmembrane signalling by transmitting signals 
from seven-transmembrane helix receptors to phospholipase C (Iismaa et al. 2000). 
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Following the stimulation of these transmembranal helix receptors, TG2 binds to and 
activates phospholipase C and proper regulation of the transmembrane signalling is ensured 
by its endogenous GTPase activity (Murthy et al. 1999). Transglutaminase 2 interaction with 
specific molecules such as sphingosylphosphocholine, could reduce the Ca
2+
 requirement for 
the transglutaminase activity (Lai et al. 1997). This activity is highly influenced by nitric 
oxide such that up to 15 of the 18 cysteine residues can be nitrosylated and denitrosylated in a 
Ca
2+
 -dependent fashion, resulting in TG2 inhibition and activation respectively (Lai et al. 
2001).  
 
A very striking part of TG2 function is its translocation to the nucleus under certain unknown 
conditions, with the help of importin-α3 (Peng et al. 1999); where it can crosslink histones  
by nuclear Ca
2+ 
-dependent activation, serving as a transamidase (Ballestar et al. 2001) or 
functioning as a G protein (Singh et al. 1995). In a different vein, TG2 has been reported to 
be involved in the determination of the apoptotic fate of cells. The over-expression of TG2 
primes cells for apoptosis (Fesus et al. 1987) and its inhibition by antisense strategy results to 
reduced cell death (Oliverio et al. 1999). Piacentini et al. (2002) suggested that TG2 
sensitizes cells for apoptosis by interacting with mitochondria, resulting in mitochondrial 
shift to higher polarised state and altered redox status; which might lead to the activation of 
transglutaminase cross-linking activity (Lesort et al. 2000). During the later stage of 
apoptosis, membrane polarity is usually negated, resulting in a massive influx of Ca
2+ 
into the 
cytosol. This increase in cytosolic Ca
2+ 
leads to the acute activation of originally inactive 
TG2 to its cross-linking configuration in all sub-cellular compartments; and consequent 
extensive polymerization of intracellular proteins and formation of detergent-insoluble 
structures (Fesus et al. 1989). These insoluble protein scaffolds are functionally significant as 
they stabilize the structure of a dying cell prior to its phagocytotic clearance, hence, 
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preventing the release of harmful intracellular components and the concomitant inflammatory 
or autoimmune responses (Piredda et al. 1997). 
 
1.4.1: Regulation of TG2 expression and catalytic activity 
Transglutaminase 2 is involved in diverse physiological responses and as such, its expression 
is regulated by many factors. It can be regulated by various cytokines, hormones, and drugs 
(see reviews by Mehta & Chen, 1999; Lesort, et al. 2000; Aeschlimann & Thomázy, 2000). 
The pattern of TG2 regulation has been demonstrated to be cell type-specific. For instance, 
the intracellular polyamines, spermine and spermidine, that serve as acyl acceptor substrates 
for transglutaminases (Folk, 1980; Janne et al. 1991) are capable of modulation of TG2 
expression (Mehta & Chen, 1999). However, the blockage of polyamine synthesis in different 
cell types was shown to differently influence TG2 expression by effecting decreased 
expression in one cell type and increased expression in another (McCormack et al. 1994; 
Wang et al. 1998). 
 
Treatment of different cell types with natural and synthetic retinoids especially retinoic acid 
(RA), have been shown to induce dramatic increase in TG2 expression, at both transcriptional 
and translational (mRNA and protein) levels (Davies et al. 1985; Chiocca et al. 1988; 
Defacque et al. 1995; Zhang et al. 1995). Retinoic acid-mediated induction of TG2 has also 
been demonstrated in vivo; where Verma et al. (1992) observed a significant reduction in the 
level of TG2 in various tissues of a vitamin A-deficient rat, and increasing production of TG2 
by the same tissues on resumption of vitamin A-containing diets. 
 
From a catalytic perspective, TG2 could be recognized as a bi-functional enzyme, owing to 
its ability to catalyse the Ca
2+ 
-dependent protein cross-linking and Ca
2+ 
-independent GTP 
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and ATP hydrolysis (Mehta & Chen, 1999). In essence, the cross-linking function of TG2 is 
allosterically activated by Ca
2+ 
-ion and reversibly inhibited by GTP, GDP, and GMP; 
whereas, it is not influenced by physiological concentrations of ATP or CTP (Lai et al. 1998; 
Lai et al. 2001). However, the GTPase and ATPase activity of TG2 occurs independent of 
Ca
2+
,
 
but depends on Mg
2+
 -ions because Mg
2+ 
-GTP and Mg
2+ 
-ATP are the true substrates 
for TG2-mediated hydrolysis reaction (Lai et al. 1998). Furthermore, Lai et al (1998) 
demonstrated that the binding of Mg
2+ 
-GTP complex to TG2 results to a conformational 
change which inhibits TG2 protein cross-linking activity without affecting its ATPase 
activity. They further established that the Mg
2+
 -ATP interaction with TG2 induces a 
conformational alteration that results in the inhibition of the GTPase activity without 
affecting its protein cross-linking propensity.
 
In essence, these results suggest that the 
concentrations of Mg
2+ 
-nucleotide complexes may be of vital importance in the modulation 
of TG2 activities. Furthermore, a membrane lipid, sphingosylphosphocholine (lyo-SM), has 
been suggested to be a potent activator of TG2 cross-linking activity (Lai et al. 1997). 
 
The over-expression of TG2 does not necessarily lead to increased cross-linking activity. For 
instance, Smethurst and Griffin (1996), while measuring TG2 activity in permeablised human 
endothelial cell system; showed that TG2 exists as a cryptic enzyme under normal cell 
physiological conditions. This finding is particularly important as it demonstrated that the 
presence of TG2 is not always accompanied by its protein cross-linking activity inside living 
cells. 
 
1.4.2: Substrate specificity and cellular substrate proteins of TG2 
Transglutaminase 2 is a multifunctional protein with over 130 substrates at various locations 
inside and outside the cell (Csosz et al. 2009). This broad range of specificity of TG2 for its 
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targets may account for its flexibility and multi-functionality. To achieve a particular function 
out of its variety of functions necessitates that the selection of specific subset of proteins 
related to that particular biological event must be tightly regulated by additional factors. TG2-
specificity determining factors are numerous and include such factors as cell type- and tissue-
dependent abundance of the enzyme and its substrate, availability of Ca
2+
, the absence of 
inhibitors, the presence of modifying substances like sphyngosylphosphocholine (Lai et al. 
1997) and nitric oxide (Lai et al. 2001), and the physical accessibility of modification sites on 
the individual molecules. 
 
An understanding of the in situ TG2 substrates and its specificity to the substrates is needed 
in order to understand the physiological and pathological roles of TG2 (Csosz et al. 2008). 
The binding site in TG2 is organised in such a way that it permits the proper orientation of 
peptide-bound residues of glutamine, whilst neither free glutamine nor asparagine is used by 
the enzyme; even in the midst of a strong stereo-specificity towards the L-isomer (Folk, 
1983). The possession of an extended active site by TG2 and its interaction with 
oligopeptides as proposed by Folk (1983) probably influences the catalytic efficiency of TG2 
towards glutamine side chains of substrates. The role of different amino acids in TG2 
substrate effectiveness was studied by Gorman & Folk (1981; 1984). They observed that the 
positions of the different amino acids are important factors determining TG2 substrate 
requirement. 
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Table 2: In vivo substrates of TG2, reactive sites, cellular localizations, and possible 
involvement in human physiology/diseases (as reviewed by Odii and Coussons, 2014) 
 
TG2 substrate Reactive site Localization Physiology/disease 
Acetylcholine esterase Glutamine  Intracellular  Neurological disease (Hand et al. 2000) 
Actin Glutamine and lysine Intracellular  
Cytoskeleton regulation (Nemes et al. 
1997) 
Aldolase 
Reactive glutamine 
present but specific 
residue is unknown  
Intracellular  
Genetic disease, endocrine and metabolic 
diseases, autoimmune and inflammatory 
diseases (Lee et al. 1992)  
Androgen receptor  
Intracellular 
(nuclear 
receptor) 
Endocrine and metabolic diseases 
(Mandrusiak et al. 2003) 
Annexin I (lipocortin I) Glutamine  Intracellular  
Autoimmune and inflammatory diseases, 
cytoskeleton regulation (Ando et al. 1991) 
Calgizzarin - S100C 
protein - MLN 70 – 
S100A11 
Glutamine and lysine 
Keratinocyte 
cornified 
envelope  
Endocrine and metabolic diseases, 
dermatological diseases (Robinson & 
Eckert, 1998) 
Collagen alpha 1(III) Glutamine  Extracellular  
Extracellular matrix interaction and 
stabilization, autoimmune and 
inflammatory diseases (Orban et al. 2004)  
α - B-crystallin Lysine Intracellular  
Cell life and death, cytoskeleton regulation, 
protein stabilization (Groenen et al. 1992) 
β - A3 crystallin Glutamine  Intracellular  
Cell life and death, cytoskeleton regulation, 
protein stabilization (Groenen et al. 1994) 
β -  B3 crystallin Glutamine  Intracellular  
Cell life and death, cytoskeleton regulation, 
protein stabilization (Berbers et al. 1984) 
β -  Bp (betaB2) 
crystalline 
Glutamine  Intracellular  
Cell life and death, cytoskeleton regulation, 
protein stabilization (Berbers et al. 1984) 
Cytocrome c Glutamine  Intracellular  
Cell life and death (Butler & Landon, 
1981) 
Fibronectin Glutamine  Extracellular  
Protein stabilization, extracellular matrix 
interaction and stabilization (Mehta et al. 
2006) 
Fibrinogen A alpha Glutamine and lysine  Extracellular  
Extracellular matrix interaction and 
stabilization, autoimmune and 
inflammatory diseases (Murthy et al. 2000) 
Glutathione S-
transferase 
Glutamine, lysine, 
fluorescine  
Intracellular  
Extracellular matrix interaction and 
stabilization (van den Akker et al. 2011) 
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Gluten proteins Glutamine  Extracellular Celiac disease (Kim et al. 2002) 
Glyceraldeheyde 3 
phosphate 
dehydrogenase 
Lysine  Intracellular  Neurological diseases (Orru et al. 2002) 
H3 histone Glutamine Intracellular  Cell life and death (Ballestar et al. 1996) 
H4 histone Glutamine  Intracellular  Cell life and death (Ballestar et al. 1996) 
H2A histone Glutamine  Intracellular  Cell life and death (Ballestar et al. 1996) 
H2B histone Glutamine  Intracellular  Cell life and death (Ballestar et al. 1996) 
Importin alpha3  
Nuclear 
transport 
protein  
Cell life and death (Kuo et al. 2011) 
α - Ketoglutarate 
dehydrogenase 
Lysine  Intracellular  
endocrine and metabolic diseases (Cooper 
et al. 1997) 
Latent TGF-beta 
binding protein-1 
(LTBP-1) 
 Extracellular  
Carcinogenesis, autoimmune and 
inflammatory diseases (Verderio et al. 
1999)  
α --2-Macroglobulin 
receptor-associated 
protein 
Glutamine  Extracellular  
autoimmune and inflammatory diseases 
(Rasmussen et al. 1999) 
Microtubule-associated 
protein tau - isoform 
Tau-F (Tau-4) 
Glutamine and lysine  Intracellular  
Cytoskeleton regulation, neurological 
diseases (Murthy et al. 1998) 
Myosin  Intracellular  
Cytoskeleton regulation (Eligula et al. 
1998) 
Nidogen  Glutamine  Extracellular  
Extracellular matrix interaction and 
stabilization (Aeschlimann et al. 1992) 
Osteocalcin  Extracellular  
Autoimmune and inflammatory diseases 
(Kaartinen et al 1997) 
Osteonectin Glutamine  Extracellular  
Autoimmune and inflammatory diseases, 
extracellular matrix interaction and 
stabilization (Aeschlimann et al 1995) 
Osteopontin Glutamine  Extracellular  
Autoimmune and inflammatory diseases, 
extracellular matrix interaction and 
stabilization (Kaartinen et al. 2002) 
Phospholipase A2 Glutamine  Extracellular  
Endocrine and metabolic diseases, Signal 
transduction, autoimmune and 
inflammatory diseases (Cordella-Miele et 
al 1990; Fesus & Piacentini, 2002) 
Troponin T  Intracellular  Cytoskeleton regulation (Gorza et al. 1996) 
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TG2 substrates are widely localised within the cellular and sub-cellular spaces of the cell 
(table 2). The recognition and post-translational modification of extracellular TG2 substrates 
have been implicated in some extracellular physiological functions like the stabilisation of 
extracellular matrix (ECM) and cell-ECM interactions through the cross-linking of matrix 
proteins (Aeschlimann & Thomazy, 2000). FN, an abundant extracellular protein, is a major 
TG2 substrate in vitro and in vivo (Jones et al. 1997). Under normal cellular physiological 
conditions, TG2 externalised from cells becomes tightly bound to FN and forms ternary 
complexes with collagens that function as a cementing substance in the ECM. This 
mechanism is used to clean up TG2 from the circulation, hence preventing it from causing 
any adverse effects (Esposito and Caputo, 2005). Other TG2 substrates that are involved in 
the assembly, remodelling and stabilisation of the ECM are fibrinogen, fibrin (Ritchie et al. 
2000), von Willebrand factor (Takagi et al. 1995), vitronectin (Skorstengaard et al. 1990), 
laminin and nidogen (Aeschlimann et al. 1992), liprotein(a) (Borth et al. 1991). TG2 
stabilises the reversible interactions between molecules that form heteromeric complexes in 
the ECM of specific tissues, e.g. laminin-nidogen (Aeschlimann et al. 1992), FN-collagen 
(Kleman et al. 1995), osteonectin-vitronectin (Rosenblatt et al. 1997). 
 
Intracellularly, a large number of TG2 substrates abound, especially proteins involved in the 
organisation of the cytoskeleton. As a result of its auto-catalytic activity, TG2 isoform in the 
cytoskeleton co-localises with stress fibres and cross-links myosin (Esposito and Caputo, 
2005). Upon activation by Ca
2+
, TG2 contributes to the organisation of the cytoskeleton by 
cross-linking various cytoskeletal proteins, such as β-tubulin, actin, microtubule protein tau, 
myosin, spectrin, thymosin β, troponin, and vimentin (Tucholski et al. 1999; Piredda et al. 
1999; Orru et al. 2003). The function of this extensive polymerisation which occurs at the 
final step of apoptosis is thought to be involved in the stabilisation of the structures of the 
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dying cells, hence, preventing the release of cellular components that could cause 
inflammatory or autoimmune responses (Fesus & Piacentini, 2002). Furthermore, actin, 
retinoblastoma gene product, and nuclear proteins such as core histones, are TG2 substrates 
in vivo (Nemes et al. 1997; Ballestar et al. 1996); and the extensive polymerisation of these 
proteins has been established as a key signal for the initiation of apoptosis (Oliviero et al. 
1997).  
 
1.5.0: PHYSIOLOGY OF TG2 
Physiologically, the Ca
2+
-dependent activation of TG2 has been implicated in many 
biological functions as diverse as extracellular matrix stabilization during development and 
wound healing, hormone receptor signal transduction as G-protein, cell growth and 
differentiation, cell adhesion and morphology, receptor-mediated endocytosis, cornified 
envelope formation in the keratinocytes, apoptosis, and cancer drug resistance and metastasis 
(Mehta & Chen, 1999).  
 
1.5.1: Transglutaminase 2 in apoptosis 
Fesus et al. (1987), on observing that lead-induced hypertrophy in the liver of rats was 
associated with an increased expression of TG2, suggested the initial link between TG2 and 
apoptosis. Since then, many reports have shown the involvement of TG2 in apoptosis (see 
Piacentini et al. 2005 for a review). TG2’s involvement in apoptosis could be better described 
as a double-edged sword as it could be pro-apoptotic or anti-apoptotic. Cells undergoing 
apoptosis show an increased level of TG2 expression, which primes the cell to undergo 
apoptosis. Its inhibition however, results in a decreased propensity for cell death (Mehta et al. 
2006; Verma & Mehta, 2007).   
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TG2-mediated pro-apoptosis is underlied by its cross-linking configuration, which requires a 
millimolar concentration of calcium. Stressful conditions such as ultraviolet radiation, and/or 
chemotherapeutic agent, can generate reactive oxygen species (ROS) with resultant induction 
of TG2 (figure 1.6). Increase in the stressful conditions further triggers the release of Ca
2+
 
from the endoplasmic reticulum (ER), resulting in the activation of TG2 and extensive cross-
linking of intracellular proteins, which in turn, initiates the apoptotic process (Mangala & 
Mehta, 2005; Mehta et al. 2006). A major physiological significance of TG2’s involvement 
in apoptotic initiation is its mediation of the crosstalk between dying and phagocytic cells, to 
ensure tissue and cellular integrity. The focal function of TG2 in apoptosis is to ensure that 
once the apoptotic process is initiated, it is completed without inflammation of tissue injury 
resulting from the process (Fesus & Szondy, 2005). TG2 can achieve maintenance of a 
cellular environment devoid of inflammation, whilst promoting apoptosis by directly 
promoting apoptosis in certain cell types (Oliverio et al. 1999; Rodolfo et al. 2004), or 
indirectly promoting the activation of TGF-β release by the macrophages, that can promote 
the death of various cells (Szondy et al. 2003; Huang & Lee, 2003), to ensure that all 
unwanted cells are efficiently killed preventing the occurrence of necrosis. Additionally, TG2 
can promote chemo-attractant formation and the release of phosphatidylserine to respectively 
aid macrophage migration to the site of apoptosis and the recognition of apoptotic cells 
(Nishiura et al. 1998; Fesus & Szondy, 2005).   
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Figure 1.6: Mechanisms of TG2-mediated pro-apoptosis and anti-apoptosis. In the presence 
of cellular stressors such as chemotherapy or UV radiation, release of intracellular Ca
2+
 from 
endoplasmic reticulum (ER) results in the activation of TG2 and intracellular protein 
crosslinking. Consequently, apoptosis is initiated and cellular contents are prevented from 
spillage, hence inflammation is prevented. Conversely, the activation of TG2 can result in 
concomitant activation of NFKβ and induction of anti-apoptotic genes and inhibition of pro-
apoptotic genes (adapted from Mehta et al. 2006). 
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Just as TG2 could prime the cells to commit to death, so also could it protect the cells from 
dying. The anti-apoptotic effect of TG2 is mediated by TG2 in the nucleus and cell 
membrane. Nuclear TG2 protect cells from death by interacting with pRb, polymerising the 
alpha-inhibitory sub-unit of the transcription factor, NF-kappaB, hence, activating, 
transcriptional regulation of several key anti-apoptotic genes (Boehm et al. 2002). Similarly, 
TG2 can translocate to the cell membrane where it serves as a co-receptor for integrins, 
promoting their interaction with FN (figure 1.6). TG2-mediated interaction between integrins 
and FN could result to the activation of cell survival and anti-apoptotic signalling pathways, 
and extracellular matrix stabilisation (Mehta et al. 2006). Also, in the extracellular space, 
TG2 can maintain self-sustainability by activating latent transforming growth factor beta 
(TGF-β), which in turn up-regulates TG2 (Fesus & Szondy, 2005).  
 
From the foregoing review, it is tempting to conclude that the pro-apoptotic or anti-apoptotic 
effect of TG2 is dependent on the activation pathways and location; with nuclear and 
extracellular TG2 effecting anti-apoptosis while cytosolic TG2 is pro-apoptosis in agreement 
with the findings of Milakovic et al. (2004). 
 
1.5.2: Transglutaminase 2 in disease pathology 
For the multi-functionality and ubiquitous tissue distribution of TG2, it is not surprising that 
its involvement in many pathological conditions has been variously demonstrated. TG2 has 
been shown to be involved in many chronic diseases, especially in (a) inflammatory diseases, 
including wound healing, tissue repair and fibrosis, and autoimmune diseases; (b) chronic 
degenerative diseases such as arthritis, atherosclerosis, and neurodegenerative conditions like 
Alzheimer’s and Parkinson disease; (c) malignant diseases; and (d) metabolic diseases such 
as diabetes mellitus (Griffin et al. 2002; Facchiano et al. 2006).  In most of these diseases, the 
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role of TG2 has been related to the deregulation of its functions, especially those pertinent to 
its interaction with, and stabilisation of cellular matrix, rather than its involvement in 
apoptosis. 
 
1.5.2.1: Transglutaminase 2 in autoimmune diseases 
In autoimmune diseases such as celiac disease, the presence of autoantibodies against TG2 
and other substrates is an indication that TG2 may cross-link potential autoantigens to itself 
and to other protein substrates, in order to trigger an immunological response typical for 
autoimmune diseases (Sollid et al. 1997; Kim et al. 2002). TG2 function in celiac disease is 
related to the deamidation of the side chains of glutamine, which is abundant in gluten 
proteins. This deamidation reaction results to an improvement in the binding capacity of 
gluten to DQ2 and response of T-cell clones (Quarsten et al. 1999; Arentz-Hansen et al. 
2000). Additionally, it has been reported that gluten peptides incubated with TG2 create 
covalent complexes through thioester bond to active site cysteine of TG2 and via isopeptide 
bonds to particular lysine residues of TG2 (Fleckenstein et al. 2004). Hence, gluten proteins 
and their peptide derivatives serve as substrates of various TG2-catalysed reactions 
(Facchiano et al. 2006). Recently, deamidation of gluten-derived gliadin peptides by TG2 
was shown to be responsible for gliadin-induced toxicity and immune response in the small-
intestinal mucosa (Rauhavirta et al. 2013). Consequently, Rauhavirta and colleagues 
suggested that the inhibition of TG2 can reduce gliadin-induced effects (Rauhavirta et al. 
2013). In another study, Oh et al. (2013) reported that the initiation of allergen response in 
pulmonary epithelial cells requires TG2. 
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1.5.2.2: Transglutaminase 2 in inflammatory diseases   
In inflammatory diseases, TG2 plays its role via its regulatory action on granule secretion and 
macrophage function, or by regulating the function of major inflammatory mediators like 
phospholipase A2 (Cordella-Miele et al. 1990). The involvement of TG2 in inflammatory 
diseases and related processes such as angiogenesis and wound healing has been reported 
(Sohn et al. 2003; Verderio et al. 2005). It is an important player in the pathogenesis of 
chronic inflammatory diseases like rheumatoid arthritis and osteoarthritis by transforming the 
latent transforming growth factor binding protein-1 into its active form, TGF-β (Nunes et al. 
1997). Recently, TG2 has been reported to be directly involved in chronic kidney disease 
(CKD), where it is involved in the pathogenesis of vascular calcification through the 
enhancement of matrix vesicle-ECM interaction (Chen et al. 2013). Similarly, on analysis of 
TG2:creatinine ratio in relation to albumin:creatinine ratio in CKD patients, (da Silva et al. 
2013) suggested TG2 as a potential biomarker for CKD detection and progression 
assessment.  
 
1.5.2.3: Transglutaminase 2 in neurological and metabolic diseases 
In vitro and/or in vivo, many TG2 substrates  have been found in the neuronal cellular 
compartments, e.g. amyloid beta-A4 peptide, alphasynuclein, the microtubule-associated tau 
protein, synapsin I, and myelin basic protein (reviewed by Facchiano et al. 2006). TG2-
mediated cross-linking is believed to be implicated in neurodegenerative diseases such as 
Huntington’s, Alzheimer’s and Parkinson’s diseases (Kim et al. 2002; Bailey et al. 2005) and 
in diseases related to neurotransmitter release (Deloye et al. 1997). Similarly, the possible 
involvement of TG2 in neurotransmitter release and related pathological conditions like 
tetanus neurotoxin intoxication has been reported (Pastuszko et al. 1986; Facchiano & Luini, 
1992). 
33 
 
1.5.2.4: Transglutaminase 2 in metabolic diseases 
The covalent modification of TG2 substrates such as GAPDH, alpha-ketoglutarate 
dehydrogenase, phosphoglycerate dehydrogenase and fatty acid synthase (Orru et al. 2003) 
involved in energy metabolism, could account for the role of TG2 in metabolic diseases. 
Additionally, TG2-mediated covalent modification of hormones receptors or hormone-
binding proteins is an indication that TG2-catalysed cross-linking may be involved in 
controlling complex metabolic responses to hormones (Sakai et al. 2001; Mandrusiak et al. 
2003). The involvement of TG2 in the regulation of insulin secretion, and diabetes mellitus 
has also been suggested (Bernassola et al.2002; Bungay et al. 1984).  
 
1.5.3:  Transglutaminase 2 and cancer 
The body of an animal is analogous to a society or an ecosystem; the constituent members are 
cells, which reproduce by cell division and form collaborative assemblies, i.e. tissues. 
However, unlike conventional human society, where survival of the fittest is the order of the 
day, self-sacrifice is the rule in normal cellular society. Thus, cells of a multicellular 
organism are subject to tightly regulated form of collaboration, apparently devoid of 
competition and selfishness. Consequently, each cell behaves in a socially responsible 
manner, and must rest, grow, divide, differentiate, or die, as needed for the good of the 
cellular community and the organism. The behaviours of the cells are regulated by a social 
control network that ensures that the cells send, receive, and interpret an elaborate set of 
extracellular signals- this is done via the cell cycle control system (Tlsty and Coussens, 2006; 
Albert et al. 2008). Any attempt to disobey the societal rules by a given cell or group of cells 
could be disastrous for the multicellular society. Most dangerously, a successful defiance of 
the cell cycle control system through molecular disturbances, such as mutations may result in 
a given cell becoming selectively advantaged, hence, growing and dividing more vigorously 
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and surviving more readily than its neighbours. This cell therefore, becomes the progenitor of 
a growing mutant clone, promoting selfishness among members of the cellular society as 
opposed to the original selflessness. Over time, this new wave of successive rounds of 
mutation, competition, and natural selection operating within the cellular population could 
degenerate to serious cellular conditions, characterised by over-proliferation resulting in 
cancer (Albert et al. 2008).    
 
Cancers are heterogeneous multicellular entities constituted by cells of multiple lineages, 
interacting with one another, the ECM, and soluble molecules within their vicinities in 
dynamic fashions that favour cell proliferation, movement, differentiation, and ECM 
metabolism; whilst restricting cell death, stationary polarised growth and ECM stability 
(Tlsty and Coussens, 2006). They are cellular diseases, especially emanating from the 
disruption of cellular programs either intrinsically or extrinsically. For instance, genomic 
alterations affecting intrinsic cellular programs, such as cell cycle check-point control, 
apoptosis, differentiation, metabolism, and cell adhesion; or/and those affecting the extrinsic 
programs, such as tissue oxygenation, matrix metabolism, immune response, and vascular 
status (McCormick, 2004).  
 
1.5.3.1: Roles of TG2 in definition of cancer hallmarks 
Tumorigenesis in humans is a multistep process, with each step reflecting the genetic 
alterations that drive the progressive transformation of normal human cells into highly 
malignant sub-clones. Studies of human cancers and animal models have shown that the 
process of tumour development is analogous to Darwinian evolutionary processes, in which a 
succession of genetic changes, each conferring a given type of growth advantage, results to 
the progressive conversion of normal human cells into cancer cells (Nowell, 1976; Hanahan 
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& Weinberg, 2000).   Hanahan & Weinberg, (2000) proposed that the vast catalogues of 
cancer cells’ genotype are testaments of this succession of genetic alterations in cell 
physiology that lead to development of malignant phenotype. They classified such genetic 
alterations into six essential features, termed the hallmark capabilities of cancer, including 
sustaining proliferative signalling, insensitivity to antigrowth signals, evasion of apoptosis, 
unlimited replicative potential, sustained angiogenesis, and tissue invasion and metastasis 
(see figure 1.7).  
 
TG2, as a multifunctional protein with a broad range of substrate specificity has been 
implicated in many genetic alterations in cellular physiology that define these hallmark 
capabilities in different types of cancer. The abundant distribution of TG2 in various cells of 
different origins and its broad substrate specificity support its involvement in definition of 
many important cancer cells’ physiologies that encourage selfishness. TG2-related activities 
have been implicated in the enhancement of cell to cell interaction, ECM stabilisation, and 
interaction with and modification of intracellular and extracellular proteins in favour of 
cellular proliferation, migration, evasion of apoptosis, and insensitivity to death signals. The 
involvement of TG2 in the determination of these features that define the hallmark 
capabilities of cancer cells is discussed in the sections below.    
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Figure 1.7: The Hallmarks of cancer as proposed by Hanahan & Weinberg, (2000), 
representing the acquired capabilities of cancer cells. Tumour cells defy the cell cycle control 
system and become insensitive to anti-growth signals, self-sufficient in growth signals, 
insensitive to death signals (evade apoptosis) and uncontrollably proliferative. Consequently, 
mutant clones accumulate in excess of the carrying-capacity of the basement membrane of 
the host tissue, resulting in invasion of neighbouring tissues. The need for oxygen and 
nutrient through blood supply triggers development of new, defective blood vessels 
(angiogenesis) that encourage leakage of mutant cells to distant sites (metastasis).  
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1.5.3.1.1: Transglutaminase 2 in cancer acquisition of self-sufficiency in growth signals 
Normal cells typically move from quiescent state into active proliferative state only when 
there is appropriate supply of necessary mitogenic growth signals. These signals are 
transmitted into the cell by transmembrane receptors that interact with various classes of 
signalling molecules, including diffusible growth factors, ECM components, and inter-cell 
adhesion/interaction molecules, including TG2 (Witsch et al. 2010). In one hand, the role of 
TG2 in growth promotion and maintenance of self-sufficiency in tumour cells could be 
attributed to its activation of the growth factor, TGFβ leading to promotion of cell growth and 
survival. On the other hand, TG2 can be involved in tumour growth sufficiency through its 
interactions with various adhesion molecules, including integrin and FN, resulting in 
stabilization of extracellular matrix and activation of cell survival signalling (Mehta et al. 
2006). The production and release of growth-promoting signals are carefully controlled in 
normal tissues, ensuring the homeostasis of cell number and maintenance of normal tissue 
architecture; whilst entering into and progressing through the cell growth and division cycles 
(Hanahan & Weinberg, 2011). One of the fundamental features of cancer cells is their 
acquired ability to sustain proliferation, as they mostly show reduced dependence on 
stimulation from their normal tissue microenvironment. They maintain self-sufficiency in 
growth signal by dysregulating the mitogenic signals to their own advantage; thus, becoming 
independent of exogenous signals (Hanahan & Wienberg, 2000; Witsch et al. 2010). 
 
1.5.3.1.2: Transglutaminase 2 in tumour insensitivity to antigrowth signals 
To maintain cellular quiescence and tissue homeostasis, myriads of anti-proliferative signals 
operate within a normal tissue. These antigrowth signals include both soluble growth 
inhibitors and immobilised inhibitors both in the ECM and on the surfaces of neighbouring 
cells. They are received by transmembrane cell surface receptors within the intracellular 
38 
 
signalling circuits; inhibiting proliferation via two discrete mechanisms. One mechanism 
involves forcing cells into quiescent (G0) state, from which they could regain proliferative 
feature when the extracellular signals become favourable. Alternatively, cells may be 
compelled to infinitely relinquish their proliferative potentials by being induced into post-
mitotic state (Hanahan & Wienberg, 2000; Deshpande et al. 2005).  
 
Besides their acquired capability of inducing and sustaining proliferation-promoting signals, 
cancer cells have the tendency to evade anti-proliferative signals. Much of the circuitry that 
determines the ability of normal cells to respond to antigrowth signals is associated with the 
cell cycle clock, especially the parts governing cellular transit through the G1 phase of its 
growth cycle. During this period, cellular decision to enter into proliferative or quiescent or 
post-mitotic state is dependent on the sensed signals from the external environment (Hanahan 
& Wienberg, 2000). At the molecular level, most anti-proliferative signals are funnelled 
through the retinoblastoma protein (pRb), which is regulated by nuclear TG2 (Kuo et al. 
2011). In a hypophosphorylated state, pRb inhibits proliferation by altering the functions of 
transcription factors responsible for controlling the expression of catalogue of genes 
necessary for transition from G1 to S phase of the cell cycle (Weinberg, 1995; Burkhart & 
Sage, 2008). Additionally, TG2 has been shown to modulate pRb, depending on its 
phosphorylation state, leading to cell cycle arrest (Boehm et al. 2002), and possible transition 
to quiescence.  
 
1.5.3.1.3: Tumour cells’ evasion of apoptosis: implications of TG2 
Over the past two decades, the idea that programmed cell death by apoptosis naturally serves 
as a barrier to cancer development, has been established by functional studies (Adams and 
Cory, 2007, Hanahan and Weinberg, 2011, and references therein). Elucidation of the 
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signalling pathways of apoptosis has revealed how apoptosis is ignited in response to various 
physiologic stresses undergone by cancer cells in the course of tumorigenesis, or those due to 
anticancer therapy. Such apoptosis-inducing stresses include signalling imbalances emanating 
from elevated levels of oncogene signalling, and DNA damage associated with hyper-
proliferation. However, other research has shown apoptosis is attenuated in those tumours 
that successfully progress to advanced states of malignance and resistance to therapy (Lowe 
et al. 2004; Adams and Cory, 2007). 
 
Cancer cells can acquire the ability to resist apoptosis through various strategies. The most 
prominent strategy is through the loss of p53 tumour suppressor function, with the resultant 
removal of a key component of the DNA damage sensor capable of inducing the apoptotic 
cascade (Harris, 1996). Alternatively, tumours may adopt the strategy of increasing 
expression of anti-apoptotic regulators (Bcl-2, Bcl-xL) or of survival signals, by down-
regulating pro-apoptotic factors (Bax, Bim, Puma), or short-circuiting the extrinsic ligand-
induced death route. The multiplicity of apoptosis-evading mechanisms reflects the diversity 
of apoptosis-inducing signals encountered by cancer cell populations during their transition to 
the malignant state (Hanahan and Weinberg, 2011).  
 
TG2 has been shown to be involved in these multiple apoptosis-evading mechanisms. For 
instance, Boehm et al (2002) reported that nuclear TG2 exerts anti-apoptotic effect by up-
regulating retinoblastoma protein pRb, leading to the polymerization of the alpha-inhibitory 
sub-unit of the transcription factor NF-kappaβ and concomitant cell protection from apoptosis 
with the help of other key anti-apoptotic proteins. Also, TG2 can translocate to the plasma 
membrane where it serves as a co-receptor for integrin, promoting its interaction with FN, 
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resulting in the activation of cell survival and anti-apoptotic signalling pathways (as reviewed 
in Odii and Coussons, 2014). 
 
1.5.3.1.4: Acquisition of unlimited replicative potential by cancer cells: implications of 
TG2 
For cancer cells to generate macroscopic tumours, they require unlimited replicative potential 
(Hanahan and Weinberg, 2011). Limitless replicative potential of cancer cells is dependent on 
three acquired capabilities – growth signal autonomy, insensitivity to antigrowth signals, and 
apoptotic resistance, all of which lead to an uncoupling of cell’s growth program from the 
prevailing signals in its environment (Hanahan and Weinberg, 2000). The unlimited 
replicative capability of cancer cells remarkably contrasts the behaviour of the cells in most 
normal cell lineages in the body, which are only able to pass through a limited number of 
successive cell growth-and-division cycles (Hanahan and Weinberg, 2011). This limited 
replication ability exhibited by normal cells is mediated by two distinct barriers to cell 
proliferation: senescence, cell transition to irreversible non-proliferative but viable state, and 
crisis, which involves cell death (Hayflick, 1997).  
 
When cells are propagated in culture, cellular senescence is first induced by repeated cell 
division cycles and subsequently, cells that are able to circumvent senescence will enter crisis 
phase, in which most of the cells in the population die. Rarely, cells from a population in 
crisis survive and assume unlimited replicative potential - immortalization, a feature 
possessed by most established tumour cell lines due to their ability to proliferate in culture 
without evidence of senescence or crisis (Hayflick, 1997; Hanahan and Weinberg, 2011). 
This is an indication that limitless replicative potential (immortalization) is a phenotype 
acquired by cancer cells in vivo during tumour progression and could be vital to their 
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development into malignant growth state (Hayflick, 1997). By implication, at some point 
during the course of multistep tumour progression, developing premalignant cell populations 
usually resort to evasion of mortality barrier, and assume unlimited replication so as to 
achieve tumorigenesis. 
 
TG2 has been variously reported to enhance cancer cells’ development of stem cell 
phenotype, through the induction of epithelial mesenchymal transition (EMT) and consequent 
activation of survival signalling molecules, including FAK, Akt, and NF-ƙβ (as reviewed by 
Mehta et al. 2010). Additionally, Kumar et al (2011, 2012) reported that TG2-expressing 
mammary epithelial cells showed increased tendency to form mammospheres, self-renewal 
ability, and plasticity (unlimited replication). Consequently, Agnihotri et al. (2013) suggested 
that sustained expression of TG2 leads to the induction of EMT and stem cell-like 
characteristics in breast cancer cells, contributing to development of drug-resistant and 
metastatic phenotypes. 
 
1.5.3.1.5: Transglutaminase 2 in angiogenesis:  
In normal tissues, oxygen and nutrients supplied by the vasculature are essential for cell 
survival and function; hence, it is obligatory for virtually all cells in a tissue to reside within 
100µm of a capillary blood vessel (Hanahan and Weinberg, 2000). Tumour 
microenvironments are mostly characterised by poor vascularisation and consequent 
deficiency in oxygen and nutrient supplies. However, like normal tissues, tumours require 
sustenance in the form of oxygen and nutrients just as they need to get rid of waste 
metabolites and carbon dioxide (Hanahan and Weinberg, 2011). Consequently, tumours tend 
to abrogate these deficiencies by generating tumour-associated neo-vasculature through the 
process of angiogenesis.  
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During embryogenesis, vasculature development involves the birth and assembly of new 
endothelial cells into tubes, in addition to the development of new vessels from pre-existing 
ones. Subsequent to this morphogenesis, the normal vasculature becomes largely quiescent 
(Hanahan and Weinberg, 2011). As part of the physiologic processes in the adult, as in the 
cases of female reproductive cycling and wound healing, angiogenesis is transiently turned 
on. However, the process of tumour progression contrasts the transient switching in normal 
physiological scenario, as an angiogenic switch is almost always activated and remains on, 
resulting in normally quiescent vasculature to resort to sustained angiogenesis in order to 
keep with the needs of expanding tumour growth (Hanahan and Folkman, 1996; Baeriswyl 
and Chistofori, 2009). 
 
The formation of new blood vessel is dependent on changes in the behavioural features of 
endothelial cells, particularly their proliferation, migration, and differentiation into tubular 
structures, which is influenced by changes in the ECM (Jones et al. 2006). TG2 is abundantly 
distributed in endothelial cells (Korner et al. 1989), and there have been many reports 
suggesting the importance of TG2 in the angiogenic process (Griffin et al. 2002). It is well 
known that many ECM proteins serve as TG2 substrates (Aeschlimann and Thomázy, 2000), 
and the crosslinking of these proteins by endothelial cells’ TG2 result in the stabilisation of 
the basement membrane (Martinez et al. 1994). Recently, Wang et al. (2013) reported that 
angiogenesis is attenuated in cell culture, the aorta ring assay and in vivo models following 
the inhibition of the crosslinking activity of extracellular TG2 or down-regulation of its 
expression. They further posited that inhibition of the activity of extracellular TG2 in human 
umbilical vein endothelial cell (HUVEC) co-culture model can halt angiogenic progression, 
even after the commencement of tubule formation and in the presence of excess vascular 
endothelial growth factor (VEGF). Additionally, Wang and colleagues suggested that down-
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regulation of TG2 expression by short hairpin (shRNA) inhibited HUVEC migration and 
tubule formation (Wang et al. 2013), hence, TG2-related activity has an angiogenic role.    
 
1.5.3.1.6: Development of invasion and metastasis phenotype by cancer cells: 
implications of TG2  
During tumour development, aggregate of primary tumours tend to amass within the confines 
of the basement membrane of the host tissue until the carrying-capacity of the membrane is 
exceeded, with resultant breakage of the membrane. Consequently, neighbouring tissues are 
invaded by the tumours, which thence, migrate to distant sites where they may successfully 
establish as new colonies – metastasis (Albert et al. 2008). The invasive and metastatic 
capabilities of cancer cells enable them to escape the primary tumour site and colonise new 
body areas devoid of nutrient deficiency and space limitation. Similar to the primary tumour 
formation, successful invasion and metastasis are dependent on other acquired hallmark 
capabilities (Hanahan and Weinberg, 2000). The role of TG2 in tumour invasion is reviewed 
in section 1.5.3.2 below. 
 
1.5.3.2: Transglutaminase 2 in cancer drug resistance and metastasis 
Exhibition of apoptotic resistance is a common characteristic of advanced cancers (Srinivasan 
et al. 1996). This feature not only gives the tumour cells the ability to metastasise but also the 
ability to develop a drug-resistant phenotype (Lundin et al. 2003). In essence, drug resistance 
and metastasis share many features in common. For example, tumour cells selected for drug 
resistance in vitro are more metastatic in vivo. Conversely, metastatic tumours generally show 
higher resistance to chemotherapy than their primary counterparts (Mehta et al. 2010). 
Transglutaminase 2 is involved in the modulation of apoptosis and cell fate through many 
crucial cellular functions (reviewed in section 1.5.1). When aberrantly regulated, TG2 is 
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thought to have a role in cancer cell’s ability to evade apoptosis. Evidently, there seems to be 
direct connection of TG2 with cancer drug resistance (Mehta, 1994; Chen et al. 2002) and 
mechanism of metastatic progression (Mehta et al. 2004).  
 
Many studies have demonstrated elevated TG2 expression as a hallmark of many types of 
cancer cells, including pancreatic carcinoma (Verma et al. 2006), ovarian carcinoma 
(Satpathy et al. 2007; Hwang et al. 2008), malignant melanoma (Fok et al. 2006), lung 
carcinoma (Park et al. 2010), glioblastoma (Yuan et al. 2007), and breast carcinoma (Mehta 
et al. 2004). For instance, Iacobuzio-Donahue et al (2003) on analysing the genes from 
tumour samples observed that out of over 30,000 genes analysed, TG2 was among those that 
recorded the highest expression in pancreatic carcinoma. Similarly, Jiang et al (2003), while 
attempting to identify metastasis-associated proteins through proteomic analysis, observed 
that TG2 was one of the eleven proteins that were constitutively elevated in metastatic human 
lung carcinoma. In another development, Antonyak et al (2004) showed that cancer cells 
treated with epidermal growth factor (EGF) expressed high levels of TG2 and were 
consequently, protected cells from doxorubicin-induced apoptosis. These observations are 
strong reflectors of the implications of aberrant TG2 expression in the conferment of 
apoptotic resistance and consequent drug resistance and metastatic potentials of cancer cells.  
 
Park et al (2009) reported that TG2-specific cross-linking activity resulted in the 
polymerization and inhibition of nucleophosmin, and concomitant increase in drug resistance 
potential of cancer cells. Recent evidence shows that aberrant expression of TG2 in 
mammary epithelial cells bestows stem cell characteristics on the cells (Kumar et al. 2011). 
Similarly, Kumar and colleagues reported that high basal expression of TG2 in breast cancer 
cells promotes the development of stem cell features, but did not encourage their terminal 
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differentiation (Kumar et al. 2011). Additionally, Caffarel et al (2013) observed that the 
activation of TG2:integrin-α5ß1 interactions through the stimulation of oncostatin M receptor 
in cervical squamous cell carcinoma, induced pro-malignant changes.  
 
Clinically, TG2 has been reported to serve as a predictive indicator of anticancer therapeutic 
efficacy. For instance, Jeong et al (2013) suggested that TG2 expression is a promising 
indicator of the effectiveness of epidermal growth factor receptor tyrosine kinase inhibitor 
(EGFR-TKI) therapy in patients suffering from non-small cell lung cancer. Similarly, Assi et 
al. (2013) reported that the accumulation of TG2 in tumour stroma can serve as an 
independent risk factor for the identification of invasive ductal carcinomas (IDCs) of breast, 
and can establish breast cancer patients at high risk of recurrence. They also observed that 
overexpression of TG2 can serve as an indicator of poor prognosis for IDC of the breast. 
Agnihotri et al. (2013) proposed that inflammation-induced progression of breast cancer and 
acquisition of survival and invasive capabilities by breast cancer cells are mediated by TG2. 
In acute myeloid leukemia, Pierce et al (2013) demonstrated that increased expression of 
TG2 characterized a more advanced state of the disease in relapse patients. They further 
established that increased TG2 expression correlates with the expression of proteins involved 
in apoptosis, motility and extracellular matrix association; processes that have been linked 
with leukemia development and progression.  
 
Metastatic tumours from patients with breast carcinoma (Mehta et al. 2004), malignant 
melanoma (Fok et al. 2006), and ovarian carcinoma (Satpathy et al. 2007; Hwang et al. 2008) 
have been shown to express higher level TG2 relative to their primary counterparts. 
Conversely, TG2 down-regulation or inhibition by small interfering RNA (siRNA), antisense 
RNA, ribozyme, or small molecule inhibitors have been shown to increase the susceptibility 
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of various cancer cell types to chemotherapy-induced cell death, and to inhibit invasion, both 
in vitro and in vivo (Verma & Mehta, 2007; Hwang et al. 2008; Verma et al. 2008). Satpathy 
et al. (2007) observed that increased TG2 expression promoted the adhesion of ovarian 
cancer cells to FN and facilitated directional cell migration, while TG2 down-regulation in 
similar cells decreased tumour dissemination on the peritoneal surface and in mesentery in an 
intra-peritoneal ovarian xenograft mouse model. Collectively, these observations strongly 
support that overexpression of TG2 may confer resistance to chemotherapeutic drugs and 
promotes the invasive potential of malignant cells. 
 
1.6: CISPLATIN AND 5-FLUOUROURACIL (5-FU) IN LIVER CANCER THERAPY 
 
1.6.1: Hepatocellular carcinoma 
Worldwide, human hepatocellular carcinoma (HCC) is the most frequent type of malignant 
liver tumour, rated as the third leading cause of cancer-related death in adults; with over 
600,000 deaths annually (Anderson et al. 1992; Parkin et al. 2005). It accounts for up to 90% 
of all primary liver tumours, with its incidence predominating in Southeast Asia and sub-
Saharan Africa (Kumar et al. 2011). For most HCC patients, the disease is usually 
accompanied by liver cirrhosis, which is a major risk factor for hepatic cancer and is 
correlated to viral infection due to hepatitis B or C virus. However, non-viral cirrhosis such 
as alcoholic, heamochromatosis and primary biliary cirrhosis are also associated with 
increased risk of liver tumour (as reviewed in Tomuleasa et al. 2010). Due to its close 
relationship to the growing incidence of liver cirrhosis, HCC incidence is increasing globally 
and over the next two decades, mortality and incidence are expected to double (Marin et al. 
2008; Rampone et al. 2009). 
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1.6.2: Cisplatin and 5-FU therapy 
Clinically, a platinum compound, cisplatin, and an antimetabolite, 5-fluourouracil are the 
most commonly used and most successful combined treatment regimen for advanced 
hepatocellular carcinoma patients (Nagai & Sumino, 2008). Various doses of cisplatin and 5-
FU combination regimen have been reported to be successfully administered in patients with 
advanced HCC, either as long-term, low dosage or short-term high dosage, through repetitive 
hepatic arterial infusion chemotherapy (HAIC) (Ando et al. 2002; Park et al. 2007). On a 
long-term, low dose serial courses of HAIC, Ando et al. (2002) reported a response rate of 
48% after four courses, using a treatment regimen consisted of daily cisplatin (7 mg/m
2
 for 1 
hour on days 1-5) followed by 5-FU (170 mg/m
2
 for 5 hours on days 1-5) per course. 
However, similar response rate of 48% was recorded by Park et al. (2007) using repetitive 3 
days short course of HAIC with high dose 5-FU (500 mg/m
2
 on days 1-3) and cisplatin (60 
mg/m
2
 on day 2). Thus, hepatic arterial infusion chemotherapy using cisplatin and 5-FU is an 
effective treatment option for patients with advanced HCC. 
 
Cisplatin (cis-diamminedichloroplatinum (CDDP) has been used as a chemotherapeutic agent 
in many cancers, especially in testicular cancer and epidermal carcinomas of many organs, 
for which treatment is very successful (Wang & Lippard, 2005). Treatment of human 
hepatocellular carcinoma with cisplatin has shown more effectiveness than any other anti-
neoplastic agents, and when combined with 5-FU, cisplatin has been shown to induce 
additive and synergistic results (Tanioka et al. 2003; Okamura et al. 2004). 5-fluorouracil (5-
FU), a pyrimidine antimetabolite, is one of the first-line treatment options for gastrointestinal 
tumours and represents the most widely used chemotherapeutic agent in the management of 
hepatocarcinoma (Li et al. 2004). Regardless of the direct independent anti-tumour abilities 
of cisplatin and 5-FU, cisplatin synergistically acts as a modulator of 5-FU through the 
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inhibition of neutral amino acid uptake into the cells with concomitant enhancement of the 
antineoplastic activity of 5-FU (Scanlon et al 1989; Shirasaka et al. 1993). Consequently, the 
combined use of cisplatin and 5-FU provides room for the use of lower doses to achieve 
optimum effectiveness with fewer side effects (Nagai & Sumino, 2008). 
 
1.6.3: Mechanism of action of cisplatin 
Chemically, the molecular structure of cisplatin (figure 1.8) is made up of a central platinum 
atom surrounded by two chlorine atoms and two ammonia groups in a cis configuration (Page 
et al. 1985). Core platinum compound and a cis configuration are common denominators 
between cisplatin and other platinum-derived drugs; however, they are differentiated by the 
variation in their leaving groups (as reviewed by Barabas et al. 2008). Cisplatin was first 
described in 1845 by Michel Peyrone (when it was referred to as Peyrone's salt); and its 
structure was established in 1893 by Alfred Werner. However, the antineoplastic capability of 
cisplatin was discovered in the 1960s following the observations by Rosenberg and 
colleagues, that it has the capacity to inhibit bacterial fission (Rosenberg et al., 1965) and the 
growth of sarcomas transplanted in mice (Sancho-Martínez et al., 2012). Hill and colleagues 
demonstrated its efficacy against several human malignancies (Hill et al., 1975), and it was 
first approved for clinical use in 1978 (Hill and Speer, 1982). 
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Figure 1.8: A representation of the molecular structure of cisplatin, showing central platinum 
(Pt) atom surrounded by two chlorine (Cl) atoms and two ammonia (H2N) atoms in cis 
configuration.  
 
Pharmacodynamically, cisplatin activation involves an aquation reaction resulting from the 
exchange of two chloride-leaving groups with water or hydroxyl ligands (Rosenberg, 1979).   
In the presence of high chloride concentration (as in isotonic saline or extracellular fluid), 
cisplatin remains neutral and biologically inactive, hence the aquation reaction does not take 
place (Rosenberg, 1979; Litterst, 1984). However, intracellular fluid has about one-thirteenth 
the chloride concentration of extracellular fluid, and such condition favours aquation reaction 
with resultant DNA damage (Rosenberg, 1979).  
 
Cisplatin primarily inhibits DNA synthesis in cancerous cells through the formation of 
adducts, with its damage to DNA assuming a similar fashion to that caused by alkylating 
agents (Barabas et al. 2008 and references therein). Upon aquation of the platinum 
compound, the two chloride groups and replaced with water and will bind to two sites in 
DNA (figure 1.9), forming DNA adducts (if the binding sites are on same DNA strand) or 
DNA cross-link (if binding sites are on different DNA strands) (Reed, 2006).  
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Figure 1.9: Representation of the pharmacodynamics of cisplatin, showing how cancerous 
cells are killed by DNA damage resulting from DNA adducts formation through aquation 
reaction (Barabas et al. 2008). 
 
1.6.4: Mechanisms of 5-FU action 
The anticancer effects of 5-fluourouracil (5-FU) occurs through two mechanisms (figure 
1.10): (a) inhibition of DNA synthesis through the inactivation of thymidylate synthase via 
the formation of a complex between methylenetetrahydrofolate (CH2FH4) and 5-fluoro-2’-
deoxyuridine 5’-monophosphate (FdUMP), which is synthesized from 5-FU. (b) Interference 
with RNA metabolism by blocking the uptake of phosphated 5-fluorouridine 5’-triphosphate 
into RNA (reviewed by Nagai & Sumino, 2008).  
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Figure 1.10: Antineoplastic mechanisms of 5-FU, RNA dysfunction and inhibition of DNA 
synthesis. Metabolism of 5-FU follows a reduction in 5-fluordeoxyuridine 5'monophosphate 
(FdUMP), which binds to thymidylate synthetase (TS) and blocks the methylation of uracil 
towards thymine. Phosphorylation of 5-FU to triphosphate (FUTP) and its incorporation in 
RNA instead of uracil results in blockage of RNA transcription (Nagai & Sumino, 2008). 
 
 
 
 
 
 
 
 
Figure 1.11: The molecular structure of 5-fluourouracil (Nagai & Sumino, 2008).  
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1.7:  FURTHER PERSPECTIVES  
Regardless of the wide range of biological functionalities associated with TG2, amidst its 
unique cellular biochemistry, its exact physiological function remains unclear. This could be 
substantiated by the fact that homozygous deletion of TG2 in mouse does not result in an 
embryonic lethal phenotype (De Laurenzi & Melino, 2001; Nanda et al. 2001); suggesting a 
compensation for its absence by other family members. However, Bernassola et al. (2002) 
observed that TG2- deficient mice displayed characteristic glucose intolerance and 
hyperglycaemia due to reduced insulin secretion, a condition equivalent to a subtype of 
diabetes called maturity-onset diabetes of the young (MODY). In humans, TG2-deficiency 
disease is yet to be identified. 
 
1.7.1: Compensation for TG2 
Whilst there is existing evidence suggesting the possible compensation for the absence of 
TG2 by another member of the transglutaminase family, it is rational to think that the enzyme 
is actually involved in many physiological processes. This could be substantiated by the 
understanding that TG2 is relatively more abundant than other members of Tgase family. 
Consequently, its wide tissue distribution and the possession of specialised functional 
structure that allows for flexibility of interaction with assorted proteins are some of the 
factors that give TG2 a physiological advantage over other Tgases. Additionally, it is 
appropriate to argue that the compensation for TG2 function could only be possible for a role 
that is determined by its cross-linking activity, which is a common feature of the 
transglutaminase family. For example, TG2-mediated functions that are independent of its 
cross-linking actions such as its role as a G-protein, and regulation of energy metabolism, are 
seemingly impossible roles to be undertaken by any other member of the Tgase family. 
Similarly, TG2-mediated integrin-FN interaction which is one of the major primary routes of 
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extracellular survival signalling activation and consequent apoptotic evasion; is independent 
of TG2 cross-linking activity and could not be compensated for by another Tgase (reviewed 
by Odii & Coussons, 2014).  
 
1.8: RESEARCH AIMS AND OBJECTIVES 
Primary liver cancers, especially human hepatocellular carcinoma (HCC), are associated with 
very low survival rate and high mortality rate, occasioned by high degree of chemo-
resistance. TG2 is highly abundant in human liver cells, hence, its common name, “liver 
transglutaminase”. For advanced HCC patients, intra-arterial combination chemotherapy is 
one of the few successful options, and continuous use of cisplatin /5-fluourouracil (5-FU) has 
been shown to prolong such patients’ survival and yield highest response rate of 47% (Marin 
et al. 2008).  
 
From the foregoing review, the involvement of TG2 in cancer drug resistance and metastasis 
has become evident. Ironically, however, amidst the low survival rate of HCC due to its 
specialised ability to resist chemotherapy, the abundance of TG2 in liver cells and reports of 
its involvement in the development of chemotherapeutic resistance and metastatic potentials 
by many cancer types; its role in liver cancer remains to be determined. Consequently, the 
investigation of TG2 abundance in liver cells, its link with drug resistance/metastasis in 
several cancer types, and high mortality rate of HCC due to chemo-resistance are some of the 
rationales for this research.  
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1.8.1: Research aims 
1. Investigation of the expression and activity profiles of TG2 in parental and drug-
resistant hepatocarcinoma cell lines with the view to gaining insight into its role in 
liver cancer drug resistance and metastasis. 
2. Development of an in vitro model of TG2-based liver cancer therapy that may 
subsequently be extended to an in vivo mouse model, and possibly clinical 
applications in the future.  
 
1.8.2: Research objectives 
1. To develop a simplified model of drug-resistant HCC that could allow for a probe into 
its mechanism of resistance and possible metastatic potential. 
2. To investigate the behaviour of TG2 in response to different stress conditions in 
different cell lines. 
3. To investigate the effects of down-regulation of TG2 expression by RNA interference 
and inhibition of its activity in parental and drug-resistant HEPG2 cell lines, with the 
views to understanding the exact implications of the protein in liver cancer drug 
resistance and metastasis. 
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CHAPTER TWO 
ESTABLISHMENT OF DRUG-RESISTANT CLONES OF HEPATOCELLULAR 
CARCINOMA (HEPG2) CELL LINE 
 
2.1: INTRODUCTION  
Patients whose liver tumours are at advanced stage are mostly refractory to chemotherapy, 
resulting in disease progression and death (Tomuleasa et al. 2010). The etiological agents of 
HCC are not well known and its molecular and cellular pathogeneses are yet to be properly 
understood (Tomuleasa et al. 2010), probably due to the complex routes through which the 
disease can originate. In recent years, there has been an emerging model for the development 
of drug-resistant tumours that invokes a pool of immortal, self-renewing malignant 
progenitors called tumour initiating cells or cancer stem cells (CSCs) (Tomuleasa et al. 2010; 
Mondello et al. 2011).  
 
Clinically, the critical problem of the emergence of tumour recurrences after therapy has been 
ascribed to the inherent high resistance ability of CSCs to chemotherapy (Singh et al. 2004; 
Al-Hajj et al. 2004). Hence, irrespective of the shrinkage of bulk of the tumour, the 
remaining recalcitrant CSCs can eventually reproduce the entire malignant phenotype (Clarke 
& Fuller, 2006; Dalerba et al. 2007). Like other cancers, HCC is composed of heterogeneous 
cell populations; with subset of cells (CSCs) peculiarly characterised by the ability to induce 
tumours when grafted into host animals (self-renewal and immortality), giving rise to 
differentiated progeny (Mondello et al. 2011).  
 
Many resistant tumour cells in humans are gradually acquired during chemotherapeutic 
administration and isolation of CSCs based on chemoresistance can provide vital tools for the 
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validation of drugs targeted at them (Masters, 2000). In addition to their isolation based on 
chemotherapeutic resistance, tumour initiating cells can also be isolated based on other 
conditions, including specific surface marker repertoires, ability to exclude fluorescent dyes, 
or particular culture conditions (Mondello et al. 2011). Drug-resistant cell lines, selected by 
exposure to anticancer agents therefore may serve as valuable tools for the illumination of 
factors underlying drug resistance (Yan et al. 2007). The development of good experimental 
model of drug resistant cell line is therefore, a prerequisite for any study to understand the 
cellular mechanisms that determine drug resistance.  
 
Tumour initiating cells were originally isolated in leukemic tumour and then in solid tumours 
(Bonnet & Dick, 1997; Hemmati et al. 2003; Collins & Maitland, 2006; Li et al. 2007). Since 
the advent of drug-based selection of drug-resistant cell lines, various cell types have been 
successfully selected for resistance pharmacologically. For instance, human leukemic (KG1a) 
cell line selected against 5-fluorouracil (Zhang et al. 2010); breast cancer cell line selected 
against doxorubicin and nicotine (Calcagno et al. 2010; Hirata et al. 2010); ovarian cancer 
cell line selected against cisplatin and paclitaxel (Ma et al. 2010; Bapat, 2010); prostate 
cancer cell line selected against inorganic arsenic (Achanzar et al. 2002; Benbrahim-Tallaa & 
Waalkes, 2008; Tokar et al. 2010); and human lung cancer (H460) cell line against cisplatin 
or doxorubicin (Levina et al. 2008). For HCC, the first isolation of tumour initiating cells was 
reported by Sell et al. (2002) and more recently Tomuleasa et al. (2009). However, they did 
not select the cells based on clinical treatment patterns. This approach was recently reported 
by Odii & Coussons (2012), where selection of drug-resistant HCC was achieved based on 
chemotherapeutic resistance by mimicking clinical treatment pattern for hepatocarcinoma.  
 
57 
 
Cisplatin and 5-fluourouracil (5-FU) are frequently used but are mechanistically different 
antineoplastic agents with wide range of anti-tumour activities. The use of cisplatin and 5-
fluourouracil in liver cancer treatment has been discussed earlier (see section 1.6). 
 
2.2: MATERIALS AND METHODS 
 
2.2.1: Pharmacologic agents 
Cisplatin and 5-FU (Sigma Aldrich, UK) were dissolved in double distilled water to yield 
working stocks at concentration of 2mM and 20mM respectively. The working stocks were 
stored at room temperature, and diluted into cell culture media as required. Working stocks 
were kept away from light and discarded after one month. 
 
2.2.2: Cell line and culture conditions 
The parental human hepatocellular carcinoma (HEPG2) cell line was obtained from the 
European Collection of Animal Cell Cultures (ECACC). Cells were cryopreserved and then 
rapidly thawed and grown in RPMI 1640 medium (Invitrogen, UK), fully supplemented with 
10% heat-inactivated foetal bovine serum (FBS) (Invitrogen, UK), 1% glutamine (Invitrogen, 
UK) and 1% penicillin streptomycin (Invitrogen, UK). The physiological conditions of the 
cells were maintained at 5% CO2 and 37ºC in a humidified atmosphere. Logarithmically 
growing cells were at the second passage when they were cryopreserved with a freezing 
medium containing 10% dimethylsulphoxide (DMSO) (Sigma Aldrich, UK) and 90% 
supplemented RPMI 1640 medium (Invitrogen, UK). The freezing vials containing the cells 
were cryo-preserved in a cryovial containing isopropanol and maintained at -80ºC for 24 
hours; subsequently, the vials containing the parental cells were stored and maintained as 
working stock immersed in liquid nitrogen at -196ºC.  
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2.2.3: Assay of HEPG2 cells’ susceptibility to cisplatin- and 5-FU-induced death  
The susceptibility of HEPG2 cells to chemotherapy-induced death and the degrees of 
cytotoxicity of cisplatin or 5-FU on the cells were measured using cell counting kit (CCK-8) 
(Sigma Aldrich, UK). The CCK-8 is made up of Dojindo's highly water-soluble tetrazolium 
salt, WST-8[2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-
tetrazolium, monosodium salt], which produces a water-soluble, yellowish formazan dye 
upon reduction in an electron carrier (Shibata et al. 2006). The number of viable cells is 
directly proportional to the amount of the formazan dye generated in cells.  
 
Assays were conducted following the manufacturer's instructions.  Briefly, cells were seeded 
at density of 10
4 
cells per well in 96-well plates, then pre-incubated overnight to induce 
adherence, at physiological conditions of 5% CO2 and 37ºC, in a humidified atmosphere. The 
cells were then treated at concentrations of 0µM to 16µM for cisplatin; or 0µM to 100µM for 
5-FU respectively. After twelve to twenty four hours incubation, 10µl of CCK-8 was added 
to each well and incubated at 37ºC for 2 hours; followed by the measurement of absorbance 
using an automated micro-plate reader ELx 800 (BioTek, UK) at 450nm. Each experiment 
was done in triplicate and the results were calculated as the mean of at least three independent 
measurements in relation to the absorbance of untreated control cells ± standard deviation. 
 
2.2.4: Determination of median effective concentrations (EC50) 
The median effective concentration, otherwise known as EC50, is the concentration of a drug 
at which half-maximal effectiveness is achieved (Zhang et al. 2010). Determination of this 
concentration (EC50) is a prerequisite to the selection of drug-resistant cells against any given 
anticancer drug. Briefly, cells at the logarithmic growth phase (80% confluence) were 
harvested and seeded at a density of 10
4
 cells per well in 96-well plates and incubated 
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overnight for adherence. Subsequently, the drug-free medium was replaced with pre-warmed, 
fully supplemented, fresh medium containing 0µM to 100µM of 5-FU or 0µM to 16µM of 
cisplatin. The cells were incubated for 24 hours, while maintaining the physiological 
conditions at 5% CO2 and 37ºC, in a humidified atmosphere. After twenty four hours 
incubation, cell susceptibility to pharmacological agents was conducted as previously 
described (section 2.2.3). Cell response to chemotherapy was calculated as a measure of the 
optical density (OD) of treated cells relative to the optical density of the untreated controls, 
excluding the OD of blank controls. Concentration-dependent response curves were plotted 
and the respective EC50(s) of cisplatin and 5-FU were calculated using the GraphPad Prism 6 
software and following the software instruction manual for such command. Specifically, 
determination of EC50 was done automatically using the command (enter 50 in the last 
column of the data table) that enables the GraphPad Prism software to estimate the EC50. A 
student t-test was carried out to check the difference between the EC50 of parental and those 
of the drug-resistant HEPG2 cells. Statistical significance was defined at p values less than 
0.05 (p < 0.05) and 95% confidence interval of mean differences.  
 
2.2.5: Flow cytometric analysis of cell death 
The EC50(s) were confirmed by flow cytometric analysis of cell death using Annexin V-FITC 
kit (BD Biosciences, San Diego). Briefly, HEPG2 cells were grown to 80% confluence, and 
detached using 0.25% (w/v) trypsin in 5mM EDTA (Invitrogen). The cells were seeded at the 
rate of 2x10
5
 per ml of RPMI 1640 medium (Invitrogen), supplemented with 10% foetal 
bovine serum (Invitrogen), 1% Penicillin streptomycin (Invitrogen), and 1% L-glutamine 
(Invitrogen). After twenty four hours incubation in appropriate concentrations of cisplatin (0-
16µM) or 5-FU (0-100µM), under physiological conditions of 5% CO2, 37ºC, in a humidified 
atmosphere; the cells were detached by trypsinization, washed and re-suspended in binding 
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buffer. The cells were analysed for apoptosis following mixing with Annexin V-FITC and 
propidium iodide (PI), and incubation in the dark for five minutes. Analysis of cell death was 
done using flow cytometer FACSCalibur (BD Biosciences, Europe). 
 
2.2.6: Selection of cells for drug resistance 
In selection of the cells for resistance, clinical method of treatment was mimicked by treating 
the parental HEPG2 cell line in pulse pattern, at the EC50 of either cisplatin or 5-FU for four 
to six hours. Induction was repeated six times, whilst allowing the cells to attain at least 70% 
confluence between induction intervals. After six complete cycles of induction, selected cells 
were maintained in drug-free RPMI 1640 medium containing appropriate supplements, and 
allowed to reach 70-80% confluence. No further experiment was performed on the cells until 
after four weeks maintenance in drug-free medium. 
 
2.2.7: Assay for drug resistance 
The stabilities of the selected clones (HEPG2CR) and (HEPG2FR) were tested after two 
weeks, one month and three months of drug withdrawal. Briefly, the selected clones were 
harvested at exponential growth phase using 0.25% trypsin-EDTA. Cell counting was 
performed using haemocytometer, and the cells were seeded in 96-well plate at the rate of 10
4 
cells per well, in triplicate. Plates were maintained at 37ºC in a humidified atmosphere of 5% 
CO2. After overnight incubation for attachment, cells were incubated for twenty four hours in 
RPMI 1640 medium containing appropriate concentration of cisplatin (0-16µM) or 5-FU (0-
100 µM). Following the twenty four hours incubation, the cells were further incubated for 
two hours in the presence of 10 µl of CCK-8 per well. The optical densities were measured 
and the new EC50 was obtained from a concentration-dependent cytotoxicity curve for each of 
the drugs as previously described. The difference between the EC50 of the resistant clones and 
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that of the parental cell line defines the degree of resistance to the drug against which the 
cells are selected; and the significance of the difference was determined statistically by 
student t-test.    
 
2.3: RESULTS 
 
2.3.1: Pharmacological induction of cell death, cellular susceptibility to chemotherapy 
and determination of median effective concentrations (EC50). 
To understand the effect of cisplatin or 5-FU on HEPG2 cell viability and establish the 
degree of cytotoxicity due to these drugs, HEPG2 cells were incubated for twenty four hours 
with 0µM to 16µM of cisplatin or 0µM to 100µM of 5-FU. Cellular susceptibility to drug-
induced death was measured by CCK-8 assay and cells were found to be more susceptible to 
cisplatin than 5-FU. Furthermore, with 5-FU, cytotoxicity was found to be directly 
proportional to drug concentration and time. However, for cisplatin, an approximately similar 
degree of cytotoxicity was obtained at both twelve hours treatment in drug-containing 
medium, followed by forty eight hours incubation in drug-free medium and twenty four hours 
continuous treatment in drug-containing medium at similar concentration (Figure 2.1). The 
respective EC50 were calculated from concentration-dependent response curves, following 
analysis of cell viability by CCK-8 assay. For cisplatin, cell survival was minimal beyond 
4µM (Figure 2.1), however, in the case of 5-FU, cell survival was minimal beyond 50µM 
(Figure 2.2). Hence, the EC50 of cisplatin was found to be 4µM while that of 5-FU was 
50µM. The EC50(s) were confirmed by the flow cytometric analyses of cell death due to 
cisplatin or 5-FU (section 3.3.3). 
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Figure 2.1: Response of HEPG2 Cells to cisplatin treatment for 12 and 24 hours and 
determination of the median effective concentration at which half-maximal response is 
obtained (EC50). A student t-test shows that there is no significant difference between the 
effectiveness of cisplatin at 12 and 24 hours, as indicated by a p value of 0.0861 which is > 
0.05; n = 6 as shown in appendix 4, tables A4.0 and A4.1. 
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Figure 2.2: CCK-8 assay of HEPG2 cells’ susceptibility to 5-FU after 24 hours continuous 
treatment and determination of the EC50 as shown by the red arrow. The EC50 was 
automatically computed using the GraphPad Prism6 software command as described in 
section 2.2.4 (appendix 4, table A4.2) 
 
2.3.2: Development of drug resistant sub-lines and test for resistance 
Following the establishment of the concentration of cisplatin or 5-FU at which HEPG2 cell 
viability is reduced by 50%, the resistant sublinesHEPG2CR and HEPG2FR were established 
by incubating the parental HEPG2 cell line at the EC50 of cisplatin (4µM) or 5-FU (50µM), 
whilst imitating the clinical method of treatment. The cells were found to have developed 
resistance to either CDDP or 5-FU following six intervals of induction. A test for resistance 
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was conducted following maintenance of the cells in drug-free medium, and a comparison of 
the EC50 of the parental cells and those of the resistant cells revealed an increase in resistance.  
For cisplatin, the EC50 for HEPG2CR is significantly different from that of the parental cell 
line, rising from 4µM to approximately 8µM, with p value of < 0.0001 at statistical 
significance defined by p < 0.05; where n = 12 (Figure 2.3) (see details in appendix 6, tables 
A6.3 and A6.4). However, for 5-FU, the EC50 for HEPG2FR is significantly different from 
that of the parental cell line, increasing from 50µM to 65µM (Figure 2.4), with p value of 
0.0317, where statistical significance is defined by p < 0.05; n = 12, and the strength of the 
statistical significance is indicated by * (see appendix 4, tables A4.5 and A4.6). 
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Figure 2.3: Comparison of the EC50 of cisplatin for parental HEPG2 cell line and that of the 
resistant sub-line (HEPG2CR). After a student t-test, a p value of < 0.0001 shows that 
HEPG2 and HEPG2CR are significantly different from each other, as per susceptibility to 
cisplatin treatment and the strength of the statistical significance is indicated by ****. The 
black arrow crossing shows the EC50 of cisplatin for HEPG2 as 4µM and the red arrow 
indicates the rise from 4µM to 8µM as the parental cells develop resistance.  
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Figure 2.4: Comparison of the EC50 of 5-FU for parental HEPG2 cells and that of the resistant 
sub-line (HEPG2FR). A student t-test shows that the resistant clone is significantly different 
from the parental cells with p value of 0.0317, where statistical significance is defined by p < 
0.05; at 95% confidence interval, n = 12, and the strength of the statistical significance is 
indicated by * (see appendix 4, tables A4.5 and A4.6). 
 
2.3.3: Evaluation of the stability of drug-resistant cells in drug-free conditions 
The ability of the selected drug-resistant cells to retain resistance in drug-free conditions was 
tested after two weeks, one month, and three months. The results show that both HEPG2CR 
and HEPG2FR are stable and there is no significant change in EC50 following a one-way 
ANOVA analysis, with multiple comparisons of each test period against another. For 
HEPG2CR, the EC50 remained unchanged at 8µM as shown in figure 2.5 (data shown in 
appendix 4, table A4.51); the p value is 0.9982, which is far greater than 0.05 which defines 
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statistical significance at 95% confidence interval (see appendix 4, table A4.52 and table 
A4.53). Similarly, the EC50 of 5-FU for HEPG2FR remained unchanged at 65µM as shown in 
figure 2.6 (see appendix 4, table A4.54 for data); the p value is 0.9992, thus > 0.05 at 95% 
confidence interval as shown in appendix 4, table A4.55). Multiple comparisons of each test 
interval against another show that there is no significant change in EC50 after three months of 
growth in drug-free medium (appendix 4, table A4.56). 
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Figure 2.5: Assessment of the stability of HEPG2CR cells in drug-free conditions after two 
weeks, one month and three months maintenance in drug-free medium, showing consistent 
EC50 of 8µM. One-way ANOVA analysis of the results show an insignificant difference in 
EC50 after two weeks, one month and three months with p value of 0.9982, which is far 
greater than 0.05 at which statistical significance is defined at 95% confidence interval 
(appendix 4, table A4.52). Also, multiple comparisons of each test interval against another by 
one-way ANOVA show no difference in EC50 in all cases (appendix 4, table A4.53). 
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Figure 2.6: Assessment of the stability of HEPG2FR cells in drug-free conditions after two 
weeks, one month and three months maintenance in drug-free medium showing consistent 
EC50 of approximately 65µM. One-way ANOVA analysis of the results show an insignificant 
difference in EC50 after two weeks, one month and three months with p value of 0.9992, 
which is statistically insignificance at p value < 0.05 at 95% confidence interval (appendix 4, 
table A4.55). Also, multiple comparisons of each test interval against another by one-way 
ANOVA show no difference in EC50 in all cases (appendix 4, table A4.56). 
 
2.4: DISCUSSION 
Drug resistant tumour cells in humans gradually accumulate during chemotherapy. 
Development of good drug-resistant cell line models serve as useful paradigms for the 
clinical scenario of anticancer drug resistance. Cell line models with acquired resistance to a 
variety of anticancer agents have been variously developed in the quest to unravel the 
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mechanisms underlying clinical drug resistance (Chen et al. 1994; Takeshita et al. 1996; Yan 
et al. 2007; Zhang et al. 2010). 
 
The first step during the development of drug-resistant cell line is the choice of parental cell 
line. This is subject to a number of factors, such as tumour type and its relevance to the 
selecting agents under consideration (Coley, 2004). The human hepatocellular carcinoma 
(HEPG2) cell line was chosen because it is the most prevalent (accounting for up to 90% of 
liver cancer cases) and deadliest (Nowak et al. 2004; Parkin et al. 2005; Kumar et al. 2011) 
form of liver cancer. In relation to the selection agents, cisplatin and 5-FU combination 
therapy is the most sensitive and preferred treatment option for patients with advanced HCC 
(Nagai & Smino, 2008). 
 
The results of the assays revealed that HEPG2 cell line is more sensitive to cisplatin than 5-
FU as evidenced in the respective concentrations at which EC50 was achieved for both drugs 
(figure 2.1 and 2.2). The EC50 of cisplatin or 5-FU was calculated as 4µM or 50µM 
respectively, from concentration-dependent cytotoxicity curves. Also, the results showed 
distinct initial decline in cell viability upon addition of cisplatin or 5-FU. This could be due to 
the heterogeneity of the cell population, where the cells are at different stages of cell cycle. 
Consequently, the initial decline may represent population of cells that have committed to 
division prior to drug introduction, hence were more susceptible to drug-induced death. 
Though, the initial drop in cell viability was also observed in drug-resistant cell lines, the 
decline was more gradual. This could be due to the fact the population of the drug-resistant 
cell lines was less heterogeneous.  
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On establishing the appropriate concentrations of cisplatin and 5-FU at which the resistant 
sub-lines of HEPG2 cell line could be produced, the resistant cell lines were then maintained 
at these concentrations. The selection process mimicked the clinical method of treatment, as 
the parental cell line was treated in pulse, whilst allowing the cells to recover between 
treatment intervals. The treatment intervals are synonymous to the clinical cycles of treatment 
while the numbers of inductions are equational to the clinical treatment courses. After the 
sixth induction, an increase in the EC50 of both drugs was an indication of resistance 
development. Statistical analysis using student t-test shows that HEPG2 and HEPG2CR are 
significantly different from each other, as per susceptibility to cisplatin treatment, with a p 
value of < 0.0001. The EC50 of cisplatin for the sub-clone of HEPG2 selected for cisplatin 
resistance doubled that of the parental cell line. Similarly, a student t-test shows that 5-FU 
resistant clone is significantly different from the parental cells with p value of 0.0317; 
however, the EC50 of 5-FU for the sub-clones of HEPG2 selected for 5-FU resistance 
increased by a shorter margin compared to cisplatin (from 50µM to 65µM). This shows that 
HEPG2 cell line has stronger cytotoxicity memory for 5-FU, hence, smaller change (increase) 
in concentration was needed for the cells to develop resistance to 5-FU relative to cisplatin. 
This can also be attributed to the stronger toxicity strength of cisplatin relative to 5-FU.  
 
The chemo-resistant cell lines were found to be very stable in drug-free medium, as indicated 
by insignificant statistical difference in the EC50 of cisplatin and 5-FU after months of 
maintenance in drug-free medium (figure 2.5 and figure 2.6, repectively). This contradicts 
some reports that drug-resistant cell lines need to continually grow in drug-containing 
medium in order to retain resistance (Twentyman et al. 1986). Therefore, this study provides 
the basis for the establishment of stable model of drug-resistant cell line, with minimal cost of 
production and maintenance.  
70 
 
CHAPTER THREE 
REDUCTION OF CISPLATIN CYTOTOXICITY IN HEPATOCARCINOMA CELLS 
BY OPTIMIZATION OF TREATMENT CONDITIONS 
 
3.1.0: INTRODUCTION  
Most organs of the body accumulate cisplatin, especially the kidneys, liver, prostate, spleen, 
bladder, testicles, pancreas, bowel, adrenal glands, heart, lungs, cerebrum, and cerebellum (as 
reviewed in Sancho-Martínez et al., 2012). However, the pattern of tissue accumulation does 
not always correlate with the pattern of tissue toxicity (Staffhorst et al. 2008; Sancho-
Martínez et al., 2012). For instance, Junior et al. (2007) reported higher accumulation of 
cisplatin in liver and spleen than the kidneys, whilst the main toxicity was witnessed in the 
kidney. This observation supported previous findings reported by Stewart et al. (1982), where 
tissue platinum concentration was higher in liver and prostate while nephrotoxicity was 
evident in the kidneys. 
 
 Tumours also accumulate cisplatin but the tumour-to-plasma coefficient is lower in many 
organs (Staffhorst et al. 2008). For instance, Sancho-Martinez et al. (2011) reported that cell 
cycle arrest requires lower concentrations of cisplatin relative to cell death induction. This 
could explain why cisplatin is able to exert antineoplastic activity at low dosages (Sancho-
Martínez et al., 2012), as low as 7 mg/m
2
 (table 3.0). 
 
3.1.1: Mechanism of cisplatin-induced death 
Cisplatin-induced cell death occurs through both apoptotic and non-apoptotic, necrotic-like 
processes (Price et al. 2004; Cepeda et al. 2007; Ramirez-Camacho et al. 2008). The mode of 
cell death is concentration-dependent; and for both tumour and non-tumour cells, low 
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cisplatin concentrations induce apoptotic cell death, whereas necrosis occurs at higher 
concentrations (Sancho-Martinez et al. 2011). Cisplatin is highly cytotoxic for proliferating 
cells, because of its characteristic interaction with DNA, during which it forms covalent 
adducts with certain DNA bases and impedes DNA replication and mitosis (Yang et al., 
2006). Unfortunately, the therapeutic use and efficacy of cisplatin are limited by its strong 
side effects, especially nephrotoxicity, ototoxicity, neurotoxicity, cardiotoxicity, 
gastrointestinal toxicity and bone marrow suppression (El-Sayed et al., 2011; López-
Hernández et al., 2012).  
 
3.1.2: Side-effects and clinical use of cisplatin 
Cisplatin, like most anticancer drugs, is not action-specific (Bodiga et al. 2012). Hence, it 
acts on both proliferating and non-proliferating cell types, with resultant side effects, 
especially at high dosage and prolonged exposure (Barabas et al., 2008; Rybak et al., 2009; 
Sanchez-Gonzalez et al., 2011a; Jaggi and Singh, 2012). Evidently, cisplatin cytotoxicity is at 
cross-roads of its therapeutic and side effects and for many years, various strategies have 
been adopted in clinical settings to curtail these side effects. One of these approaches is to 
synthesize and screen for novel cisplatin analogues that have lower toxicity in normal tissues. 
To this end, several cisplatin analogues, like carboplatin, have been identified and shown to 
have less severe side effects (Pasetto et al., 2006). Additionally, hydration of patients with 1 
to 2 litres of fluid infused 8 to 12 hours prior to cisplatin treatment is another strategy that has 
been used with some success (Cornelison and Reed, 1993). Haemodialysis (Brivet et al. 
1986; Lagrange et al. 1994), plasmapheresis (Guenter et al. 2006), molecular mediators 
(Pabla and Dong 2012) and even natural and synthetic antioxidants (Yinghua et al. 2011), 
have be reported as some of the strategies with proven effectiveness in ameliorating cisplatin 
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side effects. Irrespective of these efforts, the side effects of cisplatin remain a major factor 
militating against its use and efficacy in cancer therapy.  
The clinical use of cisplatin involves varying dosages depending on the type of cancer and 
other clinical factors, such as additional therapy, patient’s body weight, size and general 
health state (Solimando, 2010). The approximate doses of cisplatin, methods of 
administration and types of cancer are presented in table 3. 
 
Table 3: Clinical dosages of cisplatin and methods of administration for various types of 
cancer (Solimando, 2010) 
 
Cancer type Cisplatin adult 
dosage  
Method of administration 
Testicular  20 mg/m
2
 Intravenously once a day for 5 days per cycle 
Ovarian 75 to 100 mg/m
2
 Intravenously once every 4 weeks 
Bladder 50 to 70 mg/m
2
 Intravenously once every 3 to 4 weeks 
Neuroblastoma 60 to 100 mg/m
2
 Infusion 
Non-small cell 
lung 
60 to 100 mg/m
2
 Intravenously on day one of every 21 days 
Cervical  40 to 70 mg/m
2
 Intravenously weekly depending on additional therapy 
Liver 
 
7 to 100 mg/m
2
 Hepatic arterial infusion once a day for 3 to 5 days per 
cycle 
 
3.1.3: Optimizing cisplatin therapy 
In both clinical and non-clinical settings, it is important to establish the optimal treatment 
conditions for cisplatin by exploiting potential differences in its handling or response. 
Knowledge of such optimal conditions of treatment might help improve the pharmaco-
toxicological profile of cisplatin, and reduce its cytotoxic effects on non-target cells. 
Consequently, this study seeks to develop a model to understand more about the kinetics of 
cisplatin cytotoxic effects, in this case, on hepatocarcinoma cells. 
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3.2: MATERIALS AND METHODS 
 
3.2.1: Materials 
All the materials were obtained from Sigma Aldrich UK and Invitrogen UK unless otherwise 
stated.  
 
3.2.2: Cell line and cell culture establishment 
Cell line and cell culture establishment involved similar methods previously described in 
section 2.2.2. 
 
3.2.3: Cisplatin-induced cytotoxicity assay 
Assays for cisplatin-induced cytotoxicity were conducted following the methods described by 
Odii & Coussons (2012) (see section 2.2.3). 
 
3.2.4: DNA fragmentation assay of apoptosis 
To investigate the ability of cisplatin to induce apoptotic death by DNA fragmentation, 
preparation of the cell samples was conducted as described by Okamura et al. (2008). Briefly, 
HEPG2 cells were inoculated in 25cm
2
 flasks at10
5
 cells/ml and pre-incubated for overnight 
for adherence. The cells were then treated with 0µM to 16µM cisplatin for twelve hours, 
followed by forty eight hours incubation in drug-free medium, or continuously for twenty 
four or forty eight hours. Following appropriate incubation, cells were collected by 
trypsinization using 1ml trypsin-EDTA (0.1% trypsin and 0.02% EDTA in phosphate-
buffered saline) (Sigma Aldrich, UK) for every 25cm
2
 flask. Genomic DNA was extracted 
from the collected cells using QIAamp DNA Mini Kit (Qiagen, UK), following the 
manufacturer’s instructions. The isolated DNA was assayed for fragmentation and laddering 
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feature using 2% agarose gels (Sigma Aldrich, UK). For each concentration of cisplatin, 
duplicate experiments were carried out and the experiment was repeated three times for the 
treatment durations investigated. 
 
3.2.5: Time-course induction and analysis of apoptosis by flow cytometry  
Flow cytometric analysis of cellular cytotoxicity of cisplatin towards HEPG2 cells at 
different time intervals was conducted as previously described in section chapter two, section 
2.2.5. In addition, the cells were treated with 0µM to 16µM cisplatin for twelve hours, 
washed once with HBSS (Invitrogen, UK), and incubated for forty eight hours in drug-free 
medium. Alternatively, the cells were incubated continuously with similar concentration of 
cisplatin for twenty four hours or forty eight hours before analysis. Preparation of samples for 
analysis involved cell detachment by trypsinization, followed by washing of cells in 
phosphate buffered saline (PBS) (Invitrogen, UK) and re-suspension in binding buffer. 
Finally, the cells were analysed for apoptosis after mixing with Annexin V-FITC and 
propidium iodide (PI), and incubation in the dark for five minutes. Each experiment was 
repeated two times and duplicate of experiment was prepared for every concentration of 
cisplatin tested. 
 
3.2.6: Cell cycle analysis at optimal treatment time by flow cytometry 
Cell cycle distribution was assessed by flow cytometric analysis as described by Li et al. 
(2011). Briefly, HEPG2 cells at about 80% growth confluence were prepared as described in 
section chapter two, section 2.2.5, and then were treated continuously for twelve hours with 
cisplatin-containing medium at concentrations of 0µM to 16µM cisplatin, followed by forty 
eight hours incubation in drug-free medium. After harvest, cells were re-suspended in 0.5ml 
1X PBS (Invitrogen) and fixed in ice-cold 70% ethanol overnight. Ethanol was decanted and 
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cells were washed with PBS and stained with propidium iodide (PI) for 4hrs in a dark 
cupboard before cell cycle distribution was analysed.   
 
3.3: RESULTS 
 
3.3.1: Cisplatin-induced cytotoxicity  
The EC50 of cisplatin for HEPG2 cells was calculated from the concentration-dependent 
response charts, and after twelve hours or twenty four hours incubation, it was consistently 
found to be 4µM (figure 2.1). A comparison of cellular response to cisplatin at both twelve 
and twenty four hours incubation showed a uniform 30% drop of cell viability on initial 
introduction of cisplatin to HEPG2 cells followed by a steady decline after the EC50 as 
previously reported in chapter two, section 2.3.1, figure 2.1. 
 
3.3.2: Induction and detection of cisplatin-induced apoptosis by DNA fragmentation 
assay 
Most anticancer drugs including cisplatin, exhibit their antineoplastic actions by apoptosis 
induction. One of the major markers of apoptosis is the cleavage of double-stranded DNA in 
the linker regions between nucleosomes by endogenous endonucleases, which generate 
mono- and oligo-nucleosomes multiples of approximately 180 to 200 bp (Sambrook et al., 
2001; El-Sayed et al. 2011). To understand the ability of cisplatin to induce apoptosis in 
HEPG2 cells, time-course analysis of internucleosomal DNA fragmentation was carried out 
by gel electrophoresis as described in section 3.2.4. The results show that cisplatin can induce 
apoptosis as early as six hours of treatment (figure 3.0a). After twelve hours of treatment, 
uniform DNA fragments were produced across concentrations (figure 3.0b), with increased 
DNA smears, typical of necrosis, as the concentration increases. After twenty four and forty 
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eight hours of induction, DNA smears were more pronounced across concentrations of 
cisplatin (figure 3.0 c and d).  
 
       0µM     1µM    2µM     4µM     8µM   16µM                    0µM   1µM  2µM   4µM    8µM   16µM  
               
(a)                                                                     (b) 
       
   0µM    1µM   2µM    4µM     8µM   16µM                 0µM    1µM    2µM    4µM     8µM   16µM 
       
                           (c)                                                                                       (d) 
Figure 3.0: Detection of cisplatin-induced apoptosis by DNA fragmentation assay after (a) six 
hours treatment, showing more intact DNA bands and less smears (b) twelve hours 
continuous treatment followed by forty eight hours incubation in drug-free medium, with 
DNA fragments uniformly produced across concentrations (c) twenty four hours treatment, 
and (d) forty eight hours treatment, where DNA fragmentation was accompanied by 
prominent smearing, typical of necrotic cell death.  
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3.3.3: Time-course analysis of cisplatin-induced cell death by flow cytometry 
To confirm the EC50 of cisplatin and properly establish twelve hours as the optimal treatment 
time for the drug, cell death analysis by flow cytometry was carried out at intervals of twelve 
hours in cisplatin-containing medium and forty eight hours incubation in drug-free medium, 
or twenty four to forty eight hours continuous treatment in drug-containing medium. The 
EC50 remained approximately the same, regardless of duration of treatment and the 
percentage of apoptotic cells obtained at twelve hours was approximately similar to that 
obtained at twenty four to forty eight hours continuous treatment (figure 3.1). Interestingly, 
the EC50 remained constant across the various intervals of HEPG2 treatment; however, the 
stages of cell death were different. At optimal treatment time (twelve hours) 51% of the cells 
were non-apoptotic, 32% of the cells were at early stage of apoptosis, 13% of the cells were 
at late phase of apoptosis, while only 1% of the cells were necrotic (figure 3.1). Following a 
twenty four hours continuous exposure to cisplatin, the proportion of the cells at late state of 
apoptosis and necrosis increased to 18% and 19% respectively. With continued exposure up 
to forty eight hours, 27% of the cells were at secondary stage of apoptosis, 26% were at stage 
of necrosis, and only 4% of the cells were at early stage of apoptosis (figure 3.1). 
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Figure 3.1: Comparison of the patterns of cell death distribution after treatment of HEPG2 
cell line with similar cisplatin concentration, EC50 (4µM) for different durations, twelve, 
twenty four and forty eight hours. Necrotic death and late apoptosis increased with increased 
treatment duration from twelve hours to forty eight hours (see appendix 2, tables A2.2.1, 
A2.2.2, and A2.2.3). 
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Figure 3.2: An example of FACS result showing cell death distribution at EC50 (4µM) after 
twelve hours cisplatin treatment followed by forty eight hours incubation in drug-free 
medium, with cell death mainly due to primary and secondary apoptosis (R2 and R3) and 
minimal necrosis (R4) as earlier summarised in figure 3.1.    
 
3.3.4: Analysis of cell cycle at optimal treatment time 
Cisplatin initiates cell death by intercalating with DNA bases forming adducts and inhibiting 
DNA synthesis and mitosis (Yang et al., 2006). To find out the effect of cisplatin on HEPG2 
cell cycle progression at optimal treatment time, cell cycle events were analysed following 12 
hours cisplatin treatment at 0µM to 16µM and 48 hours incubation in drug-free medium. The 
results revealed that cisplatin was only able to almost completely stop cell cycle at G0/G1 
R2 
R3 
R4 
R1 
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phase at the highest concentration (16µM) (figure 3.3), while at lower concentrations, cell 
cycle progression was gradual, with significant proportions of the cells at G0/G1, S and 
G2/M phases. However, S and G2/M phases continued to decrease, while G0/G1 increased as 
the cisplatin concentration increases. 
 
         
 
(a) At 0µM, cells were properly spread across the various cell cycle phases, with a 
large number of the cells at the synthesis phase.                        
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(b) 2µM: Upon introduction of 2µM of cisplatin, the number of cells progressing from G0/G1 
through S to G2/M phase decreased with an observed increase in number of cells at G0/G1. 
 
 
 
(c) 4µM: The G0/G1 phase continued to increase while S and G2/M phases continued to 
shrink with further increase in cisplatin concentration to 4µM.                                                                            
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       (d)  8µM: At 8µM, G0/G1 became very prominent with further shrinkage of S and G2/M 
phases. 
 
 
 (e) 16 µM: At highest concentration of cisplatin, the cell cycle process was almost 
completely halted at G0/G1.   
Figure 3.3: HEPG2 cell cycle progression after twelve hours cisplatin treatment followed by 
forty eight hours incubation in drug-free medium.  
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3.4: DISCUSSION 
Very few studies have attempted to exploit patient or cellular response to cisplatin to 
establish its optimal treatment conditions. For instance, Drewinko et al. (1973) reported that 
for human lymphoma, prolonging the treatment time of cisplatin from 1 to 8 hours at 5µg/ml 
produced a magnitude of cytotoxicity similar to what was observed after one hour treatment 
at 50µg/ml. Similarly, Okamura et al. (2008) reported that treatment of various clones of 
human oral squamous carcinoma cell lines with cisplatin for twelve hours and subsequent 
thirty six-hour incubation in drug-free medium produced a comparable magnitude of 
cytotoxicity with that obtained after 48-hour continuous treatment. In agreement with these 
reports, the results presented in this thesis showed that a consistent EC50 of 4µM was 
obtained following different intervals of HEPG2 treatment with cisplatin (figure 3.1).  
 
The pattern of cell death distribution analysed by flow cytometry, further revealed the 
consequence of prolonged exposure of HEPG2 cells to cisplatin. This was evident in the 
phases of cell death observed in the cells at similar concentration (EC50) but different 
treatment durations (figure 3.1). For instance, after twelve hours treatment in drug-containing 
medium, followed by forty eight hours incubation in drug-free medium, cell death was 
mainly due to primary and secondary apoptosis, with minimal necrosis (figure 3.2). However, 
following an increase in incubation duration from twelve hours to twenty four or forty eight 
hours continuously in drug-containing medium, cell death was dominantly due to secondary 
apoptosis and necrosis (figure 3.1).    
 
Additionally, a time-course analysis of internucleosomal DNA fragmentation in HEPG2 cells 
due to cisplatin revealed a consistent pattern of cell death to the flow cytometry results. 
Within the first twelve hours of death induction, cell death was mainly due to primary and 
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secondary apoptosis, with minimal necrosis, hence, the DNA bands were more intact and 
apoptotic fragments were produced across cisplatin concentrations (figure 3.0 a and b). 
Increase in treatment duration resulted in more necrotic cell death as indicated by prominent 
DNA smearing (figure 3.0 c and d).  Furthermore, the results show that the drug is capable of 
inducing detectable DNA fragmentation within six hours of treatment (figure 3.0 a) and the 
extensive fragmentation observed at 1µM across treatment duration could be attributed to the 
similar case of heterogeneous cell population, where dividing cells are more prone to death as 
previously observed in chapter two, figure 2.1 and 2.2.   
 
Flow cytometric analysis of HEPG2 cell cycle distribution after treatment with cisplatin for 
twelve hours, followed by forty eight hours incubation in drug-free medium indicated that the 
effect of cisplatin on cell cycle progression was subtle at lower concentration, and cells were 
able to progress to G2/M phase until 8µM. However, cell cycle was almost completely halted 
at G0/G1 phase when cisplatin concentration was raised to 16µM (figure 3.3). This is an 
indication that at optimal treatment time, cellular cisplatin toxicity may be gradual and 
manageable. A comparison of cell cycle arrest and cell death due to cisplatin reveals that the 
extent of cell cycle arrest obtainable at lower concentrations was marginally higher than the 
degree of cell death. This is in agreement with the findings reported by Sancho-Martinez et 
al. (2011); that cell cycle arrest requires lower concentrations of cisplatin relative to cell 
death induction. The results presented in this chapter therefore, suggest that prolonged 
exposure of HEPG2 cells to a given dose of cisplatin might be responsible for tissue damage 
and associated toxicity characteristic of the drug. 
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CHAPTER FOUR 
TRANSGLUTAMINASE2 EXPRESSION AND ACTIVITY PROFILES IN 
PARENTAL AND DRUG-RESISTANT HEPATOCARCINOMA CELL LINES 
 
4.1: INTRODUCTION 
Many cancer deaths occur due to the ability of tumour cells to develop resistance to 
conventional drug therapy and metastasize successfully to distant sites (Verma & Mehta, 
2007). Determination of the changes in the pattern of expression of genes in tumours that 
contribute to the development of drug-resistance can reveal novel therapeutic targets for the 
treatment of cancer (Mehta et al. 2010). For over three decades, the molecular basis of drug 
resistance has been under investigation and several genes that may be involved in the 
mechanisms of drug resistance and metastasis have been identified (Jiang et al. 2003a, b; 
Mehta et al. 2010). Among these genes, TGM2, a stress-responsive gene which encodes 
transglutaminase 2 (TG2) enzyme, has been identified as a putative gene involved in tumour 
evasion of apoptosis, drug resistance, and metastasis (Iacobuzio-Donahue et al 2003; 
Agnihotri et al. 2013). 
 
A significant feature among drug-resistant and metastatic cancer cells is an increased level of 
TGM2 gene expression (Budillon et al. 2011). Elevated expression levels of TGM2 and its 
gene product TG2, have been demonstrated as a predominant feature of many advanced types 
of cancer cells, including pancreatic carcinoma (Verma et al. 2006), ovarian carcinoma 
(Satpathy et al. 2007; Hwang et al. 2008), malignant melanoma (Fok et al. 2006), lung 
carcinoma (Park et al. 2010), glioblastoma (Yuan et al. 2007), and breast carcinoma (Mehta 
et al. 2004).  
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TG2 has been shown to play a major role in apoptotic evasion, development of drug 
resistance, and metastasis in many cancer types (see Mehta et al. 2010 for a review). When 
aberrantly regulated, TG2 may aid tumour cells to evade apoptosis and have direct 
consequences on cancer drug resistance (Mehta, 1994; Chen et al. 2002 and metastatic 
progression (Mehta et al. 2004). For instance, Park et al (2009) reported that TG2-specific 
cross-linking activity resulted in the polymerization and inhibition of nucleophosmin, and 
concomitant increase in drug resistance potential of cancer cells. 
 
Recent evidence shows that aberrant expression of TG2 in mammary epithelial cells bestows 
stem cell characteristics on the cells (Kumar et al. 2011). Similarly, Kumar et al (2011) 
reported that high basal expression of TG2 in breast cancer cells promotes the development 
of stem cell features. Additionally, Caffarel et al (2013) observed that the activation of 
TG2:integrin-α5ß1 interactions through the stimulation of oncostatin M receptor in cervical 
squamous cell carcinoma, induced pro-malignant changes. Clinically, TG2 has been reported 
to serve as a predictive indicator of anticancer therapeutic efficacy. For instance, Jeong et al 
(2013) suggested that TG2 expression is a promising indicator of the effectiveness of 
epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) therapy in patients 
suffering from non-small cell lung cancer. Similarly, Assi et al. (2013) reported that the 
accumulation of TG2 in tumour stroma can serve as an independent risk factor for the 
identification of invasive ductal carcinomas (IDCs) of breast, and establish breast cancer 
patients at high risk of recurrence. They also observed that overexpression of TG2 can serve 
as an indicator of poor prognosis for IDC of the breast.  
 
Agnihotri et al. (2013) proposed that inflammation induced progression of breast cancer and 
promoted acquisition of survival and invasive capabilities by breast cancer cells. In acute 
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myeloid leukaemia, Pierce et al (2013) demonstrated that increased expression of TG2 
characterized a more advanced state of the disease in relapse patients. They further 
established that increased TG2 expression is correlated with the expression of proteins 
involved in apoptosis, motility and extracellular matrix association, processes that have been 
linked with leukaemia development and progression. This is a testament to the specialized 
ability of TG2 to interact with several proteins as substrates in various biological events, 
probably due to the unique biochemical structure of TG2 that is uncharacteristic of any other 
transglutaminase enzyme. 
 
From the available literature, it has become evident that TG2 is involved in cancer drug 
resistance and metastasis. Though, TG2 expression profile has been widely studied and 
reported in different cancer cell types as reviewed above, the involvement of TG2 in primary 
liver cancers such as human hepatocellular carcinoma (HCC) has not been reported; even 
though, the protein is abundant in liver cells. To date, no report has shown the expression 
pattern of TGM2 gene and its product, TG2, in parental hepatocellular carcinoma cell line in 
relation to the drug-resistant and possibly metastatic sub-clones. This loophole exists, 
notwithstanding the low survival rate of HCC due to its specialized ability to resist 
chemotherapy. TG2 abundance in liver cells, its link with drug resistance and metastasis in 
several cancer types, and the high mortality rate of HCC due to chemo-resistance, are some 
of the factors that informed the entire thesis. Here, the patterns of expression and activity of 
TG2 in parental and drug-resistant HEPG2 cell lines were investigated, with the view to 
gaining insights into the roles of TG2 in cancer drug-resistance and metastasis.  
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4.2: MATERIALS AND METHODS 
 
4.2.1: Materials 
Materials were obtained from Sigma Aldrich UK or Invitrogen UK, except RNA easy plus 
mini kit (Qiagen, UK), QuantiTect reverse transcription kit (Qiagen, UK), Superscript II 
reverse transcriptase with SYBR Green (Qiagen, UK), TG2-specific test kit (TG2-covtest) 
(Covalab, UK), recombinant human TG2 (rhTG2) produced in E. coli (Covalab, UK). 
 
4.2.2: RT-PCR analyses of TGM2 gene expression 
The pattern of expression of TGM2 gene in parental and drug-resistant hepatocellular 
carcinoma cell lines was determined following anticancer drug administration. The process 
involved total RNA extraction from cells, complementary DNA (cDNA) synthesis, and real-
time polymerase chain reaction (RT-PCR) as described by Kim et al. (2009) and Wang et al. 
(2012).  
 
Briefly, total RNA was extracted from parental and drug-resistant HEPG2 cell lines after 24 
hours incubation in medium containing cisplatin at 0µM to 16µM or 5-FU at 0µM to 100µM, 
using the RNA easy plus mini kit. Following cleanup of the RNA isolate through DNase 
treatment, cDNA was synthesized from 1µg of total RNA by reverse transcription process, 
using QuantiTect reverse transcription kit. Polymerase chain reaction was carried out using 
TGM2-specifc primers, forward primer 5'TAA GAG ATG CTG TGG AGG AG-3' and 
reverse primer 5'CGA GCC CTG GTA GAT AAA-3'.  Absolute mRNA molecules were 
normalized against actin forward primer AGCAGTTGTAGCTACCCGCCCA and reverse 
primer GGCGGGCACGTTGAAGGTCT. The amplification conditions used were 40 cycles 
of denaturation for 30 seconds at 94
o
C, annealing for 30 seconds at 55
o
C and 10 minutes 
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extension at 72
o
C. Potential DNA contamination was tested by the inclusion of one control 
reaction without RT enzyme.  
 
Values of TGM2 gene expression in the experimental samples were obtained by the 
interpolation of cycle threshold (Ct) values on standard amplification curves, derived from 
known amounts of cognate, amplicon-specific synthetic RNA; in this case, actin. Each set of 
experiment was done in duplicate and the actual expression level of TGM2 gene was the 
mean values of the duplicates plus or minus the standard deviation, represented as fold 
increase or decrease and represented using bar charts. The quality of the assay and the 
amplification of target gene were shown by the resulting single peaks obtained in the melting 
curves for all the reactions, which demonstrated that the experiments were devoid of 
contamination as shown in appendix three.  
 
4.2.3: Western blot analysis of TG2 protein expression 
Parental HEPG2 cell line and drug-resistant clones were treated as previously described in 
section 2.2.3. Afterwards, Western blot analyses were performed with the cell lysates 
following the methods described by Kumar et al. (2011), Wang et al. (2012), and Yakubov et 
al. (2013). Briefly, drug-treated cells were lysed directly on flasks with ice-cold RIPA buffer 
containing 50mM Tris-HCl (pH 8.0), 150mM sodium chloride, 1% igepal CA-630 (NP-40), 
0.5% sodium deoxycholate, and 0.1% sodium dodecyl sulfate (SDS); and protease inhibitor 
cocktail. Protein concentrations were determined using Bradford method as described by Lin 
et al. (2011), and lysates were snap-frozen in liquid nitrogen before storage at -80
o
C. Cell 
lysates were thawed on ice and mixed at the ratio of 1:1 with Laemmli buffer containing 4% 
SDS, 20% glycerol, 10% 2-mercaptoethanol, 0.004% bromphenol blue, and 0.125 M Tris 
HCl, pH approx. 6.8. The mixture containing 50µg of total protein was heated for ten minutes 
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at 70
o
C before separating the proteins on 10% to 12% NuPAGE Bis-Tris Mini Gels at a 
constant voltage of 100V and 70mA for one hour.  
 
Upon separation, the proteins were transferred onto nitrocellulose membranes at constant 
voltage of 100V and 400mA, using ice-cold blotting buffer containing 1% transfer buffer salt 
10X, 2% methanol, and 70% distilled water at 4
o
C. The membrane blots were subsequently 
blocked for two hours in blocking buffer containing 5% milk in TBS-Tween 20 (TBS-T), 
containing 20mM Tris-HCl, (pH 7.6), 0.8% (w/v) glycine, and 0.25% Tween-20. This was 
followed by incubation with primary antibody (anti-TGM1 (ab1), antibody produced in 
rabbit) (Sigma Aldrich, catalogue number: AV47471-50UG) in blocking buffer at the ratio of 
1:25,000, for forty minutes at room temperature. The blots were then washed three times with 
TBS-T for twenty minutes intervals, before further incubation with secondary antibody (ant-
rabbit IgG (whole molecule)-peroxidase antibody produced in goat) (Sigma Aldrich, 
catalogue number: A9169)  in blocking buffer, at the ratio of 1:25, 0000 for 30 minutes at 
room temperature. Afterwards, the blots were washed further times with TBS-T for twenty 
minutes interval, before incubation in horse radish peroxidase (HRP) substrate for twenty 
minutes to reveal the protein bands. 
 
4.2.4: General transglutaminase (Tgase) activity assay 
Transglutaminase activity was assayed by colorimetric hydroxamate method, following the 
recipe described by Montero et al. (2005) as originally designed by Folk and Cole, (1965). 
Firstly, to ascertain extent of activity of total Tgase in HEPG2 cell line and establish the 
optimal cell number with which Tgase activity is detectable, the activity of total Tgase was 
measured relative to cell number. Briefly, exponentially growing HEPG2 cells were 
harvested by trypsinization, reseeded at the range of 10
6
 cells to 40 x 10
6
 cells. Subsequently, 
91 
 
the cells were harvested at 4
o
C by direct lysis with ice-cold RIPA buffer containing 20% of 
protease inhibitor cocktail. This was followed by the preparation of a reaction mixture 
containing 200µl of 100mM CBZ-Glyn-Gly, 50µl of 100mM DTT, 50µl of 100mM calcium 
chloride, 100µl of 100mM hydroxylamine, 0.5ml of 50mM Tris-base (pH 8.0), and 50µg of 
total protein. The final reaction mixture was incubated for 10 minutes at 37
o
C before the 
addition of 0.5ml of 20mg/ml iron III chloride, following which product formation was 
measured spectrophotometrically on the basis of absorbance at 525nm. After measuring the 
enzyme activity in parental HEPG2 cell line relative to cell number, lysates from the drug-
resistant clones were tested for similar activity following treatment with cisplatin (0µM to 
16µM) for cisplatin-resistant cells or 5-FU (0µM to 100µM) for 5-FU resistant cells 
respectively. Each experiment was conducted in duplicate and the enzyme activity was 
represented as mean value ± standard deviations.    
 
4.2.5: Transglutaminase 2-specific activity assay using TG2-covtest kit 
Specific tissue transglutaminase (tTG/TG2) colorimetric microassay kit (TG2-CovTest) is 
based on the method described by Parez Alea et al. (2009). Essentially, it uses biotinylated 
T26 peptide (biotin-pepT26) as the first substrate (amine acceptor/acyl donor) and spermine 
as second substrate (amine donor/acyl acceptor). Samples thought to contain TG2 are 
incubated in the wells of microtiter plates with covalently bound spermine, in the presence of 
11.6mM calcium chloride, 50mM DTT, and biotin-pepT26. If TG2 is present in the samples, 
spermine is incorporated into the γ-carboxamide of the glutaminyl residue of biotin-pepT26, 
forming biotin-pepT26-γ-glutamyl spermine. The system is coupled to streptavidin labelled 
peroxidase (SAv-HRP), and subsequently revealed using hydrogen peroxide as HRP 
substrate and tetramethyl benzidine as electron acceptor. 
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TG2-specific activity was assayed in the three different cell lines, based on the assay 
principle described above. Accordingly, the cells from the exponentially growing cell lines 
were harvested by trypsinization, washed with 1X PBS, reseeded in T-75cm
2
 flasks, then 
incubated overnight for attachment, before appropriate treatment with cisplatin (0µM to 
16µM) or 5-FU (0µM to 100µM), and further twenty four hours incubation for drug action. 
Cell lysates were prepared as earlier described (section 4.2.3). TG2 activity was measured in 
duplicate samples for each test concentration, as described in the manufacturer’s protocol. 
 
4.3: RESULTS 
 
4.3.1: Analysis of TGM2 gene expression by RT-PCR 
The expression level of TG2 gene in untreated cells was used as the standard for the 
establishment of fold change. For each of the anticancer drugs under investigation, the pattern 
of expression of TGM2 gene in response to drug treatment was investigated in both parental 
and drug-resistant cell lines. Analyses of TGM2 gene expression in HEPG2 cell line 
following cisplatin treatment revealed that TGM2 gene expression level increased by 27%, 
44%, 52%, 27% and 20% at concentrations of 1uM, 2uM, 4uM, 8uM, and 16uM 
respectively, relative to untreated cells. Interestingly, however, a dramatic increase in TGM2 
gene expression was recorded in resistant clone (HEPG2CR) after similar treatment, where 
the expression level at 4µM nearly tripled relative to controls (figure 4.1). A p value of 
0.0313 shows that the expression of TGM2 gene in parental HEPG2 cells differs significantly 
from TGM2 gene expression in HEPG2CR cells, where significant difference is defined by a 
p value less than 0.05 (p < 0.05). 
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Additionally, target gene amplification was further confirmed by the subjecting the PCR 
products to electrophoretic separation. Agarose gel electrophoresis of the products resulted in 
uniform single banding pattern, matching the target size of about 180bp as shown in figure 
4.0.    
 
 
Figure 4.0: Confirmation of RT-PCR amplification of target TGM2 gene by gel 
electrophoresis; lane 1: marker, lanes 2, 3, 4, 5 and 6 are PCR products equivalent to 180bp 
target band size, obtained from different replicates of the experiment. The PCR product was 
sequenced by a colleague (Mark D’Arcy) and confirmed to be TGM2 gene.  
 
 
RT-PCR TGM2 Products 180bp 
200bp 
1    2          3                 4                   5                    6 
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Figure 4.1: Comparison of TGM2 gene expression in parental (HEPG2) and cisplatin-
resistant (HEPG2CR) cell lines after twenty four hours treatment with cisplatin, showing 
increased TGM2 gene expression that peaks at 4µM before decline, in both HEPG2 and 
HEPG2CR cells. The resistant clone (HEPG2CR) showed significantly higher expression 
levels of TGM2 gene relative to the parental cell line as indicated by a p value of 0.0313, 
where statistical significance is defined by a p value less than 0.05 (see appendix 4, table 
A4.8 and appendix 2, tables A2.3.1 and A2.3.2).   
 
A closer inspection of the pattern of expression of TGM2 gene in both HEPG2 and 
HEPG2CR revealed two common denominators between the two cell lines, namely: (a) A 
general pattern of initial increase in expression followed by a decline in expression with 
increase in cisplatin concentration. (b) A maximum expression level of TGM2 gene at 4µM 
of cisplatin in both cell lines. However, in addition to the similarity in the pattern of TGM2 
gene expression in both cell lines, the results also revealed a significant increase in the gene 
expression in the drug-resistant cell line relative to the parental cell line (p value = 0.0313). 
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For 5-FU, a comparison of TGM2 expression in HEPG2 and HEPG2FR cell lines after 
treatment with varying concentrations of 5-FU as described in section 4.2.2, revealed that the 
pattern of the gene expression was considerably different from what was obtained in 
cisplatin-treated lines. Though, a steady initial increase and final uniform decrease was 
recorded in both cell lines, the expression of TGM2 gene in HEPGFR cell line was lower 
than the expression level of the gene in the parental cell line (figure 4.2). This is a direct 
opposite of the results obtained in cisplatin-resistant cell line and the parental cell line. 
  
0 1
0
3
0
5
0
7
0
9
0
0 .0
0 .5
1 .0
1 .5
2 .0
               E x p re s s io n  o f T G M 2  g e n e  in  H E P G 2  a n d  H E P G 2 F R  c e lls
5 -F U  (M )
T
G
M
2
 f
o
ld
 c
h
a
n
g
e
H E P G 2
H E P G 2 F R
Paired t test
P value
P value summary
Significantly different? (P < 0.05)
0.0478
*
Yes
Figure 4.2: Expression of TGM2 gene in HEPG2 and HEPG2FR cell lines after twenty four 
hours treatment with 5-FU, showing opposing patterns of TGM2 gene expression relative to 
figure 4.1. In this case, a dramatic decrease in TGM2 gene expression was observed in the 
resistant clone relative to the parental cell line. A student paired t-test shows that TGM2 gene 
expression in HEPG2 cells is significantly different from that of HEPG2FR with p value of 
0.0478 where statistical significance is defined by a p value less than 0.05 at 95% confidence 
interval (see appendix 4, table A4.10 and appendix 2, tables A2.3.3 and A2.3.4). 
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4.3.2: Western Blot Analyses of TG2 Expression 
To understand the pattern of expression of TGM2 gene product, transglutaminase 2 (TG2), in 
both parental and drug-resistant hepatocellular carcinoma cell lines, Western blot analyses 
were carried out on the lysates from the cell lines. Essentially, the cell lines were treated as 
described in section 4.2.3 and 50µg of total protein in the lysate from each of the cell line was 
subjected to SDS-PAGE gel electrophoresis for separation as shown in figure 4.3. From the 
image shown below, the strength of the protein bands as an indication of the amount of 
soluble protein present in cell extracts prepared from six different replicates. 
 
 
Figure 4.3: SDS-PAGE gel image showing protein bands before Western blotting; lanes 1 to 
6: protein bands from six different cell extracts, containing 50µg of protein each; lane 7: 
marker of different sizes, up to 120 kDa as shown. 
 
4.3.2.1: Effect of cisplatin on TG2 protein 
A comparison of the expression pattern of TG2 with that of its gene, TGM2, in HEPG2 and 
HEPG2CR cell lines after cisplatin treatment for twenty four hours, the results showed a 
sustained increase in expression of TGM2 and TG2 in the drug-resistant cell line relative to 
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the parental cell line. Taken together, cisplatin-resistant hepatocellular carcinoma cell lined 
expressed higher level of TG2 messenger RNA and TG2 protein than the parental cell line in 
response to drug treatment. Additionally, results from the Western blot analysis showed that 
the expression TG2 increases with increased concentration of cisplatin in both HEPG2 and 
HEPG2CR as shown in figure 4.4 and figure 4.5. Interestingly, similar to TGM2 gene 
expression which was at its peak at 4µM in both parental and cisplatin-resistant cell lines, 
highest expression of TG2 protein was obtained at 4µM in HEPG2CR, before a gradual 
decline, also characteristic of the gene expression.  
  
 
 
Figure 4.4: Transglutaminase 2 protein (77.3kDa) expression in HEPG2 cell line following 
twenty four hours cisplatin treatment at different concentrations; lane 1: 0µM, lane 2: 4µM, 
lane 3: 8µM, lane 4: 16µM, land 5: 2.2µg of recombinant human TG2 (rhTG2), and lane 6: 
marker. 
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Figure 4.5: Expression of transglutaminase 2 protein (77.3kDa) in HEPG2CR cell line 
following twenty four hours cisplatin treatment different concentrations; lane 1: marker, lane 
2: 2.2µg of rhTG2, lane 3: 0µM, lane 4: 4µM, land 5: 8µM, and lane 6: 16µM. 
 
4.3.2.2: Effect of 5-FU on TG2 expression 
The expression of TG2 in parental and 5-FU-resistant hepatocellular carcinoma cell lines 
after 5-FU treatment assumed different pattern relative to the expression pattern of TGM2 
gene. Essentially, the results obtained from the Western blot analyses of cell extracts from 
both cell lines following drug induction, showed a steady increase in TG2 expression in both 
HEPG2 and HEPG2FR cell lines, relative to what was obtained in the gene expression 
results. A direct comparison of TG2 expression in HEPG2 and HEPG2FR cell lines showed a 
higher expression level in HEPG2FR than in HEPG2, however, increased TG2 expression 
with increasing 5-FU concentration was a common denominator between both cell lines 
(figure 4.6 and figure 4.7).    
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Figure 4.6: The expression pattern of TG2 protein (77.3kDa) in HEPG2 cell line in response 
to twenty four hours treatment with different concentrations of 5-FU; lane 1: 0µM, lane 2: 
30µM, lane 3: 50µM, lane 4: 100µM, land 5: 2.2µg of rhTG2, and lane 6: marker. 
 
 
 
Figure 4.7: Transglutaminase 2 protein (77.3kDa) expression in HEPG2FR cell line in 
response to twenty four hours treatment with different concentrations of 5-FU; lane 1: 2.2µg 
of rhTG2, lane 2: 100µM, lane 3: 50µM, lane 4: 30µM, land 5: 0µM, and lane 6: empty, lane 
7: marker. 
rhTG2         100µM     50µM     30µM       0µM                      Marker          
80kDa 
 
70kDa 
TG2 
77.3kDa 
  0µM      30µM       50µM      100µM       rhTG2      Marker 
 
80kDa 
 
70kDa 
TG2 
77.3kDa 
100 
 
4.3.3: Transglutaminase (Tgase) Activity Profiles in Parental and Drug-Resistant 
Hepatocellular Carcinoma Cell Lines  
In order to get general idea of the activity profiles of the entire transglutaminase (Tgase) 
family existent in hepatocarcinoma cells, and to establish the number of cells at which 
activity level of Tgase is optimum; an initial investigation of Tgase activity relative to cell 
number was carried out (section 4.2.4). The results obtained from this assay showed that 
Tgase activity is directly proportional to cell number (figure 4.8). Additionally, the optimal 
number of cells that could be cultivated in 75cm
2
 flask to obtain reasonable activity was 
established to as 10 x 10
6
 cells at 10
6
 cells per ml.   
 
    
Figure 4.8: CBZ-Hydroxamate-based assay of Tgase activity relative to HEPG2 cell number, 
using similar amount of total protein (50µg) from lysates produced from flasks containing 
different number of cells. Increased total Tgase activity as the cell number increases was 
recorded, though the activity level was approximately the same below five million cells.  
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4.3.3.1: Effect of cisplatin on Tgase activity 
A comparative analysis of total Tgase activity in parental (HEPG2) and cisplatin-resistant 
(HEPG2CR) cell lines after cisplatin treatment revealed a pattern of expression that followed 
the same pattern with the patterns of TGM2 gene and TG2 protein expression in the same cell 
lines after similar treatment. Again, the enzyme activity initially increased, peaked at 4µM in 
both cell lines, before declining at higher concentrations. The activity of Tgase was shown to 
be a significantly higher in resistant (HEPG2CR) compared to HEPG2 as indicated by a p 
value of 0.0041, where statistical difference is defined by p value less than 0.05 (p < 0.05) at 
95% confidence interval (figure 4.9). 
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Figure 4.9: CBZ-Hydroxamate-based assay of Tgase activity in HEPG2 and HEPG2CR cells 
after twenty four hours cisplatin treatment, showing increased Tgase activity in HEPG2CR 
cells compared to the parental HEPG2 cells. The activity of Tgase in HEPG2CR is 
significantly higher than its activity in HEPG2 cells as indicated by a p value of 0.0041, 
where statistical difference is defined by p value less than 0.05 (p < 0.05) at 95% confidence 
interval (appendix 4, table A4.12 and appendix 2, tables A2.3.5 and A2.3.6). 
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4.3.3.2: Effect of 5-FU on Tgase activity 
For 5-FU, analysis of Tgase activity in both parental (HEPG2) and 5-FU-resistant 
(HEPG2FR) cell lines showed a steady increase in enzyme activity with increasing drug 
concentration (figure 4.10). The pattern of Tgase activity conformed to the expression pattern 
of TG2 protein in HEPG2 and HEPG2FR cell lines under similar treatment with 5-FU. 
Though, increased activity of Tgase was recorded in both cell lines, the enzyme activity was 
slightly higher in HEPG2FR than in HEPG2, across concentrations. 
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Figure 4.10: CBZ-Hydroxamate-based assay of Tgase activity in HEPG2 and HEPG2FR 
following twenty four hours 5-FU treatment, showing a sustained increase in Tgase activity 
as drug concentration increases in both parental cell line and drug-resistant clone, with 
greater activity in HEPG2CR. A student paired t-test shows that the activity of Tgase in 
HEPG2FR is significantly different from its activity in HEPG2 as indicated by a p value of 
0.0073 which is less than 0.05 at 95% confidence interval (see appendix 4, table A4.14 and 
appendix 2, tables A2.3.7 and A2.3.8). 
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4.3.4: Transglutaminase 2-Specific Activity Profiles in Parental and Drug-Resistant 
Hepatocellular Carcinoma Cell Lines 
Following the analyses of total Tgase activities in parental and drug-resistant hepatocellular 
carcinoma cell lines, it became pertinent to establish the proportion of the total 
transglutaminase constituted by TG2 as opposed to total Tgase activity. Additionally, it was 
imperative to establish TG2-specific activity in the cell lines following drug treatment. This 
was done with the view to comparing the activity of TG2 with its expression at 
transcriptional and post-transcriptional levels in the cell lines. Consequently, total cell lysates 
from the three cell lines (HEPG2, HEPG2CR and HEPG2FR) treated accordingly with 
appropriate drug concentrations were subjected to TG2-specific activity assay (section 4.2.5).  
 
4.3.4.1: Effect of cisplatin on TG2 activity 
The activity of TG2 in HEPG2 and HEPG2CR maintained similar pattern as TGM2 and TG2 
expressions, again with an initial increase in activity and peak activity at 4µM (optimal 
concentration) in both cell lines followed by a uniform, steady decrease in activity. Unlike 
TGM2 and TG2 expression, there is no significant difference in activity of TG2 in parental 
and cisplatin-resistant HEPG2 cells (figure 4.11). 
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Figure 4.11: TG2-specific activity in HEPG2 and HEG2CR cell lines after twenty four hours 
treatment with cisplatin. From a student paired t-test, p value of 0.1987 which is greater than 
0.05 at 95% confidence interval indicates that there is no significant difference between TG2 
activities in parental and cisplatin-resistant cells (see appendix 4, table A4.16 and appendix 2, 
table A2.3.9).   
 
4.3.4.2: Effect of 5-FU on TG2 activity 
The enzyme activity was higher in HEPG2FR cell line relative to the parental cell line 
(Figure 4.12). Analysis of TG2 activity in 5-FU-treated cells revealed that TG2 activity 
initially increased, followed by a decreased activity before another rise in activity level as 5-
FU concentration increases in both parental (HEPG2) and 5-FU-resistant (HEPG2FR) cell 
lines. The pattern of TG2 activity in both cell lines after drug induction followed similar 
pattern as that of TGM2 gene expression, with maximum activity at maximum concentration.  
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Figure 4.12: TG2-specific activity in HEPG2 and HEG2FR cell lines following twenty four 
hours incubation with 5-FU-containing medium, showing a fluctuation in TG2 activity across 
drug concentrations. A statistical analysis of this result by student paired t-test shows that 
TG2 activity in HEPG2FR is significantly different from that of the parental HEPG2 cells, 
regardless of the fluctuation in pattern of activity. Hence, a p value of 0.0331 which is less 
than 0.05 indicates statistical difference, where significant difference is defined by p < 0.05 at 
95% confidence interval (see appendix 4, table A4.18 and appendix 2, table A2.3.10).   
 
4.4: DISCUSSION 
Analyses of the patterns of expression of TGM2 gene in parental (HEPG2) and cisplatin-
resistant (HEPG2CR) cell lines following repeated cisplatin treatments indicated an elevated 
expression level of TGM2 gene in HEPG2CR than in HEPG2 cells (figure 4.1). This pattern 
of expression is in agreement with earlier reports of elevated expression levels of TGM2 gene 
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in drug-resistant and metastatic cell lines derived from many cancer types, including 
pancreatic carcinoma (Verma et al. 2006), ovarian carcinoma (Satpathy et al. 2007; Hwang et 
al. 2008), malignant melanoma (Fok et al. 2006), lung carcinoma (Park et al. 2010), 
glioblastoma (Yuan et al. 2007), and breast carcinoma (Mehta et al. 2004). Comparing these 
patterns of expression of TGM2 gene with cell death patterns following similar treatment 
with cisplatin (as shown in previous chapters), it is rational to argue that increased expression 
of TGM2 gene may be elicited as an apoptosis evasion tool, in agreement with the anti-
apoptotic function of TG2 reviewed in Mehta et al. (2006), especially judging from the fact 
that the gene expression level is higher in drug-resistant cell. However, owing to the dual 
roles of TGM2 and its gene product in apoptosis, it is tempting to suggest that increased 
expression of TGM2 gene may be necessary to excite the cells to death due to cisplatin, in 
agreement with Mehta et al. (2006) and Verma & Mehta (2007). 
 
Additionally, a critical observation of the pattern of TGM2 gene expression in HEPG2 and 
HEPG2CR following induction with cisplatin revealed two significant commonalities 
between both cell lines: (a) A general pattern of initial increase in expression followed by a 
decline in expression with increase in cisplatin concentration. (b) A maximum expression 
level of TGM2 at 4µM of cisplatin in both cell lines. Comparison of these patterns of 
expression to cell death patterns shown in cell viability assay results in previous chapters 
(sections 2.3.1 and 3.3.1), it shows that the initial increase in TGM2 gene expression 
corresponds to the initial drop in cell viability in both cell lines following cisplatin 
introduction. In one hand, the initial elevated TGM2 gene expression level may be interpreted 
as an early defence response by the cells, and on the other hand, it may be a death signal 
corresponding to the initial sub-set of dividing cells of the cell population that are more 
susceptible to death due to chemotherapeutic stress, in this case, cisplatin. This is in 
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agreement with the proposition that TGM2 gene expression is elevated in the events of 
cellular stress, such as chemotherapeutic induction, where it is necessary to ensure the 
integrity of dying cells and prevent inflammation (Fesus & Szondy, 2005; Mehta et al. 2006) 
The expression of TGM2 gene steadily increased in the cell lines, peaking at 4µM cisplatin, 
and then declining afterwards with increasing drug concentration. The peak expression of 
TGM2 gene at 4µM, which was also the EC50 of cisplatin for parental cells, is particularly 
interesting and this may be due to the domination of the remaining cellular population by 
cells with more resistance potential. Beyond the optimal concentration of cisplatin, decrease 
in TGM2 gene expression seems to provide an avenue for drug action, hence, the 
corresponding increase in cell death.  
 
In 5-FU-treated cells, the expression pattern of TGM2 in parental (HEPG2) and 5-FU-
resistant (HEPG2FR) cell lines was directly opposite to the pattern of the same gene 
expression in cisplatin-treated hepatocarcinoma cell lines. This pattern of expression is 
suggestive of the fact that TGM2 gene expression is not only stress-dependent (Agnihotri et 
al. 2013), but stress-type-dependent. Essentially, TGM2 gene expression level was grossly 
decreased in the resistant clone (HEPG2CR) compared to the parental cell line (figure 4.2). 
This is in disagreement with previous reports of increased expression of TGM2 gene in cell 
lines derived from other cancer types (as reviewed in Mehta et al. 2010). However, merging 
the expression patterns of TGM2 gene with cell death patterns following similar treatment 
with 5-FU, it is tempting to assert that the role of TGM2 gene and TG2 in apoptosis is 
dependent on the type of apoptosis-inducing stimulus, as originally suggested by Milakovic 
et al (2004). Furthermore, it is tempting to suggest that the decreased expression of TGM2 
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gene in HEPG2FR may be due to poor extractability of RNA as a consequence of massive 
TG2 cross-linking effect upon drug induction.   
 
Western blot results of TG2 protein expression in HEPG2 and HEPG2CR cell lines after 
twenty four hours cisplatin treatment showed that the patterns of TG2 protein expression 
assumed similar patterns as TGM2 gene expression in the two cell lines. Elevated TG2 
protein expression was obtained in HEPG2CR relative to the parental HEPG2 cell line (figure 
4.4 and 4.5). This expression pattern of TG2 at both gene and protein levels is in agreement 
with previous reports that drug-resistant cells express high levels of TG2 relative to the 
parental cell line in many cancer types (Mehta et al 2010). Interestingly, the expression of 
TG2 peaked at 4µM as reported in the TGM2 gene expression results, hence, further 
strengthening the view that the presence of highest number of more resistant cells at EC50 of 
cisplatin might be responsible for the peak expression levels at both gene and protein levels. 
 
Analysis of TG2 protein expression in HEPG2 and HEPG2FR cell lines after 5-FU treatment 
for twenty four hours showed an increase in TG2 expression in both cell lines upon drug 
introduction. However, the expression of TG2 protein in the resistant clone was higher 
relative to the parental cell line (figure 4.6 and 4.7), and opposite to the expression pattern 
obtained at gene level. The elevated expression level of TG2 protein in resistant clone 
relative to the parental cell line again, is in agreement with previous reports in other cancer 
types (as earlier presented). However, the decreased level of TGM2 gene expression in 
HEPG2FR relative to the elevated expression level of TG2 protein in same cell line after 
similar treatment, suggests that the expression pattern of TG2 may not always necessarily be 
the same at transcriptional and post-transcriptional levels. On the other hand, this may further 
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substantiate the earlier assertion that lower expression of TGM2 gene in drug-resistant clone 
relative to the parental cell line may be due to the impediment of extractability by TG2 
crosslinking, hence, the use of stronger lysis buffer (RIPA buffer) during protein extraction 
relative to the weak buffer used during RNA extraction, resulted in increased protein yield. 
Analyses of general transglutaminase (Tgase) activity in parental and drug-resistant (HEPG2, 
HEPG2CR and HEPG2FR) cell lines following appropriate and corresponding drug 
treatment, revealed that Tgase activity increased with increased cell number and increased 
drug concentration across the cell lines (figure 4.8, 4.9, and 4.10). The activity of Tgase in 
HEPG2CR is significantly higher than its activity in HEPG2 cells as indicated by a p value of 
0.0041, where statistical difference is defined by p value less than 0.05 (p < 0.05) at 95% 
confidence interval (figure 4.9); in agreement with TGM2 gene and TG2 protein expression 
profiles discussed previously. In same vein, a student t-test shows that the activity of Tgase in 
HEPG2FR is significantly different from its activity in HEPG2 as indicated by a p value of 
0.0073 which is less than 0.05 at 95% confidence interval (figure 4.10).  
 
Interestingly, however, TG2-specific activity assay in all the cell lines showed a similar 
pattern of activity for HEPG2FR versus HEPG2, with a p value of 0.0331 which is less than 
0.05 indicates statistical difference, where significant difference is defined by p < 0.05 at 
95% confidence interval (figure 4.12). However, there is no significant difference in activity 
of TG2 in HEPG2CR versus HEPG2 as indicated by a p value of 0.1987, where statistical 
difference is defined by p value less than 0.05 (p < 0.05) at 95% confidence interval (figure 
4.11). This implies that 5-FU and cisplatin have different effects on TG2 activity. 
Furthermore, a comparative observation of Tgase and TG2 activity levels in all the cell lines 
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revealed that TG2 is the predominant member of transglutaminase enzymes present in liver 
cells, in agreement with its name liver transglutaminase. 
 
Comparing TG2 activity profiles with apoptosis profiles for parental HEPG2 cell line and 
cisplatin-resistant (HEPG2CR), there appears to be a relationship between TG2 activity and 
apoptotic progression. This is because decreased TG2 activity just after 4µM (figure 4.11) 
corresponds to increased cell death recorded after the same concentration of cisplatin (section 
2.3.2, figure 2.3). Furthermore, the initial increase in TG2 activity may be a pro-survival 
signalling mechanism employed by the cells to evade cisplatin action. From these results, it is 
therefore, reasonable to suggest that increase in TG2 activity may account for the ability of 
HEPG2 cells to evade cisplatin-induced apoptosis, and any attempt to decrease TG2 activity 
may sensitise cells to cisplatin-induced death. In the case of 5-FU, TG2 activity continued to 
increase with increased 5-FU concentration, in a similar fashion as the TG2 protein 
expression reported in section 4.3.2.2. This may account for the lower susceptibility of 
HEPG2 cells to 5-FU compared to cisplatin. 
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CHAPTER FIVE 
EFFECTS OF TG2 SILENCING ON DRUG RESISTANCE AND METASTASIS 
POTENTIAL OF HEPATOCARCINOMA 
 
5.1: INTRODUCTION 
Cell migration and invasion are important steps in a variety of physiological processes, 
including implantation, morphogenesis, embryogenesis, neurogenesis, angiogenesis, wound 
healing and inflammation (von der Mark et al. 1999; Cho & Klemke, 2000). However, cell 
migration and invasion are also involved in the pathophysiology of many diseases such as 
cancer (Bozzuto et al. 2010). The ability of cancer cells to spread from its primary site of 
origin and its subsequent growth in another distant organ within the body is called metastasis 
(Sahai, 2005; Valestyan and Weinberg, 2011). Metastatic spread of cancer cells from the site 
of their origin rather than primary tumours, are responsible for the high mortality rates 
associated with cancer; accounting for over 90% of cancer-related deaths (Hanahan & 
Weinberg, 2000; Mangala et al. 2007). The process of tumour metastasis involves distinct 
steps, including detachment of tumour cells from primary tumour, invasion of tumour cells 
into surrounding tissues, entry into blood or lymphatic vessels, dissemination in the blood 
stream or lymphatic system and, finally, invasion of other host tissues and proliferation at 
secondary sites (Parker & Sukumar, 2003; Bozzuto et al. 2010). 
 
Each of these metastatic processes requires a distinct molecular programme, where the 
regulation of the adhesive, migratory and cytoskeletal properties of the spreading cancer cells 
play important roles (Bozzuto et al. 2010).  Over the past decade, the molecular mechanisms 
underlying the various steps of tumour metastasis has been under intense investigation. Major 
efforts have been undertaken to elucidate novel proteins and pathways that are involved in the 
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transformation of primary tumour cells into metastatic clones, and develop therapeutic 
protocols that can control the metastasis of cancer cells (Mazzocca and Carloni, 2009; Jung et 
al. 2012). For instance, in an independent study, Jiang et al. (2003a, b) reported that TG2 was 
one of the eleven metastasis-associated proteins that were selectively elevated in metastatic 
human lung and breast carcinomas. Similarly, Mehta et al. (2004) observed that metastatic 
cancer cells isolated from parental breast cancer cell line expressed elevated levels of TG2; 
and metastatic lymph node tumours from patients with breast cancer showed consistent 
higher level of TG2 relative to primary tumours from same patients (Mangala et al. 2007). 
 
Furthermore, several reports have suggested that elevated TG2 expression enhances invasive, 
metastatic and drug resistance potentials of cancer cells (see Yakubov et al. 2013 for 
reviews). Mangala et al. (2007) suggested that TG2 expression in metastatic breast cancer 
cells promotes integrin-mediated cell attachment, survival signalling pathways, as well as cell 
migration and invasive capacity; whilst conferring apoptosis-resistance capability on the 
cells. Similarly, TG2 has been suggested to regulate ß-integrin-dependent cell adhesion to the 
ECM through the extracellular signalling activation of focal adhesion kinase; thus, 
contributing to increased cell survival and invasiveness (Verma et al. 2008; Satpathy et al. 
2009). Recently, Yakubov et al. (2013) reported that extracellular TG2 induces epithelial-to-
mesenchymal transition (EMT) through a distinct pathway that results in the activation of the 
transcription factor, nuclear factor kappa β (NF-ƙβ) and consequent increase in cellular 
invasiveness and peritoneal metastasis. TG2 has also been reported to enhance tumour 
aggressiveness, facilitating distant metastasis in both xenografts animal models and in 
patients with advanced breast cancer (Oh et al. 2011). 
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As previously reviewed in chapter one (section 1.5.3.2) elevated level of TG2 expression is a 
common denominator in drug-resistant and metastatic cancer cells derived from different 
cancer types. Indeed, TG2 down-regulation by small interfering RNA (siRNA) has been 
variously reported to attenuate cell adherence, survival and migration, whilst promoting the 
susceptibility of cancer cells to chemotherapy-induced death (section 1.5.3.2). The role of 
TG2 in cancer drug resistance and metastasis is suggested to be determined by its non-
enzymatic activation of extracellular survival signalling pathways, as typified by its 
interaction with integrins and fibronectin, as well as phospholipase C (reviewed by Odii and 
Coussons, 2014). However, it is yet to be established if the actual causal relationship between 
TG2 and cancer drug resistance and metastasis is dependent on its activity or expression. It is 
therefore pertinent to investigate, and to compare the effects of TG2 down-regulation and 
activity inhibition on cancer cells’ sensitivity to anticancer agents, as well as metastatic 
potential. It is for this reason that the implication of TG2 down-regulation in liver cancer drug 
resistance and metastasis was investigated, and the results are described below.  
 
5.2: MATERIALS AND METHODS 
 
5.2.1: Materials 
All the materials were obtained from Sigma Aldrich UK and Invitrogen UK, except Annexin 
V-FITC kit (BD Biosciences, Europe), flow cytometer FACS Calibur (BD Biosciences, 
Europe), matrigel coated plates (BD Biosciences, Europe), transmembrane inserts (BD 
Biosciences, Europe), and TG2-specific test kit (TG2-covtest) (Covalab, UK). 
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5.2.2: Cell culture 
Cell line and cell culture establishment involved similar method previously described in 
chapter two, subsection 2.2.2. 
 
5.2.3: Matrigel cell invasion and migration assay 
The invasive and migration potentials of parental and drug-resistant cells were investigated 
using biocoat matrigel invasion chamber (BD Biosciences, Europe). This experiment was 
adapted from the method reported by Choi et al. (2011), and following manufacturer’s 
instructions. Briefly, matrigel-coated 6-well companion plates (BD Biosciences, Europe) 
were thawed in ice. Cells from either parental or drug-resistant clones of HEPG2 were 
prepared by trypsinization and re-suspension at a final concentration of 10
5
 per ml, in serum-
free RPMI 1640 medium (Invitrogen, UK). Subsequently, trans-membrane inserts were 
carefully placed in coated and uncoated wells (negative controls) using sterile forceps. Then, 
2ml of cell suspension was transferred to each insert, followed by careful addition of 1.5ml of 
chemo-attractant (FBS) to the wells of the test companion plates (except the negative 
controls) via the access port; avoiding air bubbles. This was followed by incubation of the 
invasion chambers at 37
o
C, 5% CO2, and humidity for twenty four hours. 
 
After twenty four hours incubation, non-invading cells were removed using moistened cotton 
swab. Afterwards, cells were fixed with 100% methanol and stained with 1% Toluidine blue 
containing 1% borax. Staining procedure involves transfer of inserts containing fixed cells 
into Toluidine stain for two minutes, after which excess stain was rinsed in distilled water. 
Inserts were allowed to air dry and migrated cells were pictured and counted under the 
microscope. Data was expressed as percentage of invasion through the matrigel matrix 
membrane relative to the migration of cells through the uncoated membranes, as shown: 
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                            Mean number of cells invading through matrigel matrix insert 
% Invasion =                                                      x100% 
                             Mean number of cells migrating through the uncoated insert 
 
5.2.4: Assessment of siRNA uptake using BLOCK-iT 
The BLOCK-iT fluorescent oligo (Invitrogen, UK) is a fluorescein-labelled double-stranded 
RNA (dsRNA) oligomer designed for use in RNA interference (RNAi) analysis to facilitate 
optimization and assessment of lipid-mediated delivery of dsRNA oligonucleotides into 
mammalian cells. It is a double-stranded RNA duplex with similar length, charge, and 
configuration as standard small interfering RNA (siRNA) (Ciccarone et al. 1999).  
 
Prior to TG2 down-regulation by siRNA, BLOCK-iT was used to check transfection 
efficiency, following manufacturer’s instructions. Briefly, 20µM stock of BLOCK-iT was 
thawed on ice and diluted to 2µM using Opti-MEM® I Reduced Serum Medium and 
incubated at room temperature for five minutes. Also, lipofectamine 2000 reagent was diluted 
with Opti-MEM® I Reduced Serum Medium at the ratio of 1:25, and incubated at room 
temperature for five minutes. Afterwards, dilute Block-iT and lipofectamine 2000 reagent 
were mixed and incubated at room temperature for twenty minutes to form a complex. After 
twenty minutes incubation, BLOCK-iT-lipofectamine complex was added to HEPG2 cells 
(except for the control) seeded onto a special slide at the density of 2x10
4 
per ml of serum-
free Opti-MEM® I Reduced Serum Medium (Invitrogen, UK), and incubated for twenty four 
hours at 37
o
C, 5% CO2, and humidified atmosphere. After twenty four hours post-transfection 
incubation, oligo uptake was qualitatively assessed using fluorescence microscope.  
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5.2.5: TG2 down-regulation by small interfering RNA (siRNA) 
Down-regulation of TG2 by siRNA was carried out as after the establishment of transfection 
protocol (described in section 5.2.4), with the method originally reported by Kim et al. 
(2006). Briefly, parental and drug-resistant cells growing at 80% confluence were 
trypsinized, re-suspended and seeded in 25cm
2
 flasks at seeding density of 10
6
 cells per 
millilitre of serum-free Opti-MEM® I Reduced Serum Medium (Invitrogen, UK). After 
overnight incubation for cell attachment, siRNA duplex (5’-
GCUCAUGUUCUCAGCACUU-3’) targeting human TG2, was introduced into the cells 
(except for the control cells) using lipofectamine 2000 reagent as described in section 5.2.4. 
After twenty four to forty eight hours incubation, cells were harvested directly on flasks, 
using ice-cold RIPA buffer and the cell lysates were examined for TG2 by Western blot 
analysis, as previously described in chapter four, section 4.2.3.       
 
5.2.6: Post-silencing cell invasion and migration assay 
After siRNA silencing of TG2 in parental and drug resistant cell lines was carried out as 
described in sections 5.2.4 and 5.2.5, the cells were subjected to cell invasion and migration 
assessment using matrigel-coated companion plates and transmembrane inserts as previously 
described in section 5.2.3.   
 
5.2.7: Post-silencing chemosensitivity assay 
Following the successful down-regulation of TG2 in parental and drug-resistant HEPG2 cells 
as previously described in sections 5.2.4 and 5.2.5, the susceptibility of the cells to the 
chemotherapeutic drugs with which they were selected was tested using the method 
previously described in chapter two, section 2.2.7. 
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5.2.8: Post-silencing apoptosis assay by flow cytometry 
After TG2 down-regulation by siRNA, the three cell lines under investigation were treated 
with appropriate concentrations of cisplatin or 5-FU and cell death distribution was analysed 
using flow cytometry, as previously described in chapter three (section 3.2.5).  
 
5.2.9: Cystamine inhibition of TG2 activity 
The therapeutic benefit of cystamine (mecaptoethanolamine (MEA) disulfide) is partly 
attributed to its ability to inhibit transglutaminase activity (Karpuj et al. 2002; Dedeoglu et al. 
2002). Within cells, cystamine has been shown to be reduced to MEA with the amine group 
of MEA acting as substrate to TG2, resulting in the formation of N
β
-(γ-L-glutamyl)-MEA 
bonds, consequently competing with TG2-catalysed reactions like polyamination, 
deamination, and cross-linking reactions (Jeitner et al. 2005). 
 
To ascertain the best concentration of cystamine at which TG2 activity is inhibited, parental 
and drug resistant cells growing at logarithmic phase were harvested by trypsinization, 
washed with 1% PBS and re-suspended in fully supplemented RPM 1640 medium. The cells 
were seeded in six-well plates at density of 10
6
 cells per millilitre of medium, incubated 
overnight at 37
o
C, 5% CO2, and humidified atmosphere. Subsequently, the cells were treated 
with different concentrations of cystamine, ranging from 0mM to 4mM, and maintained at 
similar incubation conditions for twenty four hours. Afterwards, the cells were harvested and 
the resulting cell lysates were examined for TG2 activity using TG2-specific colorimetric 
microassay kit (TG2-CovTest) as described in chapter four, section 4.2.5.   
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5.2.10: Chemosensitivity assay after cystamine inhibition of TG2 activity  
After the inhibition of TG2 activity using cystamine, sensitivity of parental and drug resistant 
cells to cisplatin or 5-FU was examined using similar method previously reported in chapter 
two (section 2.2.7). 
 
5.2.11: Analysis of cell invasion and migration after the inhibition of TG2 activity  
Following the inhibition of TG2 activity by cystamine, parental HEPG2 cell line and the 
drug-resistant clones were assessed for invasion and migration capabilities using matrigel-
coated companion plates and transmembrane inserts as earlier described in section 5.2.3.   
 
5.2.12: Analysis of cell death distribution after cystamine inhibition of TG2 activity  
Following the inhibition of TG2 activity using cystamine, parental and drug resistant cells 
were treated with appropriate concentrations of cisplatin or 5-FU, and cell death distribution 
was analysed by flow cytometry as previously described in chapter three (section 3.2.5). 
 
5.3: RESULTS 
 
5.3.1: In vitro assay of invasive and migration potentials of parental and drug-resistant 
HEPG2 cells  
The ability of parental and drug-resistant HEPG2 cells to invade and migrate to distant sites 
was investigated in vitro using matrigel coated plates and transmembrane inserts as 
schematically represented in figure 5.0. This test also provided room to compare the invasive 
and migration capacities of the parental HEPG2 cell line and the drug-resistant clones. The 
results indicate that the three cell lines are capable of migrating to distant sites and they all 
invaded the membrane inserts as shown in figure 5.1b. 
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Figure 5.0: Schematic representation of matrigel invasion assay processes: (1) thaw matrigel 
at 37
o
C and seed cells in culture medium (2) incubate cells for twenty four hours at 37
o
C in 
culture medium containing chemo-attractant (foetal bovine serum in this case) (3) scrape un-
migrated cells using cotton bud and fix the migrated cells in methanol (4) stain cells with 
Toluidine blue containing 1% borax (5) wash excess dye and allow to dry (6) count migrated 
cells under microscope.  
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                                                                         (a) 
   
                                                              (b) 
Figure 5.1: (a) Surface of matrigel showing un-migrated cells before scrapping to reveal 
(x400) (b) migrating cells invading the membrane insert as shown by the arrowheads (x400). 
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Figure 5.2: Percentage invasion and migration of parental and drug-resistant hepatocarcinoma 
cell lines on matrigel-coated surface. The three clones of HEPG2 displayed invasive and 
migration potential and a statistical analysis by ANOVA shows that there is no significant 
difference in the invasiveness of parental HEPG2 cells and the drug-resistant clones; p value 
= 0.4115 which is greater than 0.05 which defines significance (appendix 4, table A4.19). 
Additionally, student t-test comparing the invasive abilities of resistant clones with that of the 
parental cells shows that they have similar invasive propensity. For HEPG2 vs HEPG2CR, p 
value = 0.2539; HEPG2 vs HEPG2FR, p value = 0.0820; HEPG2CR vs HEPG2FR, p value = 
0.8581; all of which are greater than 0.05 at 95% confidence interval (appendix 4, tables 
A4.20, A4.21 and A4.22 respectively, and appendix 2, table A2.4.1).  
 
5.3.2: Qualitative assessment of siRNA uptake 
Prior to TG2 down-regulation by siRNA, it is important to ascertain the possibility of lipid-
mediated siRNA incorporation into the cells under investigation. To achieve this, a 
fluorescein-labelled double-stranded RNA duplex with similar length, charge, and 
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configuration as standard siRNA was introduced into the cells using similar lipid-based 
protocol for siRNA transfection. The intake of siRNA was qualitatively assessed under 
fluorescence microscope. The result revealed that the lipid-mediated transfection protocol is 
very efficient and suitable for the planned assay. Over 90% of the transfected cells showed 
fluorescence, while cells in the control (without BLOCK-iT) showed no fluorescence (figure 
5.3 a and b). 
 
                                                                   (a) 
 
                                                                   (b) 
Figure 5.3: Fluorescent microscopy analysis of siRNA incorporation into cells (a) uptake of 
siRNA by the cells as shown by the red arrowheads (x100) (b) Untreated control showing no 
fluorescence as indicated by the black arrowheads (x100). 
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5.3.3: TG2 down-regulation in parental and drug-resistant HEPG2 cells  
To determine the role of TG2 in cancer drug resistance and metastasis, siRNA was used to 
down-regulate its expression. After twenty four hours incubation of either parental HEPG2 
cell line or the drug-resistant clones with siRNA, results obtained from the Western blot 
examination of the cell lysates revealed only a slight reduction in TG2 expression in the 
treated cells relative to the untreated control. This could be seen in figure 5.4 a, lanes 1 
(HEPG2CR), 2 (HEPG2FR), and 4 (HEPG2), relative to lane 5 (untreated control). However, 
Western blot analysis of cell lysates obtained from HEPG2 clones forty eight hours after 
siRNA was introduced into the cells showed a significantly reduced expression of TG2 in the 
lysates of treated cells relative to the untreated cells. The expression levels of TG2 in the 
three cell lines after forty eight hours incubation with or without siRNA are shown in figure 
5.4b, where lane 1 contains a combined lysates from all siRNA-treated cells; lane 2 (treated 
HEPG2CR); lanes 3 and 4 (2.2µg rhTG2 as positive control); lane 5 (treated HEPG2); lane 6 
(treated HEPG2FR); lanes 7 to 9 (untreated controls for HEPG2CR, HEPG2 and HEPGFR 
respectively); and lane 10 (molecular marker). 
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                                                               (a) 
 
 
                                                                    (b) 
Figure 5.4: Western blot analysis of TG2 protein expression following the introduction of 
siRNA into the cells and incubation for (a) twenty four hours: lane 1 (HEPG2CR), lane 2 
(HEPG2FR), lane 3 (rhTG2 as positive control), lane 4 (HEPG2), lane 5 (untreated control), 
and lane 6 (molecular marker); (b) forty eight hours: lane 1 contains a combined lysates from 
all siRNA-treated cells; lane 2 (treated HEPG2CR); lanes 3 and 4 (2.2µg and 0.5µg rhTG2 
respectivels, as positive controls); lane 5 (treated HEPG2); lane 6 (treated HEPG2FR); lanes 
7 to 9 (untreated controls for HEPG2CR, HEPG2 and HEPGFR respectively); and lane 10 
(molecular marker). 
HEPG2CR             HEPG2FR            rhTG2                 HEPG2      Untreated control     Marker 
Combined        Treated        2.2µg          0.5µg    Treated    Treated                         untreated 
all treated        HEPG2CR   rhTG2        rhTG2    HEPG2   HEPG2FR  HEPG2CR  HEPG2  HEPG2FR    Marker 
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5.3.4: Analysis of cell invasion and migration after TG2 down-regulation 
Following the result that both parental and drug-resistant HEPG2 clones have invasive and 
migration potential as shown in the results previously presented in section 5.3.1, it is 
therefore, pertinent to establish the possible involvement of TG2 in facilitation of the invasive 
and migration features of the cells. Consequently, TG2 down-regulation was carried out as 
previously reported in section 5.2.5, followed by the assessment of the invasive and migration 
behaviours of the different cell line under investigation. The results revealed that TG2 down-
regulation has a considerable effect on the invasive and migration capabilities of the cells. A 
comparison of the results shown in figure 5.5 with the results of invasion and migration assay 
shown in figure 5.2 (section 5.3.1), revealed a reduced percentage of cell invasion and 
migration after TG2 down-regulation. However, TG2 down-regulation has an obvious 
minimal effect on the invasiveness of 5-FU-resistant (HEPG2FR) cells, where only 11% 
reduction was achieved relative to parental HEPG2 (21%) and cisplatin-resistant (HEPG2CR) 
(19%) cells respectively (figure 5.5). 
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Figure 5.5: Comparison of percentage invasion and migration of parental and drug-resistant 
HEPG2 clones on matrigel-coated surface before and after TG2 down-regulation. Reduction 
in cell invasion and migration was recorded in all the cell lines relative to the results recorded 
before TG2 silencing. Statistical analysis using one-way ANOVA shows that the 
invasiveness of both parental and drug-resistant cells was significantly reduced following 
TG2 protein down-regulation by siRNA, with a p value of 0.0001 and strength of statistical 
significance (***) as shown in appendix 4, table A4.23. A further statistical analysis of the 
invasive ability of each HEPG2 clone with and without siRNA was done using student t-test. 
For HEPG2 vs HEPG2+siRNA, p value = 0.0339; HEPG2CR vs HEPG2CR+siRNA, p value 
= 0.0094; and HEPG2FR vs HEPG2FR+siRNA, p value = 0.0332; all of which indicate that 
the siRNA down-regulation of TG2 protein expression significantly reduced cellular 
invasiveness at 95% confidence interval and where p < 0.05 equals statistical significance 
(see appendix 4, tables A4.24, A4.25 and A4.26 respectively, and appendix 2, table A2.4.2).  
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5.3.5: Assay of cellular susceptibility to chemotherapy after TG2 down-regulation 
After TG2 down-regulation by siRNA interference, it is important to investigate if the causal 
relationship between TG2 and cancer drug resistance is dependent on its expression. 
Consequently, the susceptibility of parental and drug-resistant HEPG2 clones to cisplatin or 
5-FU was evaluated in the presence of reduced TG2 expression. The results obtained from 
these experiments relative to the results previously presented in chapter two, section 2.3.3 
(figure 2.3 and figure 2.4) showed that both parental and drug-resistance cells were less 
susceptible to chemotherapy-induced death after TG2 down-regulation. Statistical analysis of 
HEPG2 and HEPG2CR susceptibility to cisplatin-induced death after down-regulation of 
TG2 protein expression by siRNA shows that HEPG2 cells  are significantly more to cisplatin 
following TG2 down-regulation, with p value of 0.0167 (figure 5.6). However, a student t-
test evaluation of the effect of cisplatin on HEPG2CR vs HEPG2CR+siRNA shows that TG2 
down-regulation has no significant effect on the susceptibility of HEPG2CR cells to cisplatin-
induced death (p value = 0.3103 > 0.05 at 95% confidence interval) (figure 5.6). On the other 
hand, analysis of the susceptibility of HEPG2 and HEPG2FR to 5-FU following TG2 down-
regulation by siRNA using one-way ANOVA shows that TG2 down-regulation has no 
significant effect on the susceptibility of both parental and 5-FU-resistant HEPG2 clones to 
5-FU treatment, with p value of 0.0774 which is greater than 0.05 at 95% confidence interval 
(figure 5.7). A student t-test of the effect of TG2 down-regulation on the susceptibility of 
HEPG2 clones to 5-FU-induced death further confirmed that it has insignificant effect on 
both HEPG2 and HEPG2FR, where the p value for HEPG2 vs HEPG2+siRNA is 0.1144 and 
the p value for HEPG2FR vs HEPG2FR+siRNA is 0.3198, all of which are greater than 0.05 
at 95% confidence interval (figure 5.7). 
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Figure 5.6: Assessment of HEPG2 and HEPG2CR response to cisplatin-induced death after 
down-regulation of TG2 protein expression by siRNA, showing significant increase in 
sensitivity of HEPG2 cells to cisplatin following TG2 down-regulation, with p value of 
0.0167 after a student t-test (appendix 4, table A4.27). However, a student paired t-test 
evaluation of the effect of cisplatin on HEPG2CR with and without siRNA (HEPG2CR vs 
HEPG2CR+siRNA), shows that TG2 down-regulation has no significant effect on the 
sensitivity of HEPG2CR cells to cisplatin-induced death (p value = 0.3103 > 0.05 at 95% 
confidence interval) (appendix 4, table A4.28). Additionally, a further statistical analysis by 
one-way ANOVA shows that TG2 down-regulation by siRNA significantly increased cell 
death due to cisplatin; p value = 0.0103, where p value < 0.05 defines statistical significance 
at 95% confidence interval (see appendix 4, table A4.29 and appendix 2, table A2.4.4).  
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Figure 5.7: A representation of the susceptibility of HEPG2 and HEPG2FR to 5-FU 
following TG2 down-regulation by siRNA. Statistical analysis by one-way ANOVA shows 
that TG2 down-regulation has no significant effect on the susceptibility of both parental and 
5-FU-resistant HEPG2 clones to 5-FU treatment, with p value of 0.0774 which is greater than 
0.05 at 95% confidence interval (see appendix 4, table A4.30). A student paired t-test of the 
effect of TG2 down-regulation on the susceptibility of HEPG2 clones to 5-FU-induced death 
confirmed that it has insignificant effect, where the p value for HEPG2 vs HEPG2+siRNA is 
0.1144 and the p value for HEPG2FR vs HEPG2FR+siRNA is 0.3198, all of which are 
greater than 0.05 at 95% confidence interval (appendix 4, tables A4.31 and A4.32 
respectively, and appendix 2, table A2.4.5). 
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5.3.6: Flow cytometric analysis of drug-induced cell death after TG2 down-regulation  
After the downregulation of TG2 protein expression by siRNA interference, flow cytometric 
assay of cellular susceptibility to drug-induced death revealed that there is no significant 
improvement in the susceptibility of HEPG2CR or HEPG2FR to cisplatin or 5-FU treatment, 
respectively. A student paired t-test of the susceptibility HEPG2+siRNA vs HEPG2 to 
cisplatin-induced death shows that the downregulation of TG2 protein expression has 
significant effect on the susceptibility of the parental cells to cisplatin with p value of 0.0399, 
which is less than 0.05 at which statistical significance is defined (figure 5.8). However, a 
student paired t-test of HEPG2CR+siRNA vs HEPG2CR shows that the downregulation of 
TG2 protein expression has no significant effect on the susceptibility of HEPG2CR to 
cisplatin-induced death, with p value of 0.1887 > 0.05, which defines statistical significance 
at 95% confidence interval (figure 5.8). In the case of 5-FU, both HEPG2 and HEPG2FR 
cells show no improvement in their susceptibility to 5-FU-induced death after TG2 protein 
downregulation, as indicated by a p value of 0.2484 for HEPG2+siRNA vs HEPG2, and a p 
value of 0.0703 for HEPG2FR+siRNA vs HEPG2FR, where p < 0.05 is statistically 
significant at 95% confidence interval (figure 5.9). 
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Flow cytometric analysis of cisplatin-induced cell death after TG2 down-regulation
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Figure 5.8: Flow cytometric analysis of the susceptibility of HEPG2 clones to cisplatin-
induced death after the downregulation of TG2 protein expression by siRNA interference. 
Student paired t-test of the susceptibility of HEPG2+siRNA vs HEPG2 to cisplatin-induced 
death shows a significant increase in HEPG2 cells’ death due to cisplatin, with a p value of 
0.0399, where p < 0.05 is statistically significant at 95% confidence interval (appendix 4, 
table A4.61). Conversely, a student paired t-test of death response of HEPG2CR+siRNA vs 
HEPG2CR to cisplatin shows no significant improvement in HEPG2CR susceptibility to 
cisplatin, with p value of 0.1887 (see appendix 4, table A4.62). 
 
P = 0.0399 
P = 0.1887 
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Flow cytometric analysis of 5-FU-induced cell death after TG2 down-regulation
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Figure 5.9: Flow cytometric analysis of the susceptibility of parental and 5-FU-resistant 
HEPG2 cells to 5-FU-induced death after the downregulation of TG2 protein expression by 
siRNA interference. Student paired t-test of the susceptibility of HEPG2+siRNA vs HEPG2 
to death due to 5-FU shows that downregulation of TG2 protein expression has no significant 
effect on the susceptibility of HEPG2 cells to 5-FU-induced death, with a p value of 0.2484, 
where p < 0.05 is statistically significant at 95% confidence interval (appendix 4, table 
A4.63). Similarly, a student paired t-test of death response of HEPG2FR+siRNA vs 
HEPG2FR to 5-FU shows no significant improvement in HEPG2FR susceptibility to 5-FU-
induced death, with p value of 0.0703 (see appendix 4, table A4.64). 
 
5.3.7: Analysis of TG2 activity after inhibition by cystamine   
To establish the optimum concentration of cystamine at which TG2 activity was inhibited, 
without affecting the viability of the cells, varying concentrations of cystamine, ranging from 
0mM to 4mM were applied to the different cell lines and the resulting lysates were 
P = 0.2484 
P = 0.0703 
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subsequently analysed for TG2-specific activity. The results showed a steady decline in TG2 
activity as cystamine concentration increased, with lowest activity of TG2 recorded at highest 
concentration (2.5mM) for all the cell lines (figure 5.10). Prior to cell lysis, a fraction of the 
cells were with trypan blue and examined under the microscope to ascertain their viability, 
and the cells looked healthy across the concentration range tested. 
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Figure 5.10: Inhibition of TG2 activity using different cystamine concentrations, ranging 
from 0mM to 4mM; to establish the best concentration of cystamine at which TG2 activity 
will be optimally inhibited without affecting the viability of the cells. Statistical analysis by 
One-way ANOVA shows that cystamine significantly reduced the activity of TG2 in all 
HEPG2 clones, with p value of 0.0018 at p < 0.05 = statistical significance (see appendix 4, 
table A4.34, and appendix 2, table A2.4.6). 
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5.3.8: Evaluation of cell invasion and migration after the inhibition of TG2 activity 
After establishing that 2.5mM concentration of cystamine is the optimal concentration needed 
to inhibit TG2 activity, without adversely affecting cell viability, the three clones of HEPG2 
cells under investigation were treated with 2.5mM of cystamine and evaluated for their 
invasive and migration capabilities. The results obtained from this experiment revealed that 
the ability of the cells to invade matrigel-coated surface and migrate to distant site was 
significantly reduced in comparison with the results obtained from similar experiment 
(without inhibition of TG2 activity) earlier presented in section 5.3.1, figure 5.2. From figure 
5.11 below, it is evident that the percentage of invasion and migration recorded in all the cell 
lines decreased markedly. Furthermore, comparing the percentage of cell invasion and 
migration after TG2 down-regulation (section 5.3.4, figure 5.5) and the post-TG2 inhibition 
percentage of invasion and migration (figure 5.11), showed that the invasive and migration 
behaviours of parental and drug-resistant HEPG2 cells were reduced in both cases. However, 
inhibition of TG2 activity has more effect on cellular invasion and migration relative to TG2 
down-regulation, whilst HEPG2FR cell line was less affected in both circumstances, relative 
to HEPG2 and HEPG2CR cells.  
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Figure 5.11: A representation of percentage invasion and migration of parental and drug-
resistant HEPG2 clones on matrigel-coated surface before and after the inhibition of TG2 
activity with 2.5mM cystamine. A marked reduction in cell invasion and migration was 
recorded in all the cell lines relative to the results recorded before TG2 activity inhibition. 
Again, the invasiveness of HEPGFR was relatively affected less. Statistical analysis of the 
effect of inhibition of TG2 activity on the invasive capacity of parental and drug-resistant 
HEPG2 clones by One-way ANOVA shows that cellular invasiveness was significantly 
reduced following TG2 activity inhibition, with a p value of 0.0009 at p < 0.05 = statistical 
significance as shown in appendix 4, table A4.35. A t-test of each clone of HEPG2 with 
cystamine against same clone without cystamine further confirmed that the inhibition of TG2 
activity significantly inhibits the invasive ability of both parental and drug-resistant cells. For 
HEPG2 vs HEPG2+cystamine, p value = 0.0063; HEPG2CR vs HEPG2CR+cystamine, p 
value is 0.0019; and HEPG2FR vs HEPG2FR+cystamine, p value is 0.0013, all of which are 
statistically significant with p values < 0.05 at 95% confidence interval (appendix 4, table 
A4.36, A4.37 and A4.38 respectively, and appendix 2, table A2.4.3). 
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5.3.9: Assessment of cellular sensitivity to chemotherapeutic drugs after the inhibition 
of TG2 activity  
Following the inhibition of TG2 activity, it is pertinent to establish if the causal relationship 
between TG2 and cancer drug resistance is determined by its activity. Consequently, parental 
and drug-resistant HEPG2 cells were tested for their susceptibilities to cisplatin or 5-FU after 
the inhibition of TG2 activity. Comparing the results with the results previously reported in 
chapter two, section 2.3.3 (figure 2.3 and 2.4), both parental HEPG2 cell line and drug-
resistant clones show an increased susceptibility to both cisplatin and 5-FU toxicity, with 
highest susceptibility recorded in parental cells relative to the drug-resistant cells. One-way 
ANOVA analysis of the susceptibility of HEPG2 and HEPG2CR cells to cisplatin-induced 
death with or without cystamine inhibition of TG2 activity shows signigicant increase in the 
susceptibility of the cells to cisplatin, with p value of 0.0106 (figure 5.12). Interestingly, a 
student t-test of the susceptibility of HEPG2 vs HEPG2+cystamine shows that HEPG2 cells 
are highly susceptible to cisplatin-induced death but the inhibition of TG2 activity makes no 
significant difference in cells’ response to cisplatin, with p value of 0.4165 (figure 5.12). 
However, for HEPG2CR vs HEPG2CR+cystamine, inhibition of TG2 activity significantly 
improved cellular susceptibility to cisplatin-induecd death, with a p value of 0.0188, 
following a student t-test (figure 5.12) . 
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Figure 5.12: Percentage respone of HEPG2 and HEPG2CR cells to cisplatin treatment after 
the inhibition of TG2 activity with 2.5mM of cystamine. One-way ANOVA analysis of the 
susceptibility of HEPG2 and HEPG2CR cells to cisplatin-induced death with or without 
cystamine inhibition of TG2 activity shows signigicant increase in the sensivity of the cells to 
cisplatin following inhibition of TG2 activity, with p value of 0.0106 which is less than 0.05 
at which statistical significance was defined (appendix 4, table A4.39). Interestingly, a 
student paired t-test of the susceptiblity of HEPG2 vs HEPG2+cystamine shows that HEPG2 
cells are highly sensitive to cisplatin-induced death and the inhibition of TG2 activity makes 
no significant difference in cells’ response to cisplatin, with p value of 0.4165 which is 
greater than 0.05 (appendix 4, table A4.40). However, for HEPG2CR vs 
HEPG2CR+cystamine, inhibition of TG2 activity significantly improved cell response to 
cisplatin-induecd death, with a p value of 0.0188 after a student t-test at 95% confidence 
interval and p value < 0.05 = statistical significance (see appendix 4, table A4.41 and 
appendix 2, table A2.4.7). 
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Figure 5.13: Susceptibility of HEPG2 and HEPG2FR to 5-FU-induced death following the 
inhibition of TG2 activity with 2.5mM of cystamine. Statistical analysis of the results by one-
way ANOVA shows that cystamine inhibition of TG2 activity significantly increased the 
susceptibility of HEPG2 and HEPG2FR cells to 5-FU-induced death, with p value of 0.0054, 
where p value < 0.05 = statistical significance (see appendix 4, table A4.42). The increased 
sensitivity of HEPG2 clones to 5-FU-induced death following inhibition of TG2 activity was 
further confirmed for both HEPG2 and HEPG2FR cells using student paired t-test. For 
HEPG2 vs HEPG2+cystamine, p value is 0.0456 (appendix 4, table A4.43), while HEPG2FR 
vs HEPG2FR+cystamine, p value is 0.0239 (appendix 4, table A4.44). These p values are less 
than 0.05, hence, statistically significant at 95% confidence interval (see also appendix 2, 
table A2.4.8). 
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5.3.10: Comparison of the effects of TG2 protein silencing and TG2 activity inhibition 
on cellular sensitivity to cisplatin and 5-FU 
Direct comparison of the implications of TG2 protein expression down-regulation and TG2 
activity inhibition in parental and drug-resistant HEPG2 cells revealed that the enzyme 
activity of TG2 is more important in the definition of its role in drug resistance than its 
expression.  As shown in figure 5.14 and figure 5.15, when TG2 protein is present and its 
enzymatic activity is absent due to cystamine inhibition, both parental and drug-resistant 
HEPG2 cells were markedly sensitive to cisplatin and 5-FU treatment. Conversely, when the 
TG2 protein expression is down-regulated with residual enzymatic activity present (though 
not measured), HEPG2 cells were less sensitive to cisplatin and 5-FU drug therapy.  
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Figure 5.14: Comparison of the effects of TG2 expression down-regulation and TG2 activity 
inhibition on the susceptiblity of parental and cisplatin-resistant HEPG2 cells to cisplatin 
therapy. The expression of TG2 protein without its activity in parental and cisplatin-resistant 
cells (HEPG2+cystamine and HEPG2CR+cystamine) resulted in pronouced sensitivity of the 
cells to cisplatin treatment. However, with the down-regulation of TG2 protein expression 
and residual enzymatic activity (HEPG2+siRNA and HEPG2CR+siRNA) the cells were 
comapratively less susceptible to cisplatin-induced death. One-way ANOVA analysis of the 
results shows that there is significant difference in cellular response to cisplatin-induced 
death following the inhibition of TG2 activity and the down-regulation of its expression, with 
p value of 0.0056 as shown in appendix 4, table A4.45. Further statistical comparison of 
HEPG2+cystamine vs HEPG2+siRNA by student paired t-test shows that response to HEPG2 
to cisplatin-induced death significantly increased when TG2 activity was inhibited compared 
to when its expression was down-regulated, with a p value of 0.0212, where p < 0.05 = 
statistical significance at 95% confidence interval (appendix 4, table A4.46). Similarly, 
HEPG2CR+cystamine was more susceptible to cisplatin-induced death compared to 
HEPG2CR+siRNA, with a p value of 0.0083 as shown in appendix 4, table A4.47.  
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Figure 5.15: Comparison of the effects of TG2 expression down-regulation and TG2 activity 
inhibition on the susceptibility of parental and 5-FU-resistant HEPG2 cells to 5-FU-induced 
death. The expression of TG2 protein without its activity in parental and 5-FU-resistant cells 
(HEPG2+cystamine and HEPG2FR+cystamine) resulted in an increased susceptibilit of the 
cells to 5-FU therapy. However, with the down-regulation of TG2 protein expression and 
residual enzymatic activity (HEPG2+siRNA and HEPG2FR+siRNA) the cells were relatively 
less susceptible to 5-FU-induced death. One-way ANOVA analysis of the results shows that 
there is significant difference in cellular response to 5-FU therapy following the inhibition of 
TG2 activity and the down-regulation of its expression, with p value of 0.0005 as shown in 
appendix 4, table A4.48. Furthermore, comparison of HEPG2+cystamine vs HEPG2+siRNA 
by student t-test shows that response to HEPG2 to 5-FU-induced death significantly increased 
when TG2 activity was inhibited compared to when its expression was down-regulated, with 
a p value of 0.0051, where p < 0.05 = statistical significance at 95% confidence interval 
(appendix 4, table A4.49). Similarly, HEPG2FR+cystamine was more susceptible to 5-FU-
induced death compared to HEPG2FR+siRNA, with a p value of 0.0066 as shown in 
appendix 4, table A4.50.  
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5.3.11: Flow cytometric analysis of drug-induced cell death after inhibition of TG2 
activity  
After the inhibition of TG2 activity using cystamine, both parental and drug-resistant HEPG2 
clones became significantly susceptible to chemotherapy-induced death. Student paired t-test 
of the susceptibility of HEPG2+cystamine and HEPG2 to cisplatin-induced death shows that 
TG2 activity inhibition significantly increased HEPG2 death due to cisplatin, with a p value 
of 0.0486, where p < 0.05 is statistically significant at 95% confidence interval (figure 5.14). 
Similarly, a student paired t-test of death response of HEPG2CR+cystamine vs HEPG2CR to 
cisplatin shows that HEPG2CR susceptibility to cisplatin was significantly increased 
following TG2 activity inhibition, with p value of 0.0435 (figure 5.16). These results are in 
conformity with the results of the CCK8 post-inhibition susceptibility assays previously 
reported in section 5.3.9, figure 5.12 and 5.13. For 5-FU, both parental and 5-FU-resistant 
cells were shown to be more susceptible to 5-FU-induced death after TG2 activity inhibition, 
as indicated by a p value of 0.0489 for HEPG2 vs HEPG2+cystamine, and a p value of 
0.0399 for HEPG2FR vs HEPG2FR+cystamine, where p < 0.05 is statistically significant at 
95% confidence interval (figure 5.17). 
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Figure 5.16: Flow cytometric analysis of the susceptibility of parental and cisplatin-resistant 
cells to cisplatin-induced death following TG2 activity inhibition with cystamine. Student t-
test of the susceptibility of HEPG2+cystamine and HEPG2 to cisplatin-induced death shows 
that TG2 activity inhibition significantly increased HEPG2 death due to cisplatin, with a p 
value of 0.0486, where p < 0.05 is statistically significant at 95% confidence interval 
(appendix 4, table A4.57). Similarly, a student paired t-test of death response of 
HEPG2CR+cystamine vs HEPG2CR to cisplatin shows that HEPG2CR susceptibility to 
cisplatin was significantly increased following TG2 activity inhibition, with p value of 0.0435 
(see appendix 4, table A4.58). 
 
 
 
 
P = 0.0486 
P = 0.0435 
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Figure 5.17: Flow cytometric analysis of the susceptibility of parental and 5-FU-resistant 
cells to 5-FU-induced death following TG2 activity inhibition with cystamine. Student t-test 
of the susceptibility of HEPG2+cystamine and HEPG2 to 5-FU-induced death reveals that 
TG2 activity inhibition significantly increased HEPG2 death due to 5-FU, with a p value of 
0.0489, where p < 0.05 is statistically significant at 95% confidence interval (appendix 6, 
table A6.59). Similarly, a student paired t-test of the susceptibility of HEPG2FR+cystamine 
vs HEPG2FR to 5-FU shows that HEPG2FR susceptibility to 5-FU was significantly 
increased following TG2 activity inhibition, with p value of 0.0399 (see appendix 4, table 
A4.60). 
 
 
 
P = 0.0489 P = 0.0399 
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5.4: DISCUSSION 
Evasion of apoptosis is a common feature of advanced cancer cells, which gives the tumour 
cells the ability to develop drug-resistant phenotype and metastasize to distant sites (Lundin 
et al. 2003). Characteristically, drug resistance and metastasis are intertwined and share many 
commonalities. For instance, Mehta et al. (2010) suggested that cancer cells selected for drug 
resistance in vitro, show more aggressive metastatic potential in vivo; and metastatic tumour 
cells show more resistance to anticancer agents than the primary tumour cells. The results 
presented in this thesis suggest that both parental and drug-resistant HEPG2 cells have 
moderately increased metastatic potential, as evidenced in their ability to invade and migrate 
through the matrigel-coated transmembrane inserts. However, there is no significant 
difference in the invasiveness of drug-resistant cells relative to the parental cells (figure 5.2). 
Thus, with reference to the views of Mehta et al (2010), it is rational to argue that the ability 
of drug-resistant cells to show more invasiveness than their parental counterparts is not a 
common denominator of all drug-resistant cancer cells but dependent on the cancer type from 
which the cancer cells were derived. 
 
The results presented in chapter four, section 4.3.2 (figure 4.5, 4.6 and 4.7) showed higher 
expression level of TG2 in drug-resistant clones of HEPG2 relative to the parental cell line; 
aligning with previous reports that TG2 was one of the eleven metastasis-associated proteins 
that were selectively elevated in metastatic cancer cells (Jiang et al 2003; Mangala et al. 
2007; Yakubov et al. 2013). In the light of the above findings and in accordance with the 
report that the selective knockdown of TG2 protein using siRNA reduced the adherence, 
survival and invasion capabilities of cancer cells on matrigel-coated plates (Mangala et al. 
2007); this thesis investigated the relationship between TG2 expression and the metastasis 
ability of HEPG2 clones. Analysis of invasion and migration of the three HEPG2 cell lines on 
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matrigel-coated transmembrane inserts after the down-regulation of TG2 expression by 
siRNA showed a reduced invasive and migration potential in all the cell lines as shown in 
figure 5.5. However, the level of reduction in the invasive and migration potential of the 
HEPG2 cell lines was not as profound as reported in breast cancer cells (Mangala et al. 
2007), ovarian cancer (Satpathy et al. 2007), and malignant melanoma (Fok et al. 2006). 
Hence, it is rational to argue that the relationship between TG2 expression and cancer 
metastasis may be dependent on cell type. 
 
Flow cytometric analyses of cellular susceptibility to drug-induced death following the 
downregulation of TG2 protein expression by siRNA interference show no significant 
improvement in the susceptibility of drug-resistant cells to cisplatin or 5-FU treatment. 
Although, the downregulation of TG2 protein expression has significant effect on the 
susceptibility of the parental cells to cisplatin with p value of 0.0399 (figure 5.8); the 
susceptibility of HEPG2CR to cisplatin-induced death was not improved, with p value of 
0.1887 > 0.05 (figure 5.8). In the case of 5-FU, both parental and 5-FU-resistant cells show 
no improvement in their susceptibility to 5-FU-induced death after TG2 protein 
downregulation, as indicated by a p value of 0.2484 for parental cells, and a p value of 0.0703 
for HEPG2FR cells (figure 5.9). These results distinctly oppose the various reports in other 
cell types that down-regulation of TG2 protein expression by siRNA interference sensitizes 
drug-resistant cancer cells to chemotherapy-induced death both in vitro and in vivo (Verma & 
Mehta, 2007; Hwang et al. 2008; Verma et al. 2008; Mangala et al. 2007; Yakubov et al. 
2013).  
 
This thesis is the first to evaluate the implication of TG2 down-regulation in hepatocellular 
carcinoma and the results presented herein, may be an indication that the relationship 
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between TG2 and cancer drug-resistance is characteristic of cancer cells derived from 
hepatocytes alone. Furthermore, the decrease in cellular susceptiblity to anticancer drugs 
reported here highlights the importance of TG2 as a major pro-survival protein and points to 
the possibility that HEPG2 cell line may possess a distinct, alternative, strong survival 
signalling protein that might not be present in other cell types previously reported. 
Consequently, the reduced expression of TG2 following the introduction of siRNA may upset 
the survival signalling network, triggering the “backup” protein as an augmentative defence 
strategy. This may be the reason behind the suggestion that the absence of TG2 can be 
compensated by other transglutaminase family members, when it is a possible case of 
functional substitution by a different survival signalling protein.  
 
Conversely, investigation of the causal relationship between TG2 activity and cellular 
invasion and migration revealed a direct link between the enzyme activity and metastasis. 
Following the inhibition of TG2 activity using cystamine, a further analysis of invasion and 
migration of the three HEPG2 cell lines on matrigel-coated plates, cell invasion and 
migration were strongly attenuated in all the cell lines (figure 5.11). Similarly, both parental 
and drug-resistant cells were markedly susceptible to drug-induced death when TG2 activity 
was inhibited (figures 5.12, 5.13, 5.16, and 5.17). The results presented in this thesis are the 
first to suggest a causal relationship between TG2 enzyme activity and cancer drug resistance 
and metastasis. Additionally, direct comparison of the effects of down-regulation of TG2 
protein expression and inhibition its activity on the susceptibility of parental and drug-
resistant HEPG2 cells to cisplatin and 5-FU therapy (figure 5.14 and figure 5.15), showed 
that TG2’s crosslinking activity is more important in defining its role in liver cancer drug 
resistance than its expression. Interestingly, TG2’s role in cancer drug resistance and 
metastasis has been suggested to be dependent on TG2-mediated integrin-FN interaction, 
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which is non-enzymatic and independent of TG2 transamidation and cross-linking activities 
as reviewed by Odii & Coussons (2014). However, these results indicate that activation of 
cellular survival signaling pathway and consequent drug resistance and metastasis may 
require the ability of TG2 to cross-link and post-translationally modify some intracellular and 
extracellular proteins. Hence, the inhibition of TG2 activity may render such proteins 
ineffective and latent, with resultant increase in cellular susceptibility to chemotherapy-
induced death and decrease in invasive and migration potential of the cells. 
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CHAPTER SIX 
GENERAL SUMMARY, FUTURE DIRECTIONS AND CONCLUSIONS 
 
6.1: GENERAL SUMMARY 
In order to study the cellular and molecular mechanisms of drug resistance for any given 
cancer type, development of good models of drug-resistant cells is indispensable to the 
success of such studies. This is because such scenario could mimic what happens in vivo, and 
could as well be useful for testing new therapeutic agents. The high mortality rate associated 
with advanced HCC calls for a probe into its mechanism of resistance to chemotherapy. 
Consequently, drug-resistant HEPG2 sub-clones were produced from the parental cell line. 
The protocol reported herein, serves as a simplified method of selection of drug-resistant 
hepatocellular carcinoma cells from human hepatocellular carcinoma (HEPG2) cell line using 
pharmacologic agents and mimicking clinical treatment pattern. The stepwise method of 
selection as outlined, can serve as a first-hand guide for the selection of drug-resistant cell 
line needed for any liver cancer-related drug-resistance studies; and serves as a protocol for 
the establishment of drug-resistant cell line models of other cancer types.  
 
Following the assessment of dose-dependent toxicity of cisplatin to HEPG2 cells and the 
observation that the drug is highly toxic to the cells, in agreement with many clinical reports 
of wide range of cisplatin-induced toxicities, this thesis investigated the kinetics of cisplatin 
toxicity to hepatocellular carcinoma cells. This was done with a view to understanding how 
the drug action leads to tissue/organ damage and suggesting a model for further test. The 
study shows that the optimal concentration of cisplatin for HEPG2 cell line is 4µM, and the 
optimal treatment duration is 12 hours. It has also shown that the shorter the treatment time, 
the less the cellular toxicity and the less the damage to organ system. The study has furthered 
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the importance of exploiting response to cisplatin in attempts to understand its cytotoxic 
kinetics and establish the optimal treatment conditions.  
 
To understand the expression patterns of TGM2 gene and TG2 protein, as well as the enzyme 
activity in parental and drug-resistant HEPG2 cells, the profiles of TGM2 gene and TG2 
protein expression, and the enzyme activity were investigated. The results showed that the 
expression patterns of TGM2 and its gene product, TG2, in drug-resistant hepatocellular 
carcinoma cell lines are in agreement with earlier reports of elevated TG2 expression in drug-
resistant and metastatic cells derived from other cancer types (Mehta et al. 2010). However, 
any variation in expression or activity of the enzyme could be due to the differences in the 
mechanisms of actions of the induction stimuli. Furthermore, the observation that TG2 is the 
predominant member of the Tgase family in liver cells is particularly fascinating. This thesis 
has shown the specific patterns of expression of TG2 in liver carcinogenesis by providing for 
the first time, first-hand information on the pattern of expression and activity of the enzyme 
in a hepatocellular carcinoma cell line; hence, providing insights into the involvement of TG2 
in liver cancer drug resistance.  
 
Additionally, a comparison of TG2 activity profiles with apoptosis profiles for parental and 
drug-resistant HEPG2 cell lines revealed an apparent relationship between TG2 activity and 
cell death progression.  This is because decreased TG2 activity is directly proportional to 
increased cell death in both parental and drug-resistant clones of HEPG2. Though, for 5-FU-
treated cells, TG2 protein expression and enzyme activity continued to increase with increase 
in drug concentration, explaining why HEPG2 cells are less susceptible to 5-FU than 
cisplatin. It is therefore, reasonable to conclude that increase in TG2 protein expression and 
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enzyme activity may be pro-survival signalling strategies employed by the cells to evade 
drug-induced death.  
 
Following the observation that drug-resistant HEPG2 clones express higher levels of TG2 
protein relative to the parental cell line (figures 4.4 to 4.7), the causal relationship between 
TG2 protein and cancer drug resistance and metastasis was investigated. The results show 
that siRNA down-regulation of TG2 expression enhances cellular susceptibility to anticancer 
agents, and leads to reduced invasion and migration potential of parental and drug-resistant 
cells on matrigel-coated surface. The inhibition of TG2 activity using cystamine profoundly 
increased chemosensitivity of parental and drug-resistant cells and attenuated their potential 
to invade and migrate through matrigel-coated surface.  
 
Interestingly, the role of TG2 protein in cancer drug resistance and metastasis has been 
suggested to be dependent on TG2-mediated integrin-FN interaction, which is non-enzymatic 
as reviewed by Odii & Coussons (2014). However, this thesis reports for the first time, that 
activation of cellular survival signaling pathway and consequent drug resistance and 
metastasis may require the ability of TG2 to cross-link and/or post-translationally modify 
certain specific intracellular and extracellular proteins. Thus, the roles of TG2 protein in liver 
cancer drug resistance and metastasis are determined by its enzymatic activity rather than 
protein – protein interactions. Even though protein – protein interactions may be contributory 
to TG2’s functions in liver cancer drug resistance and metastasis, the crosslinking activity of 
TG2 is necessary to modify the proteins and activate such interactions. Furthermore, the roles 
of TG2 in cancer drug resistance and metastasis may not be compensated for by any other 
member of the transglutaminase family because they lack specialized structural 
conformations needed for such functions in agreement with Odii and Coussons, (2014). 
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6.2: FUTURE DIRECTIONS 
It is important to test cisplatin on 5-FU-resistant cells and vice versa; development of cell line 
model resistant to cisplatin/5-FU combination is hereby suggested. This will enable the study 
of the susceptibility of drug-resistant HEPG2 cells to the combined therapy of cisplatin and 5-
FU. 
 
To gain more insights into the kinetics of cisplatin toxicity in the clinic, the work reported in 
chapter three of this thesis should be repeated in normal/non-cancerous cells and perhaps 
eventually extended to animal models to enable the establishment of a clinical optimal 
treatment time for cisplatin. Thus, this thesis suggests animal model experiments at optimal 
treatment time of cisplatin using an appreciable cisplatin dosage, followed by the removal of 
the drug by plasmapheresis (Guenter et al. 2006) or haemodialysis (Lagrange et al. 1994). 
 
The striking observation in liver cancer cells that the inhibition of TG2 activity is more potent 
in promoting the susceptibility of the cells to anticancer drugs and reducing their invasion and 
migration potential relative to the down-regulation of TG2 expression requires further 
investigation in cancer cells derived from other cancer types. It is also important to 
investigate the protein – protein interactions that define TG2 roles in liver cancer drug-
resistance and metastasis whilst identifying the set of in vivo substrates of TG2 that determine 
its functions in liver cancer cells. This will help to unmask the survival signalling proteins 
that may be activated to substitute for TG2 absence following its down-regulation, thus, 
accounting for the surprising increase in cell survival observed after TG2 down-regulation. 
This may provide further answers to the proposition of compensation for TG2 function by 
other members of the transglutaminase family in the event of absence, when it may be a case 
of functional substitution by a different survival signalling protein.  
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It is important to measure the residual activity of TG2 after the down-regulation of its 
expression. This will enable us to understand whether the poor susceptibility of parental and 
drug-resistant HEPG2 cells to cisplatin and 5-FU therapy following TG2 silencing was due to 
residual TG2 enzymatic activity. Additionally, there is the need to investigate the effects of 
TG2 activity inhibition on the sensitivity of normal cells (hepatocytes) to drug therapy. This 
is to ensure such feature is only characteristic of cancer cells and not of normal cells, and the 
incorporation of TG2 activity inhibitors in anticancer drug therapies will not affect non-target 
normal cells. Subsequently, animal model experiments investigating the role of TG2 enzyme 
activity in cancer drug resistance and metastasis will be envisaged.  
 
Statistically, student paired t-test and one-way AVOVA were used throughout the thesis to 
establish statistical significance. Generalised Linear Model (GLM) would be necessary to 
define statistical differences between concentrations, particularly in chapter four; however, 
this could not be applied because the experiments in chapter four were done in duplicates. 
Future experiments will therefore, require GLM, hence, should be done in triplicates to give 
the data enough power. 
 
The suggestion that in the event of TG2 absence its biological functions could be successfully 
compensated for by other members of the transglutaminase family (reviewed by Odii and 
Coussons, 2014) has been made without recourse to the distinguishing features of TG2 
among the transglutaminase family. It is therefore, necessary to carry out further 
investigations to ascertain the main reasons why TG2 knockout is not embryonic lethal; 
instead of relying on the assertion that its functions are compensated for by other 
transglutaminase enzymes. Furthermore, a systematic investigation should be carried out to 
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establish with certainty, the possibility of and premise for the replacement of TG2 function 
by any other member of the transglutaminase family.  
 
6.3: CONCLUSIONS 
Gene regulation determines enzyme availability and level of activity. Consequently, increase 
in TG2 expression leads to increase in the enzyme activity, with resultant increase in cancer 
drug resistance and metastasis; depending on cell type and stimulation. From the results 
presented in this thesis, it is tempting to conclude that the causal relationship between TG2 
and cancer drug resistance and metastasis may be dependent on both TG2 expression 
(availability) and enzymatic activity. However, either TG2 protein expression or its 
enzymatic activity or both, can lead to drug resistance and metastasis depending on cell type 
and the conditions of treatment (type of stimulation). Additionally, the surprising increase in 
cell survival and reinforcement of resistance by the HEPG2 cells after the down-regulation of 
TG2 expression are indications of inherent, strong survival signalling network that might be 
responsible for the characteristic drug resistance and refractory properties of advanced 
hepatocellular carcinoma. It may also be due to the residual activity of TG2 after silencing. 
Consequently, modulation of TG2 expression and activity may serve as useful therapeutic 
target for liver cancer treatment. 
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APPENDIX TWO 
RESULT TABLES 
 
A2.1: Chapter two result tables 
Table A2.1.1: Analysis of HEPG2 cell viability using cell counting kit-8 (CCK8) after 
treatment with cisplatin for twelve hours 
 
Replicates 
 
% 
Viability 
0.267 
   
Cisplatin 
(µM) 
A B C A B C 
Mean 
(%) 
STDEV 
0 0.68 0.673 0.686 100 100 100 100 0 
1 0.538 0.549 0.536 66 69 64 66 2.720 
2 0.529 0.521 0.53 63 63 63 63 0.458 
4 0.48 0.473 0.478 52 51 50 51 0.622 
8 0.421 0.433 0.428 37 41 38 39 1.839 
16 0.355 0.352 0.349 21 21 20 21 0.915 
 
Table A2.1.2: Analysis of HEPG2 cell viability using cell counting kit-8 (CCK8) after 
treatment with cisplatin for twenty four hours 
 
Replicates 
 
% 
Viability 
0.263 
   
Cisplatin 
(µM) 
A B C A B C 
Mean 
(%) 
STDEV 
0 0.547 0.559 0.571 100 100 100 100 0 
1 0.438 0.469 0.453 62 70 62 64 4.585 
2 0.402 0.442 0.428 49 60 54 54 5.802 
4 0.4 0.409 0.434 48 49 56 51 3.928 
6 0.389 0.411 0.377 44 50 37 44 6.512 
8 0.357 0.371 0.365 33 36 33 34 1.951 
10 0.337 0.345 0.351 26 28 29 27 1.277 
12 0.329 0.317 0.319 23 18 18 20 2.902 
14 0.326 0.314 0.322 22 17 19 20 2.497 
16 0.319 0.318 0.311 20 19 16 18 2.136 
18 0.306 0.314 0.309 15 17 15 16 0.884 
20 0.299 0.302 0.307 13 13 14 13 0.824 
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Table A2.1.3: Assessment of level of resistance in HEPG2 cells selected for resistance 
against cisplatin 
 
Replicates 
 
% 
Viability 
0.277 
   
Cisplatin 
(µM)  
A B C A B C 
Mean 
(%) 
STDEV 
0 0.608 0.59 0.606 100 100 100 100 0 
1 0.58 0.579 0.576 92 96 91 93 3.063 
2 0.555 0.549 0.552 84 87 84 85 1.809 
4 0.48 0.485 0.489 61 66 64 64 2.582 
6 0.479 0.472 0.476 61 62 60 61 0.931 
8 0.436 0.439 0.44 48 52 50 50 1.872 
10 0.392 0.401 0.392 35 40 35 36 2.754 
12 0.388 0.379 0.382 34 33 32 33 0.814 
14 0.382 0.38 0.377 32 33 30 32 1.257 
16 0.37 0.368 0.371 28 29 29 29 0.488 
18 0.374 0.369 0.365 29 28 27 28 1.279 
20 0.36 0.364 0.364 25 28 26 26 1.360 
 
Table A2.1.4: CCK8 analysis of HEPG2 cell viability after treatment with various 
concentrations of 5-FU for twenty four hours 
 
Replicates 
 
% 
Viability 
0.262 
   
5-FU 
(µM) 
A B C A B C 
Mean 
(%) 
STDEV 
0 0.539 0.535 0.542 100 100 100 100 0 
10 0.489 0.491 0.489 82 84 81 82 1.438 
20 0.476 0.488 0.489 77 83 81 80 2.829 
30 0.453 0.46 0.457 69 73 70 70 1.896 
40 0.43 0.426 0.421 61 60 57 59 2.085 
50 0.397 0.405 0.402 49 52 50 50 1.851 
60 0.391 0.376 0.383 47 42 43 44 2.468 
70 0.344 0.358 0.351 30 35 32 32 2.802 
80 0.342 0.346 0.346 29 31 30 30 0.949 
90 0.341 0.334 0.336 29 26 26 27 1.224 
100 0.333 0.331 0.337 26 25 27 26 0.789 
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Table A2.1.5: Assessment of resistance level of HEPG2 cells selected for resistance against 
5-FU  
 
Replicates 
 
% 
Viability 
0.231 
   
5-FU 
(µM) 
A B C A B C 
Mean 
(%) 
STDEV 
0 1.013 0.998 1.021 100 100 100 100 0 
10 0.923 0.819 0.89 88 77 83 83 5.934 
20 0.82 0.811 0.801 75 76 72 74 1.921 
30 0.807 0.798 0.809 74 74 73 74 0.385 
40 0.792 0.8 0.786 72 74 70 72 1.985 
50 0.695 0.697 0.696 59 61 59 60 0.986 
60 0.636 0.674 0.655 52 58 54 54 3.051 
70 0.599 0.599 0.587 47 48 45 47 1.491 
80 0.537 0.521 0.529 39 38 38 38 0.789 
90 0.432 0.418 0.438 26 24 26 25 0.941 
100 0.427 0.422 0.409 25 25 23 24 1.418 
 
 
A2.2: Chapter three result tables 
 
Table A2.2.1: Cell death analysis by flow cytometry after twelve hours treatment with 
cisplatin (figure 3.1) 
Cisplatin (µM) A B AVG Stdev 
0 79.02 76.05 77.535 2.100 
1 75.01 69.84 72.425 3.656 
2 67.45 60.05 63.75 5.232 
4 50.77 51.72 51.245 0.672 
8 34.73 31.6 33.165 2.213 
16 28.65 31.08 29.865 1.718 
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Table A2.2.2: Analysis of cell death by flow cytometry following twenty four hours 
treatment with cisplatin (figure 3.1) 
Cisplatin (µM) A B AVG Stdev 
0 72.99 72.08 72.535 0.643 
1 69.84 70.49 70.165 0.459 
2 59.4 59.58 59.49 0.127 
4 50.99 50.52 50.755 0.332 
8 26.74 29.53 28.135 1.973 
16 17.65 26.53 22.09 6.279 
 
Table A2.2.3: Flow cytometric analysis of HEPG2 cell death after forty eight hours treatment 
with various concentrations of cisplatin (figure 3.1)  
Cisplatin (µM) A B AVG Stdev 
0 94.46 88.76 91.61 4.031 
1 68.99 65.33 67.16 2.588 
2 63.92 57.95 60.935 4.221 
4 40.19 48 44.095 5.523 
8 23.1 21.44 22.27 1.174 
16 19.38 17.37 18.375 1.421 
 
A2.3: Chapter four result tables 
 
Table A2.3.1: TG2 expression levels in HEPG2 cells after twenty four hours treatment with 
various concentrations of cisplatin (figure 4.1) 
 
TG2 level 
   
Cisplatin (µM) A B Mean Stdev 
0 1 1 1 0 
1 1.204 1.342 1.273 0.098 
2 1.467 1.414 1.441 0.037 
4 1.576 1.469 1.523 0.076 
8 1.264 1.268 1.266 0.003 
16 1.164 1.242 1.203 0.055 
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Table A2.3.2: TG2 expression levels in HEPG2CR after twenty four hours treatment with 
various concentrations of cisplatin (figure 4.1) 
 
TG2 
level    
Cisplatin (µM) A B Mean Stdev 
0 1 1 1 0 
1 1.5 1.486 1.493 0.01 
2 1.717 1.787 1.752 0.049 
4 2.833 2.759 2.796 0.052 
8 1.5 1.333 1.4165 0.118 
16 1.164 1.275 1.2195 0.078 
 
Table A2.3.3: TG2 expression levels in HEPG2 cell line after 5-FU treatment for twenty four 
hours (figure 4.2) 
 
TG2 Level 
   
5FU (µM) A B Mean Stdev 
0 1 1 1 0 
10 1.87 1.48 1.675 0.276 
30 1.26 1.24 1.25 0.014 
50 1.22 0.87 1.045 0.247 
70 0.43 0.87 0.65 0.311 
90 0.35 0.41 0.38 0.042 
 
Table A2.3.4: TG2 expression levels in HEPG2FR cell line after 5-FU treatment for twenty 
four hours (figure 4.2) 
 
TG2 Level 
   
5FU (µM) A B Mean Stdev 
0 1 1 1 0 
10 0.639 0.333 0.486 0.216 
30 0.389 0.5 0.4445 0.078 
50 0.42 0.383 0.4015 0.026 
70 0.319 0.306 0.3125 0.009 
90 0.308 0.417 0.3625 0.077 
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Table A2.3.5: Tgase activity in HEPG2 cell line after twenty four hours treatment with 
various concentrations of cisplatin (figure 4.9) 
Cisplatin (µM) A B Mean Stdev 
0 0.1 0.101 0.1005 0.001 
1 0.107 0.104 0.1055 0.002 
2 0.161 0.158 0.1595 0.002 
4 0.177 0.179 0.178 0.001 
8 0.15 0.155 0.1525 0.004 
16 0.122 0.122 0.122 0 
 
Table A2.3.6: Tgase activity in HEPG2CR cells after twenty four hours treatment with 
various concentrations of cisplatin (figure 4.9) 
Cisplatin (µM) A B Mean Stdev 
0 0.102 0.106 0.104 0.003 
1 0.112 0.112 0.112 0 
2 0.174 0.17 0.172 0.003 
4 0.193 0.183 0.188 0.007 
8 0.167 0.174 0.1705 0.005 
16 0.135 0.138 0.1365 0.002 
 
Table A2.3.7: Tgase activity in HEPG2 cells after twenty four hours 5-FU treatment (figure 
4.10) 
5-FU(µM) A B Mean Stdev 
0 0.065 0.071 0.068 0.004 
10 0.128 0.127 0.1275 0.001 
30 0.166 0.169 0.1675 0.002 
50 0.172 0.171 0.1715 0.001 
70 0.181 0.177 0.179 0.003 
100 0.193 0.19 0.1915 0.002 
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Table A2.3.8: Tgase activity in HEPG2FR cells after twenty four hours 5-FU treatment 
(figure 4.10) 
5-FU(µM) A B Mean Stdev 
0 0.082 0.078 0.08 0.003 
10 0.131 0.133 0.132 0.001 
30 0.174 0.17 0.172 0.003 
50 0.186 0.188 0.187 0.001 
70 0.191 0.187 0.189 0.003 
100 0.213 0.211 0.212 0.001 
TG 0.46 0.44 0.45 0.014 
 
Table A2.3.9: TG2-sepecific activity in HEPG2 and HEPG2CR cells after twenty four hours 
cisplatin treatment (figure 4.11) 
Cisplatin 
(µM) 
HEPG2  AVG STDEV CR  AVG STDEV 
0 0.16 0.134 0.147 0.019 0.196 0.196 0.196 0 
2 0.161 0.157 0.159 0.003 0.195 0.194 0.195 0.001 
4 0.199 0.156 0.178 0.030 0.202 0.199 0.201 0.002 
8 0.167 0.133 0.15 0.024 0.178 0.166 0.172 0.008 
16 0.144 0.137 0.141 0.005 0.112 0.112 0.112 0 
rTG2 3.498 3.278 3.388 0.156 3.498 3.278 3.388 0.156 
 
Table A2.3.10: TG2-sepecific activity in HEPG2 and HEPG2FR cells after twenty four hours 
5-FU treatment (figure 4.12) 
5FU 
(µM) 
Hep   AVG STDEV FR   AVG STDEV 
0 0.16 0.134 0.147 0.018 0.203 0.186 0.195 0.012 
10 0.122 0.173 0.1475 0.036 0.188 0.155 0.172 0.023 
30 0.169 0.166 0.1675 0.002 0.137 0.169 0.153 0.022 
50 0.127 0.116 0.1215 0.008 0.173 0.193 0.183 0.014 
100 0.13 0.163 0.1465 0.023 0.206 0.198 0.202 0.006 
rTG2 3.498 3.278 3.388 0.156 3.498 3.278 3.388 0.156 
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A2.4: Chapter five result tables 
Table A2.4.1: Percentage invasion and migration of parental and drug-resistant 
hepatocarcinoma cell lines on matrigel-coated surface (figure 5.2). 
Cell type % invasion    
 A B C AVG STDEV 
HEPG2 77 74 85 79 5.686 
HEPG2CR 89 81 84 85 4.041 
HEPG2FR 79 81 91 84 6.429 
 
Table A2.4.2: Percentage invasion and migration of parental and drug-resistant HEPG2 
clones on matrigel-coated surface after TG2 down-regulation by siRNA (figure 5.5). 
Cell type 
% invasion 
A 
B C Avg STDEV 
HEPG2 60 58 57 58 1.528 
HEPG2CR 69 67 61 66 4.163 
HEPG2FR 76 74 69 73 3.606 
 
Table A2.4.3: Percentage invasion and migration of parental and drug-resistant HEPG2 
clones on matrigel-coated surface following the inhibition of TG2 activity with 2.5mM 
cystamine (figure 5.11). 
Cell type 
% invasion 
A 
B C Avg STDEV 
HEPG2 27 29 26 27.3333 1.528 
HEPG2CR 31 28 34 31 3 
HEPG2FR 34 41 47 40.6667 6.506 
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Table A2.4.4: Susceptibility of HEPG2 and HEPG2CR cells to cisplatin-induced death after 
TG2 down-regulation by siRNA (figure 5.6). 
Cisplatin 
(µM) 
HEPG2 
+siRNA (%) 
HEPG2CR 
+siRNA (%) 
HEPG2 (%)  HEPG2CR (%) 
0 0 0 0 0 0 0 0 0 0 0 0 0 
1 20 23 9 14 22 32 38 30 38 8 6 9 
2 26 16 23 24 29 28 51 40 46 16 13 16 
4 50 31 32 33 43 36 52 51 44 39 34 34 
8 63 54 50 42 52 59 67 64 67 52 48 50 
 16 74 80 67 64 67 62 80 81 84 72 71 71 
 
Table A2.4.5: Percentage susceptibility of HEPG2 and HEPG2FR cells to 5-FU-induced 
death after TG2 down-regulation by siRNA (figure 5.7). 
5-FU 
(µM) 
HEPG2 (%) HEPG2FR (%) 
HEPG2 
+siRNA (%) 
HEPG2FR 
+siRNA (%) 
 0 0 0 0 0 0 0 0 0 0 0 0 0 
10 18 16 19 12 23 17 15 11 7 10 16 13 
30 31 27 30 26 26 27 34 31 29 19 29 25 
50 51 48 50 41 39 41 43 38 48 34 37 61 
70 70 75 78 53 52 55 54 56 59 48 64 48 
 100 74 75 73 75 75 77 67 74 70 59 55 52 
 
Table A2.4.6: Inhibition of TG2 activity in the three cell lines using different cystamine 
concentrations (0mM to 4mM) (figure 5.10). 
Cystamine HEPG2  HEPG2CR  HEPG2FR  
0.00 0.301 0.257 0.421 0.300 0.388 0.247 
0.50 0.255 0.234 0.271 0.279 0.296 0.308 
1.00 0.194 0.191 0.220 0.216 0.248 0.232 
1.50 0.172 0.190 0.231 0.250 0.230 0.217 
2.00 0.110 0.150 0.140 0.135 0.120 0.150 
2.50 0.080 0.098 0.100 0.096 0.130 0.088 
3.00 0.079 0.084 0.097 0.097 0.114 0.138 
3.50 0.075 0.090 0.083 0.094 0.117 0.119 
4.00 0.068 0.076 0.091 0.081 0.101 0.099 
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Table A2.4.7: Susceptibility of HEPG2 and HEPG2CR to cisplatin-induced death after the 
inhibition of TG2 activity with 2.5mM of cystamine (figure 5.12). 
Cisplatin 
(µM) 
HEPG2 
+cystamine (%) 
HEPG2CR 
+cystamine (%) 
HEPG2 (%) HEPG2CR (%) 
0 0 0 0 0 0 0 0 0 0 0 0 0 
1 37 36 39 28 30 26 38 30 38 8 6 9 
2 46 46 44 40 41 36 51 40 46 16 13 16 
4 62 63 61 49 53 48 52 51 44 39 34 34 
8 68 67 70 64 64 64 67 64 67 52 48 50 
16 80 77 75 70 81 76 80 81 84 72 71 71 
 
 
Table A2.4.8: Susceptibility of HEPG2 and HEPG2FR to 5-FU-induced death following the 
inhibition of TG2 activity with 2.5mM of cystamine (figure 5.13) 
5-FU(µM) 
HEPG2 
+cystamine (%) 
HEPG2FR 
+cystamine (%) 
HEPG2 (%) HEPG2FR (%) 
0 0 0 0 0 0 0 0 0 0 0 0 
 
10 33 29 38 28 36 33 18 16 19 12 23 17 
30 45 51 50 46 39 43 31 27 30 26 26 27 
50 60 58 68 58 51 57 51 48 50 41 39 41 
70 80 64 71 67 69 67 70 75 78 53 52 55 
100 81 86 93 73 74 81 74 75 73 75 75 77 
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APPENDIX THREE 
Examples of RT-PCR melting & amplification curves (see section 4.2.2) 
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APPENDIX FOUR 
STATISTICAL DATA EXTRACTS 
 
Table A4.0: HEPG2 response to cisplatin after 12 to 24 hours treatment (figure 2.1) 
Cisplatin (M) 12 hours 24 hours  
0.00 0.00 0.00 0.00 0.00 0.00 0.00 50.00 
1.00 34.00 31.00 36.00 38.00 30.00 38.00 50.00 
2.00 37.00 37.00 37.00 51.00 40.00 46.00 50.00 
4.00 48.00 49.00 50.00 52.00 51.00 44.00 50.00 
8.00 63.00 59.00 62.00 67.00 64.00 67.00 50.00 
16.00 79.00 79.00 80.00 80.00 81.00 84.00 50.00 
 
Table A4.1: Student paired t-test for figure 2.1 
Table Analyzed Cisplatin dose response curves 
Column A 12 hours 
vs. vs. 
Column B 24 hours 
Paired t test 
 
P value 0.0861 
P value summary Ns 
Significantly different? (P < 0.05) No 
One- or two-tailed P value? Two-tailed 
t, df t=2.133 df=5 
Number of pairs 6 
How big is the difference? 
 
Mean of differences -2.889 
SD of differences 3.318 
SEM of differences 1.354 
95% confidence interval -6.371 to 0.5929 
R squared 0.4764 
How effective was the pairing? 
 
Correlation coefficient (r) 0.9933 
P value (one tailed) < 0.0001 
P value summary **** 
Was the pairing significantly effective? Yes 
 
 
 
 
 
 
 
 
 
 
 
 
208 
 
Table A4.2: 5-FU dose response table 
5-FU 
(M) 
HEPG2   
0.00 0.00 0.00 0.00 50.00 
10.00 18.00 16.00 19.00 50.00 
20.00 23.00 17.00 19.00 50.00 
30.00 31.00 27.00 30.00 50.00 
40.00 39.00 40.00 43.00 50.00 
50.00 51.00 48.00 50.00 50.00 
60.00 53.00 58.00 57.00 50.00 
70.00 70.00 65.00 68.00 50.00 
80.00 71.00 69.00 70.00 50.00 
90.00 71.00 74.00 74.00 50.00 
100.00 74.00 75.00 73.00 50.00 
 
 Table A4.3: Comparison of HEPG2 and HEPG2CR cells’ response to cisplatin (figure 
2.3) 
Cisplatin (M)  HEPG2CR HEPG2   
0.00 0.00 0.00 0.00 0.00 0.00 0.00 50.00 
1.00 8.00 6.00 9.00 38.00 30.00 38.00 50.00 
2.00 16.00 13.00 16.00 51.00 40.00 46.00 50.00 
4.00 39.00 34.00 34.00 52.00 51.00 44.00 50.00 
6.00 39.00 38.00 40.00 56.00 50.00 63.00 50.00 
8.00 52.00 48.00 50.00 67.00 64.00 67.00 50.00 
10.00 65.00 60.00 65.00 74.00 72.00 71.00 50.00 
12.00 66.00 67.00 68.00 77.00 82.00 82.00 50.00 
14.00 68.00 67.00 70.00 78.00 83.00 81.00 50.00 
16.00 72.00 71.00 71.00 80.00 81.00 84.00 50.00 
18.00 71.00 72.00 73.00 85.00 83.00 85.00 50.00 
20.00 75.00 72.00 74.00 87.00 87.00 86.00 50.00 
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Table A4.4: A student paired t-test for figure 2.3 
Column B HEPG2  
vs. vs. 
Column A HEPG2CR 
Paired t test  
P value < 0.0001 
P value summary **** 
Significantly different? (P < 0.05) Yes 
One- or two-tailed P value? Two-tailed 
t, df t=6.269 df=11 
Number of pairs 12 
How big is the difference?  
Mean of differences 14.61 
SD of differences 8.074 
SEM of differences 2.331 
95% confidence interval 9.481 to 19.74 
R squared 0.7813 
How effective was the pairing?  
Correlation coefficient (r) 0.9543 
P value (one tailed) < 0.0001 
P value summary **** 
Was the pairing significantly effective? Yes 
 
Table A4.5: Comparison of HEPG2 and HEPG2FR cells’ response to 5-FU (figure 2.4) 
5FU (M) HEPG2  HEPG2FR   
0.00 0.00 0.00 0.00 0.00 0.00 0.00 50.00 
10.00 18.00 16.00 19.00 12.00 23.00 17.00 50.00 
20.00 23.00 17.00 19.00 25.00 24.00 28.00 50.00 
30.00 31.00 27.00 30.00 27.00 26.00 27.00 50.00 
40.00 39.00 40.00 43.00 28.00 26.00 30.00 50.00 
50.00 51.00 48.00 50.00 41.00 39.00 41.00 50.00 
60.00 53.00 58.00 57.00 58.00 42.00 46.00 50.00 
70.00 70.00 65.00 68.00 53.00 52.00 55.00 50.00 
80.00 71.00 69.00 70.00 61.00 62.00 62.00 50.00 
90.00 71.00 74.00 74.00 74.00 76.00 74.00 50.00 
100.00 74.00 75.00 73.00 75.00 75.00 77.00 50.00 
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Table A4.6: A student paired t-test for figure 2.4 
Table Analyzed 5FU dose-dependent response 
Column A HEPG2  
vs. vs. 
Column B HEPG2FR  
Paired t test  
P value 0.0317 
P value summary * 
Significantly different? (P < 0.05) Yes 
One- or two-tailed P value? One-tailed 
t, df t=2.087 df=10 
Number of pairs 11 
How big is the difference?  
Mean of differences 4.152 
SD of differences 6.599 
SEM of differences 1.990 
95% confidence interval -0.2815 to 8.585 
R squared 0.3033 
How effective was the pairing?  
Correlation coefficient (r) 0.9667 
P value (one tailed) < 0.0001 
P value summary **** 
Was the pairing significantly effective? Yes 
 
 
Table A4.7: Expression of TGM2 in HEPG2 and HEPG2CR after cisplatin treatment 
(figure 4.1) 
Cisplatin (µM) HEPG2  HEPG2CR 
0 1.000 1.000 1.000 1.000 
1 1.204 1.342 1.500 1.486 
2 1.467 1.414 1.717 1.787 
4 1.576 1.469 2.833 2.759 
8 1.264 1.268 1.500 1.333 
16 1.164 1.242 1.164 1.275 
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Table A4.8: t-test analysis for figure 4.1  
Table Analyzed Expression of TGM2 gene in HEPG2 and HEPG2CR cells 
Column A HEPG2  
vs. vs. 
Column B HEPG2CR 
Wilcoxon matched-pairs signed 
rank test 
 
P value 0.0313 
Exact or approximate P value? Exact 
P value summary * 
Significantly different? (P < 0.05) Yes 
One- or two-tailed P value? One-tailed 
Sum of positive, negative ranks 0.0 , -15.00 
Sum of signed ranks (W) -15.00 
Number of pairs 6 
Median of differences  
Median -0.1853 
How effective was the pairing?  
rs (Spearman) 1.000 
P value (one tailed) 0.0014 
P value summary ** 
Was the pairing significantly 
effective? 
Yes 
 
 
Table A4.9: Expression of TGM2 gene in HEPG2 and HEPG2FR cells after 5-FU 
treatment (figure 4.2) 
5-FU (µM) HEPG2  HEPG2FR  
0 1.00 1.00 1.000 1.000 
10 1.87 1.48 0.639 0.333 
30 1.26 1.24 0.389 0.500 
50 1.22 0.87 0.420 0.383 
70 0.43 0.87 0.319 0.306 
90 0.35 0.41 0.308 0.417 
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Table A4.10: A student t-test of TGM2 gene expression in HEPG2 and HEPG2FR cells 
after 5-FU treatment (figure 4.2) 
Table Analyzed Expression of TGM2 gene in HEPG2 and 
HEPG2FR cells 
Column A HEPG2  
vs. vs. 
Column B HEPG2FR  
Paired t test  
P value 0.0478 
P value summary * 
Significantly different? (P < 0.05) Yes 
One- or two-tailed P value? Two-tailed 
t, df t=2.608 df=5 
Number of pairs 6 
How big is the difference?  
Mean of differences 0.4988 
SD of differences 0.4686 
SEM of differences 0.1913 
95% confidence interval 0.007086 to 0.9906 
R squared 0.5763 
How effective was the pairing?  
Correlation coefficient (r) 0.2158 
P value (one tailed) 0.3407 
P value summary Ns 
Was the pairing significantly effective? No 
  
 
Table A4.11: Effect of cisplatin on Tgase activity in HEPG2 and HEPG2CR cells (figure 
4.9) 
Cisplatin (µM) HEPG2  HEPG2CR  
0 0.100 0.101 0.102 0.106 
1 0.107 0.104 0.112 0.112 
2 0.161 0.158 0.174 0.170 
4 0.177 0.179 0.193 0.183 
8 0.150 0.155 0.167 0.174 
16 0.122 0.122 0.135 0.138 
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Table A4.12: A student t-test of Tgase activity in HEPG2 and HEPG2CR cells after 
cisplatin treatment (figure 4.9) 
Table Analyzed CBZ-Hydroxamate assay of Tgase activity after 
cisplatin treatment 
Column A HEPG2  
vs. vs. 
Column B HEPG2CR  
Paired t test  
P value 0.0041 
P value summary ** 
Significantly different? (P < 0.05) Yes 
One- or two-tailed P value? Two-tailed 
t, df t=5.000 df=5 
Number of pairs 6 
How big is the difference?  
Mean of differences -0.01083 
SD of differences 0.005307 
SEM of differences 0.002167 
95% confidence interval -0.01640 to -0.005264 
R squared 0.8333 
How effective was the pairing?  
Correlation coefficient (r) 0.9919 
P value (one tailed) < 0.0001 
P value summary **** 
Was the pairing significantly effective? Yes 
 
 
Table A4.13: Effect of 5-FU on Tgase activity in HEPG2 and HEPG2FR cells (figure 
4.10) 
5-FU (µM) HEPG2  HEPG2FR  
0 0.065 0.071 0.082 0.078 
10 0.128 0.127 0.131 0.133 
30 0.166 0.169 0.174 0.170 
50 0.172 0.171 0.186 0.188 
70 0.181 0.177 0.191 0.187 
100 0.193 0.190 0.213 0.211 
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Table A4.14: A student t-test of Tgase activity in HEPG2 and HEPG2FR cells after 5-
FU treatment (figure 4.10) 
Table Analyzed Effect of 5-FU on Tgase activity 
Column A HEPG2  
vs. vs. 
Column B HEPG2FR  
Paired t test  
P value 0.0073 
P value summary ** 
Significantly different? (P < 0.05) Yes 
One- or two-tailed P value? Two-tailed 
t, df t=4.359 df=5 
Number of pairs 6 
How big is the difference?  
Mean of differences -0.01117 
SD of differences 0.006274 
SEM of differences 0.002561 
95% confidence interval -0.01775 to -0.004582 
R squared 0.7917 
How effective was the pairing?  
Correlation coefficient (r) 0.9922 
P value (one tailed) < 0.0001 
P value summary **** 
Was the pairing significantly effective? Yes 
 
 
Table A4.15: TG2 activity in HEPG2 and HEPG2CR cells after cisplatin treatment 
(figure 4.11) 
Cisplatin (µM) HEPG2  HEPG2CR  
0 0.160 0.134 0.196 0.196 
2 0.161 0.157 0.195 0.194 
4 0.199 0.156 0.202 0.199 
8 0.167 0.133 0.178 0.166 
16 0.144 0.137 0.112 0.112 
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Table A4.16: Student t-test of TG2 activity in HEPG2 and HEPG2CR cells shown in 
figure 4.11 
Table Analyzed TG2-specific activity in HEPG2 and HEPG2CR cells 
Column A HEPG2  
vs. vs. 
Column B HEPG2CR  
Paired t test 
 
P value 0.1987 
P value summary Ns 
Significantly different? (P < 0.05) No 
One- or two-tailed P value? Two-tailed 
t, df t=1.539 df=4 
Number of pairs 5 
How big is the difference? 
 
Mean of differences -0.0202 
SD of differences 0.02935 
SEM of differences 0.01313 
95% confidence interval -0.05665 to 0.01625 
R squared 0.3719 
How effective was the pairing? 
 
Correlation coefficient (r) 0.6675 
P value (one tailed) 0.1091 
P value summary Ns 
Was the pairing significantly effective? No 
 
 
Table A4.17: TG2 activity in HEPG2 and HEPG2FR cells after 5-FU treatment as 
shown in figure 4.12 
5-FU (µM) HEPG2  HEPG2FR  
0 0.160 0.134 0.203 0.186 
10 0.122 0.173 0.188 0.155 
30 0.169 0.166 0.137 0.169 
50 0.127 0.116 0.173 0.193 
100 0.130 0.163 0.206 0.198 
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Table A4.18: Student t-test of TG2 activity in HEPG2 and HEPG2FR cells after 5-FU 
treatment (figure 4.12) 
Table Analyzed TG2-specific activity in HEPG2 and HEPG2FR cells 
Column A HEPG2  
vs. vs. 
Column B HEPG2FR  
Paired t test 
 
P value 0.0331 
P value summary * 
Significantly different? (P < 0.05) Yes 
One- or two-tailed P value? One-tailed 
t, df t=2.508 df=4 
Number of pairs 5 
How big is the difference? 
 
Mean of differences -0.0348 
SD of differences 0.03102 
SEM of differences 0.01387 
95% confidence interval -0.07332 to 0.003721 
R squared 0.6113 
How effective was the pairing? 
 
Correlation coefficient (r) -0.5069 
P value (one tailed) 0.1917 
P value summary Ns 
Was the pairing significantly effective? No 
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Table A4.19: One-way ANOVA analysis of the invasiveness of parental and drug-
resistant HEPG2 clones as shown in figure 5.2 
Table Analyzed Metastasis assay 
ANOVA summary      
F 1.033     
P value 0.4115     
P value summary Ns     
Are differences among means 
statistically significant? (P < 0.05) 
No     
R square 0.2562     
Brown-Forsythe test      
F (DFn, DFd) 0.08553 
(2, 6) 
    
P value 0.9191     
P value summary Ns     
Significantly different standard 
deviations? (P < 0.05) 
No     
Bartlett's test      
Bartlett's statistic (corrected)      
P value      
P value summary      
Significantly different standard 
deviations? (P < 0.05) 
     
ANOVA table SS DF MS F (DFn, DFd) P value 
Treatment (between columns) 62.00 2 31.00 F (2, 6) = 
1.033 
P = 0.4115 
Residual (within columns) 180.0 6 30.00   
Total 242.0 8    
Data summary      
Number of treatments (columns) 3     
Number of values (total) 9     
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Table A4.20: A t-test of the invasive abilities of HEPG2 vs HEPG2CR (figure 5.2) 
Table Analyzed Metastasis assay 
Column A HEPG2  
vs. vs. 
Column B HEPG2CR  
Paired t test  
P value 0.2539 
P value summary Ns 
Significantly different? (P < 0.05) No 
One- or two-tailed P value? Two-tailed 
t, df t=1.585 df=2 
Number of pairs 3 
How big is the difference?  
Mean of differences -6.000 
SD of differences 6.557 
SEM of differences 3.786 
95% confidence interval -22.29 to 10.29 
R squared 0.5567 
How effective was the pairing?  
Correlation coefficient (r) 0.1233 
P value (one tailed) 0.4607 
P value summary Ns 
Was the pairing significantly effective? No 
 
Table A4.21: Student t-test of the invasiveness of HEPG2 vs HEPG2FR (figure 5.2) 
Table Analyzed Metastasis assay 
Column A HEPG2  
vs. vs. 
Column C HEPG2FR  
Paired t test  
P value 0.0820 
P value summary Ns 
Significantly different? (P < 0.05) No 
One- or two-tailed P value? Two-tailed 
t, df t=3.273 df=2 
Number of pairs 3 
How big is the difference?  
Mean of differences -5.000 
SD of differences 2.646 
SEM of differences 1.528 
95% confidence interval -11.57 to 1.572 
R squared 0.8427 
How effective was the pairing?  
Correlation coefficient (r) 0.9118 
P value (one tailed) 0.1347 
P value summary Ns 
Was the pairing significantly effective? No 
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Table A4.22: A student t-test of the invasiveness of HEG2CR vs HEPG2FR (figure 5.2) 
Table Analyzed Metastasis assay 
Column C HEPG2FR  
vs. vs. 
Column B HEPG2CR  
Paired t test 
 
P value 0.8581 
P value summary Ns 
Significantly different? (P < 0.05) No 
One- or two-tailed P value? Two-tailed 
t, df t=0.2027 df=2 
Number of pairs 3 
How big is the difference? 
 
Mean of differences -1.000 
SD of differences 8.544 
SEM of differences 4.933 
95% confidence interval -22.22 to 20.22 
R squared 0.02013 
How effective was the pairing? 
 
Correlation coefficient (r) -0.2951 
P value (one tailed) 0.4047 
P value summary Ns 
Was the pairing significantly effective? No 
 
Table A4.23: One-way ANOVA of the invasiveness of HEPG2 clones with and without 
siRNA interference with TG2 protein expression as shown in figure 5.5  
Table Analyzed Effect of TG2 silencing on cell invasion and migration 
ANOVA summary      
F 15.99     
P value < 0.0001     
P value summary ****     
Are differences among means statistically 
significant? (P < 0.05) 
Yes     
R square 0.8695     
Brown-Forsythe test      
F (DFn, DFd) 0.3020 (5, 12)     
P value 0.9024     
P value summary Ns     
Significantly different standard 
deviations? (P < 0.05) 
No     
Bartlett's test      
Bartlett's statistic (corrected)      
P value      
P value summary      
Significantly different standard 
deviations? (P < 0.05) 
     
ANOVA table SS DF MS F (DFn, DFd) P value 
Treatment (between columns) 1635 5 326.9 F (5, 12) = 15.99 P < 0.0001 
Residual (within columns) 245.3 12 20.44   
Total 1880 17    
Data summary      
Number of treatments (columns) 6     
Number of values (total) 18     
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Table A4.24: A student t-test of the invasiveness of HEPG2 cells on matrigel-coated 
plates with and without siRNA (figure 5.5) 
Table Analyzed Effect of TG2 silencing on cell invasion and migration 
Column A HEPG2  
vs. vs. 
Column D HEPG2+siRNA 
Paired t test  
P value 0.0339 
P value summary * 
Significantly different? (P < 0.05) Yes 
One- or two-tailed P value? Two-tailed 
t, df t=5.289 df=2 
Number of pairs 3 
How big is the difference?  
Mean of differences 20.33 
SD of differences 6.658 
SEM of differences 3.844 
95% confidence interval 3.793 to 36.87 
R squared 0.9333 
How effective was the pairing?  
Correlation coefficient (r) -0.5565 
P value (one tailed) 0.3122 
P value summary Ns 
Was the pairing significantly effective? No 
 
Table A4.25: A student t-test of the invasiveness of HEPG2CR cells on matrigel-coated 
plates with and without siRNA (figure 5.5) 
Table Analyzed Effect of TG2 silencing on cell invasion and migration 
Column B HEPG2CR  
vs. vs. 
Column E HEPG2CR+siRNA 
Paired t test  
P value 0.0094 
P value summary ** 
Significantly different? (P < 0.05) Yes 
One- or two-tailed P value? One-tailed 
t, df t=7.181 df=2 
Number of pairs 3 
How big is the difference?  
Mean of differences 19.00 
SD of differences 4.583 
SEM of differences 2.646 
95% confidence interval 7.616 to 30.38 
R squared 0.9627 
How effective was the pairing?  
Correlation coefficient (r) 0.3764 
P value (one tailed) 0.3772 
P value summary Ns 
Was the pairing significantly effective? No 
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Table A4.26: A student t-test of the invasiveness of HEPG2FR cells on matrigel-coated 
plates with and without siRNA (figure 5.5) 
Table Analyzed Effect of TG2 silencing on cell invasion and migration 
Column C HEPG2FR  
vs. vs. 
Column F HEPG2FR+siRNA 
Unpaired t test  
P value 0.0332 
P value summary * 
Significantly different? (P < 0.05) Yes 
One- or two-tailed P value? One-tailed 
t, df t=2.506 df=4 
How big is the difference?  
Mean ± SEM of column C 83.67 ± 3.712, n=3 
Mean ± SEM of column F 73.00 ± 2.082, n=3 
Difference between means 10.67 ± 4.256 
95% confidence interval -1.149 to 22.48 
R squared 0.6110 
F test to compare variances  
F,DFn, Dfd 3.179, 2, 2 
P value 0.4785 
P value summary Ns 
Significantly different? (P < 0.05) No 
 
Table A4.27: A t-test of HEPG2 cells’ response to cisplatin-induced death following 
TG2 protein down-regulation by siRNA as shown in figure 5.6 
Table Analyzed Cell response to cisplatin after TG2 protein downregulation by siRNA 
Column C HEPG2  
vs. vs. 
Column A HEPG2+siRNA 
Paired t test  
P value 0.0167 
P value summary * 
Significantly different? (P < 0.05) Yes 
One- or two-tailed P value? Two-tailed 
t, df t=3.531 df=5 
Number of pairs 6 
How big is the difference?  
Mean of differences 11.94 
SD of differences 8.285 
SEM of differences 3.382 
95% confidence interval 3.250 to 20.64 
R squared 0.7138 
How effective was the pairing?  
Correlation coefficient (r) 0.9552 
P value (one tailed) 0.0015 
P value summary ** 
Was the pairing significantly 
effective? 
Yes 
222 
 
Table A4.28: A student t-test of HEPG2CR sensitivity to cisplatin-induced death 
following TG2 protein down-regulation by siRNA as shown in figure 5.6 
Table Analyzed Cell response to cisplatin after TG2 protein downregulation by 
siRNA 
Column D HEPG2CR  
vs. vs. 
Column B HEPG2CR+siRNA 
Paired t test  
P value 0.3103 
P value summary Ns 
Significantly different? (P < 0.05) No 
One- or two-tailed P value? Two-tailed 
t, df t=1.129 df=5 
Number of pairs 6 
How big is the difference?  
Mean of differences -3.778 
SD of differences 8.199 
SEM of differences 3.347 
95% confidence interval -12.38 to 4.827 
R squared 0.2030 
How effective was the pairing?  
Correlation coefficient (r) 0.9647 
P value (one tailed) 0.0009 
P value summary *** 
Was the pairing significantly effective? Yes 
 
Table A4.29: One-way ANOVA of the sensitivity of parental and cisplatin-resistant 
HEPG2 clone to cisplatin-induced death following TG2 down-regulation (figure 5.6) 
Table Analyzed Cell response to cisplatin after TG2 protein downregulation by 
siRNA 
Repeated measures ANOVA summary      
Assume sphericity? No     
F 10.14     
P value 0.0103     
P value summary *     
Statistically significant (P < 0.05)? Yes     
Geisser-Greenhouse's epsilon 0.4880     
R square 0.6699     
Was the matching effective?      
F 90.65     
P value < 0.0001     
P value summary ****     
Is there significant matching (P < 0.05)? Yes     
R square 0.9089     
ANOVA table SS DF MS F (DFn, DFd) P value 
Treatment (between columns) 901.5 3 300.5 F (1.464, 7.319) = 10.14 P = 0.0103 
Individual (between rows) 13425 5 2685 F (5, 15) = 90.65 P < 0.0001 
Residual (random) 444.3 15 29.62   
Total 14771 23    
Data summary      
Number of treatments (columns) 4     
Number of subjects (rows) 6     
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Table A4.30: One-way ANOVA of the sensitivity of parental and 5-FU-resistant HEPG2 
clone to 5-FU-induced death following TG2 down-regulation (figure 5.7) 
Table Analyzed Cell response to 5FU after TG2 downregulation 
Repeated measures ANOVA summary      
Assume sphericity? No     
F 3.087     
P value 0.0774     
P value summary ns     
Statistically significant (P < 0.05)? No     
Geisser-Greenhouse's epsilon 0.7874     
R square 0.3817     
Was the matching effective?      
F 101.3     
P value < 0.0001     
P value summary ****     
Is there significant matching (P < 0.05)? Yes     
R square 0.9543     
ANOVA table SS DF MS F (DFn, DFd) P value 
Treatment (between columns) 256.3 3 85.44 F (2.362, 11.81) = 3.087 P = 0.0774 
Individual (between rows) 14019 5 2804 F (5, 15) = 101.3 P < 0.0001 
Residual (random) 415.2 15 27.68   
Total 14690 23    
Data summary      
Number of treatments (columns) 4     
Number of subjects (rows) 6     
 
Table A4.31: A t-test of HEPG2 response to 5-FU-induced death following TG2 protein 
down-regulation by siRNA as shown in figure 5.7 
Table Analyzed Cell response to 5FU after TG2 downregulation 
Column A HEPG2 
vs. vs. 
Column C HEPG2+siRNA 
Paired t test  
P value 0.1144 
P value summary Ns 
Significantly different? (P < 0.05) No 
One- or two-tailed P value? Two-tailed 
t, df t=1.910 df=5 
Number of pairs 6 
How big is the difference?  
Mean of differences 5.500 
SD of differences 7.055 
SEM of differences 2.880 
95% confidence interval -1.903 to 12.90 
R squared 0.4218 
How effective was the pairing?  
Correlation coefficient (r) 0.9778 
P value (one tailed) 0.0004 
P value summary *** 
Was the pairing significantly effective? Yes 
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Table A4.32: A student t-test of HEPG2FR response to 5-FU-induced death following 
TG2 protein down-regulation by siRNA as shown in figure 5.7 
Table Analyzed Cell response to 5FU after TG2 downregulation 
Column B HEPG2FR 
vs. vs. 
Column D HEPG2FR+siRNA 
Paired t test  
P value 0.3198 
P value summary Ns 
Significantly different? (P < 0.05) No 
One- or two-tailed P value? Two-tailed 
t, df t=1.104 df=5 
Number of pairs 6 
How big is the difference?  
Mean of differences 3.833 
SD of differences 8.503 
SEM of differences 3.471 
95% confidence interval -5.090 to 12.76 
R squared 0.1961 
How effective was the pairing?  
Correlation coefficient (r) 0.9554 
P value (one tailed) 0.0015 
P value summary ** 
Was the pairing significantly effective? Yes 
 
 
Table A4.33: Effect of cystamine on TG2 activity in parental and drug-resistant HEPG2 
clones (figure 5.10) 
cystamiine HEPG2  HEPG2CR  HEPG2FR  
0.00 0.301 0.257 0.421 0.300 0.388 0.247 
0.50 0.255 0.234 0.271 0.279 0.296 0.308 
1.00 0.194 0.191 0.220 0.216 0.248 0.232 
1.50 0.172 0.190 0.231 0.250 0.230 0.217 
2.00 0.110 0.150 0.140 0.135 0.120 0.150 
2.50 0.080 0.098 0.100 0.096 0.130 0.088 
3.00 0.079 0.084 0.097 0.097 0.114 0.138 
3.50 0.075 0.090 0.083 0.094 0.117 0.119 
4.00 0.068 0.076 0.091 0.081 0.101 0.099 
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Table A4.34: One-way ANOVA of the effect of cystamine on TG2 activity in HEPG2 
clones as shown in figure 5.10 
Table Analyzed Cystamine inhibition of TG2 activity 
      Repeated measures ANOVA summary      
Assume sphericity? No     
F 12.17     
P value 0.0018     
P value summary **     
Statistically significant (P < 0.05)? Yes     
Geisser-Greenhouse's epsilon 0.7857     
R square 0.6034     
      Was the matching effective?      
F 88.75     
P value < 0.0001     
P value summary ****     
Is there significant matching (P < 0.05)? Yes     
R square 0.9462     
      ANOVA table SS DF MS F (DFn, DFd) P value 
Treatment (between columns) 0.006247 2 0.003123 F (1.571, 12.57) = 12.17 P = 0.0018 
Individual (between rows) 0.1822 8 0.02278 F (8, 16) = 88.75 P < 0.0001 
Residual (random) 0.004106 16 0.0002566   
Total 0.1926 26    
      Data summary      
Number of treatments (columns) 3     
Number of subjects (rows) 9     
 
Table A4.35: One-way ANOVA of the effect of inhibition of TG2 activity on the invasive 
abilities of HEPG2 clones as shown in figure 5.11 
Table Analyzed Effect of TG2 activity inhibition on cell invasion 
Repeated measures ANOVA summary      
Assume sphericity? No     
F 128.2     
P value 0.0009     
P value summary ***     
Statistically significant (P < 0.05)? Yes     
Geisser-Greenhouse's epsilon 0.3234     
R square 0.9846     
Was the matching effective?      
F 3.147     
P value 0.0870     
P value summary ns     
Is there significant matching (P < 0.05)? No     
R square 0.009581     
ANOVA table SS DF MS F (DFn, DFd) P value 
Treatment (between columns) 11299 5 2260 F (1.617, 3.234) = 128.2 P = 0.0009 
Individual (between rows) 111.0 2 55.50 F (2, 10) = 3.147 P = 0.0870 
Residual (random) 176.3 10 17.63   
Total 11586 17    
Data summary      
Number of treatments (columns) 6     
Number of subjects (rows) 3     
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Table A4.36: Student t-test of the invasiveness of HEPG2 vs HEPG2+cystamine as 
shown in figure 5.11 
Table Analyzed Effect of TG2 activity inhibition on cell invasion 
  Column A HEPG2  
vs. vs. 
Column D HEPG2+cystamine 
  Paired t test  
P value 0.0063 
P value summary ** 
Significantly different? (P < 0.05) Yes 
One- or two-tailed P value? Two-tailed 
t, df t=12.53 df=2 
Number of pairs 3 
  How big is the difference?  
Mean of differences 51.33 
SD of differences 7.095 
SEM of differences 4.096 
95% confidence interval 33.71 to 68.96 
R squared 0.9874 
  How effective was the pairing?  
Correlation coefficient (r) -0.9018 
P value (one tailed) 0.1422 
P value summary Ns 
Was the pairing significantly effective? No 
 
Table A4.37: Student t-test of the invasiveness of HEPG2CR vs HEPG2CR+cystamine 
as shown in figure 5.11 
Table Analyzed Effect of TG2 activity inhibition on cell invasion 
  Column B HEPG2CR  
vs. vs. 
Column E HEPG2CR+cystamine 
  Paired t test  
P value 0.0019 
P value summary ** 
Significantly different? (P < 0.05) Yes 
One- or two-tailed P value? Two-tailed 
t, df t=23.00 df=2 
Number of pairs 3 
  How big is the difference?  
Mean of differences 53.67 
SD of differences 4.041 
SEM of differences 2.333 
95% confidence interval 43.63 to 63.71 
R squared 0.9962 
  How effective was the pairing?  
Correlation coefficient (r) 0.3712 
P value (one tailed) 0.3790 
P value summary Ns 
Was the pairing significantly effective? No 
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Table A4.38: Student t-test of the invasiveness of HEPG2FR vs HEPG2FR+cystamine 
as shown in figure 5.11 
Table Analyzed Effect of TG2 activity inhibition on cell invasion 
Column C HEPG2FR  
vs. vs. 
Column F HEPG2FR+cystamine 
Paired t test  
P value 0.0013 
P value summary ** 
Significantly different? (P < 0.05) Yes 
One- or two-tailed P value? Two-tailed 
t, df t=28.15 df=2 
Number of pairs 3 
How big is the difference?  
Mean of differences 43.00 
SD of differences 2.646 
SEM of differences 1.528 
95% confidence interval 36.43 to 49.57 
R squared 0.9975 
How effective was the pairing?  
Correlation coefficient (r) 0.9164 
P value (one tailed) 0.1311 
P value summary Ns 
Was the pairing significantly effective? No 
 
Table A4.39: One-way ANOVA of the effect of inhibition of TG2 activity on the 
susceptibility of HEPG2 clones to cisplatin-induced death as shown in figure 5.12 
Table Analyzed Cell response to cisplatin after TG2 activity inhibition 
Repeated measures ANOVA summary      
Assume sphericity? No     
F 11.02     
P value 0.0106     
P value summary *     
Statistically significant (P < 0.05)? Yes     
Geisser-Greenhouse's epsilon 0.4484     
R square 0.6879     
Was the matching effective?      
F 78.80     
P value < 0.0001     
P value summary ****     
Is there significant matching (P < 0.05)? Yes     
R square 0.8913     
ANOVA table SS DF MS F (DFn, DFd) P value 
Treatment (between columns) 1230 3 409.9 F (1.345, 6.726) = 11.02 P = 0.0106 
Individual (between rows) 14658 5 2932 F (5, 15) = 78.80 P < 0.0001 
Residual (random) 558.0 15 37.20   
Total 16445 23    
Data summary      
Number of treatments (columns) 4     
Number of subjects (rows) 6     
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Table A4.40: Student t-test of the susceptibility of HEPG2 vs HEPG2+cystamine to 
cisplatin-induced death as shown in figure 5.12 
Table Analyzed Cell response to cisplatin after TG2 activity inhibition 
Column C HEPG2  
vs. vs. 
Column A HEPG2+cystamine 
Paired t test  
P value 0.4165 
P value summary Ns 
Significantly different? (P < 0.05) No 
One- or two-tailed P value? Two-tailed 
t, df t=0.8853 df=5 
Number of pairs 6 
How big is the difference?  
Mean of differences -2.111 
SD of differences 5.841 
SEM of differences 2.385 
95% confidence interval -8.241 to 4.019 
R squared 0.1355 
How effective was the pairing?  
Correlation coefficient (r) 0.9781 
P value (one tailed) 0.0004 
P value summary *** 
Was the pairing significantly effective? Yes 
 
 
Table A4.41: Student t-test of the susceptibility of HEPG2CR vs HEPG2CR+cystamine 
to cisplatin-induced death as shown in figure 5.12 
Table Analyzed Cell response to cisplatin after TG2 activity inhibition 
Column D HEPG2CR 
vs. vs. 
Column B HEPG2CR+cystamine 
Paired t test  
P value 0.0188 
P value summary * 
Significantly different? (P < 0.05) Yes 
One- or two-tailed P value? Two-tailed 
t, df t=3.424 df=5 
Number of pairs 6 
How big is the difference?  
Mean of differences -12.83 
SD of differences 9.182 
SEM of differences 3.748 
95% confidence interval -22.47 to -3.198 
R squared 0.7010 
How effective was the pairing?  
Correlation coefficient (r) 0.9432 
P value (one tailed) 0.0024 
P value summary ** 
Was the pairing significantly effective? Yes 
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Table A4.42: One-way ANOVA of the susceptibility of HEPG2 clones to 5-FU-induced 
death following cystamine inhibition of TG2 activity as shown in figure 5.13 
Table Analyzed Cell response to 5FU after TG2 activity inhibition 
Repeated measures ANOVA summary      
Assume sphericity? No     
F 8.064     
P value 0.0054     
P value summary **     
Statistically significant (P < 0.05)? Yes     
Geisser-Greenhouse's epsilon 0.7637     
R square 0.6173     
Was the matching effective?      
F 107.3     
P value < 0.0001     
P value summary ****     
Is there significant matching (P < 0.05)? Yes     
R square 0.9319     
ANOVA table SS DF MS F (DFn, DFd) P value 
Treatment (between columns) 735.7 3 245.2 F (2.291, 11.46) = 8.064 P = 0.0054 
Individual (between rows) 16316 5 3263 F (5, 15) = 107.3 P < 0.0001 
Residual (random) 456.1 15 30.41   
Total 17508 23    
Data summary      
Number of treatments (columns) 4     
Number of subjects (rows) 6     
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Table A4.43: Student t-test of the susceptibility of HEPG2 vs HEPG2+cystamine to 5-
FU-induced death as shown in figure 5.13 
Table Analyzed Cell response to 5FU after TG2 activity inhibition 
  Column C HEPG2 
vs. vs. 
Column A HEPG2+cystamine 
  Paired t test  
P value 0.0456 
P value summary * 
Significantly different? (P < 0.05) Yes 
One- or two-tailed P value? Two-tailed 
t, df t=2.647 df=5 
Number of pairs 6 
  How big is the difference?  
Mean of differences -9.556 
SD of differences 8.843 
SEM of differences 3.610 
95% confidence interval -18.84 to -0.2749 
R squared 0.5835 
  How effective was the pairing?  
Correlation coefficient (r) 0.9583 
P value (one tailed) 0.0013 
P value summary ** 
Was the pairing significantly effective? Yes 
 
Table A4.44: Student t-test of the susceptibility of HEPG2FR vs HEPG2FR+cystamine 
to 5-FU-induced death as shown in figure 5.13  
Table Analyzed Cell response to 5FU after TG2 activity inhibition 
  Column D HEPG2FR 
vs. vs. 
Column B HEPG2FR+cystamine 
  Paired t test  
P value 0.0239 
P value summary * 
Significantly different? (P < 0.05) Yes 
One- or two-tailed P value? Two-tailed 
t, df t=3.203 df=5 
Number of pairs 6 
  How big is the difference?  
Mean of differences -10.17 
SD of differences 7.774 
SEM of differences 3.174 
95% confidence interval -18.32 to -2.008 
R squared 0.6724 
  How effective was the pairing?  
Correlation coefficient (r) 0.9593 
P value (one tailed) 0.0012 
P value summary ** 
Was the pairing significantly effective? Yes 
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Table A4.45: ANOVA comparison of the effects of TG2 down-regulation and activity 
inhibition on the susceptibility of HEPG2 clones to cisplatin-induced death (figure 5.14) 
Table Analyzed Comparative effects of TG2 inhibition and  
downregulation on cell response to cisplatin 
Repeated measures ANOVA summary      
Assume sphericity? No     
F 11.23     
P value 0.0056     
P value summary **     
Statistically significant (P < 0.05)? Yes     
Geisser-Greenhouse's epsilon 0.3275     
R square 0.6920     
Was the matching effective?      
F 134.8     
P value < 0.0001     
P value summary ****     
Is there significant matching (P < 
0.05)? 
Yes     
R square 0.8925     
ANOVA table SS DF MS F (DFn, DFd) P value 
Treatment (between columns) 1720 5 344.0 F (1.637, 8.186) = 11.23 P = 0.0056 
Individual (between rows) 20645 5 4129 F (5, 25) = 134.8 P < 0.0001 
Residual (random) 765.5 25 30.62   
Total 23130 35    
Data summary      
Number of treatments (columns) 6     
Number of subjects (rows) 6     
 
Table A4.46: Student t-test of the susceptibility of HEPG2+cystamine vs 
HEPG2+siRNA to cisplatin-induced death as shown in figure 5.14 
Table Analyzed 
Comparative effects of TG2 inhibition and downregulation 
on cellresponse to cis 
Column C HEPG2+cystamine 
vs. vs. 
Column A HEPG2+siRNA 
Paired t test 
 
P value 0.0212 
P value summary * 
Significantly different? (P < 0.05) Yes 
One- or two-tailed P value? Two-tailed 
t, df t=3.311 df=5 
Number of pairs 6 
How big is the difference? 
 
Mean of differences 14.06 
SD of differences 10.40 
SEM of differences 4.246 
95% confidence interval 3.142 to 24.97 
R squared 0.6867 
How effective was the pairing? 
 
Correlation coefficient (r) 0.9288 
P value (one tailed) 0.0037 
P value summary ** 
Was the pairing significantly effective? Yes 
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Table A4.47: Student t-test of the susceptibility of HEPG2CR+cystamine vs 
HEPG2CR+siRNA to cisplatin-induced death as shown in figure 5.14 
Table Analyzed Comparative effects of TG2 inhibition and downregulation  
on cell response to cisplatin 
Column D HEPG2CR+cystamine 
vs. vs. 
Column B HEPG2CR+siRNA 
Paired t test  
P value 0.0083 
P value summary ** 
Significantly different? (P < 0.05) Yes 
One- or two-tailed P value? Two-tailed 
t, df t=4.217 df=5 
Number of pairs 6 
How big is the difference?  
Mean of differences 9.056 
SD of differences 5.260 
SEM of differences 2.147 
95% confidence interval 3.536 to 14.58 
R squared 0.7806 
How effective was the pairing?  
Correlation coefficient (r) 0.9933 
P value (one tailed) < 0.0001 
P value summary **** 
Was the pairing significantly effective? Yes 
 
Table A4.48: ANOVA comparison of the effects of TG2 down-regulation and activity 
inhibition on the susceptibility of HEPG2 clones to 5-FU treatment (figure 5.15) 
Table Analyzed 
Comparison of cell response to 5FU after TG inhibition and  
Downregulation 
 
Repeated measures ANOVA summary 
     
Assume sphericity? No 
    
F 10.06 
    
P value 0.0005 
    
P value summary *** 
    
Statistically significant (P < 0.05)? Yes 
    
Geisser-Greenhouse's epsilon 0.6416 
    
R square 0.6679 
    
Was the matching effective? 
     
F 147.5 
    
P value < 0.0001 
    
P value summary **** 
    
Is there significant matching (P < 0.05)? Yes 
    
R square 0.9074 
    
ANOVA table SS DF MS     F (DFn, DFd) P value 
Treatment (between columns) 1513 5 302.6 
  F (3.208, 16.04) = 
10.06 
P = 0.0005 
Individual (between rows) 22188 5 4438     F (5, 25) = 147.5 P < 0.0001 
Residual (random) 752.1 25 30.08 
  
Total 24453 35 
   
Data summary 
     
Number of treatments (columns) 6 
    
Number of subjects (rows) 6 
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Table A4.49: Student t-test of the susceptibility of HEPG2+cystamine vs 
HEPG2+siRNA to 5-FU-induced death as shown in figure 5.15 
Table Analyzed 
Comparison of cell response to 5FU after TG inhibition 
and downregulation 
Column A HEPG2+cystamine 
vs. vs. 
Column C HEPG2+siRNA 
Paired t test 
 
P value 0.0051 
P value summary ** 
Significantly different? (P < 0.05) Yes 
One- or two-tailed P value? Two-tailed 
t, df t=4.744 df=5 
Number of pairs 6 
How big is the difference? 
 
Mean of differences 15.06 
SD of differences 7.773 
SEM of differences 3.173 
95% confidence interval 6.898 to 23.21 
R squared 0.8182 
How effective was the pairing? 
 
Correlation coefficient (r) 0.9731 
P value (one tailed) 0.0005 
P value summary *** 
Was the pairing significantly effective? Yes 
 
Table A4.50: Student t-test of the susceptibility of HEPG2FR+cystamine vs 
HEPG2FR+siRNA to 5-FU-induced death as shown in figure 5.15 
Table Analyzed 
Comparison of cell response to 5FU after TG inhibition 
and downregulation 
Column D HEPG2FR+siRNA 
vs. vs. 
Column B HEPG2FR+cystamine 
Paired t test 
 
P value 0.0066 
P value summary ** 
Significantly different? (P < 0.05) Yes 
One- or two-tailed P value? Two-tailed 
t, df t=4.465 df=5 
Number of pairs 6 
How big is the difference? 
 
Mean of differences -14.00 
SD of differences 7.680 
SEM of differences 3.135 
95% confidence interval -22.06 to -5.941 
R squared 0.7995 
How effective was the pairing? 
 
Correlation coefficient (r) 0.9706 
P value (one tailed) 0.0006 
P value summary *** 
Was the pairing significantly effective? Yes 
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Table A4.51: Assessment of the stability of HEPG2CR in drug-free conditions (as shown 
in figure 2.5) 
Cisplatin (M)  2 weeks 1 month 3 months   
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00  
1.00 10.00 10.00 9.00 8.00 9.00 9.00 8.00 6.00 9.00 50.00 
2.00 16.00 19.00 18.00 16.00 18.00 14.00 16.00 13.00 16.00 50.00 
4.00 35.00 37.00 35.00 39.00 36.00 34.00 39.00 34.00 34.00 50.00 
8.00 47.00 55.00 50.00 50.00 44.00 54.00 52.00 48.00 50.00 50.00 
16.00 74.00 71.00 70.00 69.00 78.00 68.00 72.00 71.00 71.00 50.00 
  
Table A4.52: One-way ANOVA of HEPG2CR stability in drug-free medium as shown 
in figure 2.5 
Table Analyzed HEPG2CR stability test     
ANOVA summary      
F 0.001823     
P value 0.9982     
P value summary ns     
Are differences among means 
statistically significant? (P < 0.05) 
No     
R square 0.0002431     
Brown-Forsythe test      
F (DFn, DFd) 0.003152 (2, 15)     
P value 0.9969     
P value summary ns     
Significantly different standard 
deviations? (P < 0.05) 
No     
Bartlett's test      
Bartlett's statistic (corrected) 0.0009865     
P value 0.9995     
P value summary ns     
Significantly different standard 
deviations? (P < 0.05) 
No     
ANOVA table SS DF MS F (DFn, DFd) P value 
Treatment (between columns) 2.704 2 1.352 F (2, 15) = 0.001823 P = 0.9982 
Residual (within columns) 11121 15 741.4   
Total 11124 17    
Data summary      
Number of treatments (columns) 3     
Number of values (total) 18     
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Table A4.53: One-way ANOVA multiple comparison of HEPG2CR stability in drug-
free medium after 2 weeks, 1 month, and three months (figure 2.5) 
Number of families 1        
Number of 
comparisons per family 
3        
Alpha 0.05        
Tukey's multiple 
comparisons test 
Mean Diff. 95% CI of diff. Significant? Summary     
2 weeks vs. 1 month 0.5556 -40.28 to 41.39 No Ns  A-B   
2 weeks vs. 3 months  0.9444 -39.89 to 41.78 No Ns  A-C   
1 month vs. 3 months  0.3889 -40.44 to 41.22 No Ns  B-C   
Test details Mean 1 Mean 2 Mean Diff. SE of diff. n1 n2 q DF 
2 weeks vs. 1 month 30.89 30.33 0.5556 15.72 6 6 0.04998 15 
2 weeks vs. 3 months  30.89 29.94 0.9444 15.72 6 6 0.08496 15 
1 month vs. 3 months  30.33 29.94 0.3889 15.72 6 6 0.03498 15 
 
Table A4.54: Assessment of the stability of HEPG2FR in drug-free conditions (as shown 
in figure 2.6) 
5-FU (M) 2 weeks 1 month 3 months   
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 50.00 
10.00 19.00 19.00 16.00 14.00 20.00 21.00 12.00 23.00 17.00 50.00 
30.00 28.00 29.00 24.00 24.00 26.00 29.00 27.00 26.00 27.00 50.00 
50.00 42.00 41.00 45.00 43.00 39.00 39.00 41.00 39.00 41.00 50.00 
70.00 53.00 50.00 56.00 56.00 48.00 53.00 53.00 52.00 55.00 50.00 
100.00 80.00 74.00 71.00 75.00 77.00 72.00 75.00 75.00 77.00 50.00 
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Table A4.55: One-way ANOVA of HEPG2FR stability in drug-free medium as shown in 
figure 2.6 
Table Analyzed 
HEPG2FR stability 
in drug-free medium     
ANOVA summary 
     
F 0.0008079 
    
P value 0.9992 
    
P value summary Ns 
    
Are differences among means statistically 
significant? (P < 0.05) 
No 
    
R square 0.0001077 
    
Brown-Forsythe test 
     
F (DFn, DFd) 0.002286 (2, 15) 
    
P value 0.9977 
    
P value summary Ns 
    
Significantly different standard deviations? 
(P < 0.05) 
No 
    
Bartlett's test 
     
Bartlett's statistic (corrected) 0.001876 
    
P value 0.9991 
    
P value summary Ns 
    
Significantly different standard deviations? 
(P < 0.05) 
No 
    
ANOVA table SS DF MS F (DFn, DFd) P value 
Treatment (between columns) 1.148 2 0.5741 F (2, 15) = 0.0008079 P = 0.9992 
Residual (within columns) 10658 15 710.5 
  
Total 10659 17 
   
Data summary 
     
Number of treatments (columns) 3 
    
Number of values (total) 18 
    
 
Table A4.56: One-way ANOVA multiple comparison of HEPG2FR stability in drug-
free medium after 2 weeks, 1 month, and three months (figure 2.6) 
Number of families 1 
       
Number of 
comparisons per 
family 
3 
       
Alpha 0.05 
       
Tukey's multiple 
comparisons test 
Mean Diff. 95% CI of diff. Significant? Summary 
    
2 weeks vs. 1 month 0.6111 -39.36 to 40.59 No Ns 
 
A-B 
  
2 weeks vs. 3 months  0.3889 -39.59 to 40.36 No Ns 
 
A-C 
  
1 month vs. 3 months  -0.2222 -40.20 to 39.75 No Ns 
 
B-C 
  
Test details Mean 1 Mean 2 Mean Diff. SE of diff. n1 n2 q DF 
2 weeks vs. 1 month 35.94 35.33 0.6111 15.39 6 6 0.05616 15 
2 weeks vs. 3 months  35.94 35.56 0.3889 15.39 6 6 0.03574 15 
1 month vs. 3 months  35.33 35.56 -0.2222 15.39 6 6 0.02042 15 
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Table A4.57: Student t-test of the susceptibility of HEPG2+cystamine vs HEPG2 to 
cisplatin-induced death as shown in figure 5.16 
 
Table Analyzed Data 1 
Column A HEPG2+cystamine 
Vs Vs 
Column C HEPG2 
Paired t test  
  P value 0.0486 
  P value summary * 
  Are means signif. different? (P < 0.05) Yes 
  One- or two-tailed P value? Two-tailed 
  t, df t=2.804 df=4 
  Number of pairs 5 
How big is the difference?  
  Mean of differences 15.70 
  95% confidence interval 0.1594 to 31.24 
  R squared 0.6629 
How effective was the pairing?  
  Correlation coefficient (r) 0.8977 
  P Value (one tailed) 0.0002 
  P value summary *** 
 Was the pairing significantly effective? Yes 
 
 
Table A4.58: Student t-test of the susceptibility of HEPG2CR+cystamine vs HEPG2CR 
to cisplatin-induced death as shown in figure 5.16 
Table Analyzed Data 1 
Column B HEPG2CR+cystamine 
Vs Vs 
Column D HEPG2CR 
Paired t test  
  P value 0.0435 
  P value summary * 
  Are means signif. different? (P < 0.05) Yes 
  One- or two-tailed P value? Two-tailed 
  t, df t=2.913 df=4 
  Number of pairs 5 
How big is the difference?  
  Mean of differences 27.10 
  95% confidence interval 1.276 to 52.92 
  R squared 0.6797 
How effective was the pairing?  
  Correlation coefficient (r) 0.6845 
  P Value (one tailed) 0.0145 
  P value summary * 
 Was the pairing significantly effective? Yes 
 Yes 
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Table A4.59: Student t-test of the susceptibility of HEPG2+cystamine vs HEPG2 to 5-
FU-induced death as shown in figure 5.17 
Table Analyzed Data 1 
Column A HEPG2+cystamine 
Vs Vs 
Column C HEPG2 
Paired t test  
  P value 0.0489 
  P value summary * 
  Are means signif. different? (P < 0.05) Yes 
  One- or two-tailed P value? Two-tailed 
  t, df t=2.798 df=4 
  Number of pairs 5 
How big is the difference?  
  Mean of differences 14.20 
  95% confidence interval 0.1092 to 28.29 
  R squared 0.6618 
How effective was the pairing?  
  Correlation coefficient (r) 0.9671 
  P Value (one tailed) P<0.0001 
  P value summary *** 
 Was the pairing significantly effective? Yes 
 
 
Table A4.60: Student t-test of the susceptibility of HEPG2FR+cystamine vs HEPG2FR 
to 5-FU-induced death as shown in figure 5.17 
Parameter Value 
Table Analyzed Data 1 
Column B HEPG2FR+cystamine 
Vs Vs 
Column D HEPG2FR 
Paired t test  
  P value 0.0399 
  P value summary * 
  Are means signif. different? (P < 0.05) Yes 
  One- or two-tailed P value? Two-tailed 
  t, df t=3.000 df=4 
  Number of pairs 5 
How big is the difference?  
  Mean of differences 20.80 
  95% confidence interval 1.554 to 40.05 
  R squared 0.6923 
How effective was the pairing?  
  Correlation coefficient (r) 0.8048 
  P Value (one tailed) 0.0025 
  P value summary ** 
 Was the pairing significantly effective? Yes 
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Table A4.61: Student t-test of the susceptibility of HEPG2+siRNA vs HEPG2 to 
cisplatin-induced death as shown in figure 5.8 
 
Column A HEPG2+siRNA 
Vs Vs 
Column C HEPG2 
Paired t test  
  P value 0.0399 
  P value summary * 
  Are means signif. different? (P < 0.05) Yes 
  One- or two-tailed P value? Two-tailed 
  t, df t=3.000 df=4 
  Number of pairs 5 
How big is the difference?  
  Mean of differences -14.30 
  95% confidence interval -27.53 to -1.070 
  R squared 0.6924 
How effective was the pairing?  
  Correlation coefficient (r) 0.9379 
  P Value (one tailed) P<0.0001 
  P value summary *** 
 Was the pairing significantly effective? Yes 
 
Table A4.62: Student t-test of the susceptibility of HEPG2CR+siRNA vs HEPG2CR to 
cisplatin-induced death as shown in figure 5.8 
Column B HEPG2CR+siRNA 
Vs Vs 
Column D HEPG2CR 
Paired t test  
  P value 0.1887 
  P value summary Ns 
  Are means signif. different? (P < 0.05) No 
  One- or two-tailed P value? Two-tailed 
  t, df t=1.583 df=4 
  Number of pairs 5 
How big is the difference?  
  Mean of differences -15.10 
  95% confidence interval -41.59 to 11.39 
  R squared 0.3851 
How effective was the pairing?  
  Correlation coefficient (r) 0.8186 
  P Value (one tailed) 0.0019 
  P value summary ** 
 Was the pairing significantly effective? Yes 
 
 
 
240 
 
Table A4.63: Student t-test of the susceptibility of HEPG2+siRNA vs HEPG2 to 5-FU-
induced death as shown in figure 5.9 
Column A HEPG2+siRNA 
Vs Vs 
Column C HEPG2 
Paired t test  
  P value 0.2484 
  P value summary Ns 
  Are means signif. different? (P < 0.05) No 
  One- or two-tailed P value? Two-tailed 
  t, df t=1.350 df=4 
  Number of pairs 5 
How big is the difference?  
  Mean of differences -11.40 
  95% confidence interval -34.85 to 12.05 
  R squared 0.3129 
How effective was the pairing?  
  Correlation coefficient (r) 0.7006 
  P Value (one tailed) 0.0120 
  P value summary * 
 Was the pairing significantly effective? Yes 
 
Table A4.63: Student t-test of the susceptibility of HEPG2FR+siRNA vs HEPG2FR to 
5-FU-induced death as shown in figure 5.9 
Column B HEPG2FR+siRNA 
vs Vs 
Column D HEPG2FR 
Paired t test  
  P value 0.0703 
  P value summary Ns 
  Are means signif. different? (P < 0.05) No 
  One- or two-tailed P value? Two-tailed 
  t, df t=2.452 df=4 
  Number of pairs 5 
How big is the difference?  
  Mean of differences -19.90 
  95% confidence interval -42.43 to 2.633 
  R squared 0.6004 
How effective was the pairing?  
  Correlation coefficient (r) 0.8615 
  P Value (one tailed) 0.0007 
  P value summary *** 
 Was the pairing significantly effective? Yes 
 
 
